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OVERVIEW 
Delayed healing of wounds is a poorly understood condition, which affects 15-30% 
of all people with diabetes (Hobizal & Wukich, 2012; Mack & Maytin, 2010). This 
delay in healing is associated with much morbidity and is costly both to the 
individual and society. The increasing numbers of persons diagnosed with diabetes 
and the ageing population will further increase the economic and human burden of 
this complication of diabetes. For this reason understanding the pathophysiology of 
poor wound healing in diabetes is of critical importance. The wound healing process 
is complex and is composed of at least three dynamic overlapping stages, which 
include inflammation, proliferation, and remodelling. During normal wound healing 
an orderly cellular response to inflammation, cytokines, and inflammatory mediators 
is required (Falanga, 2005). Impairment in this process such as occurs in diabetic 
wounds can delay the healing process. The mechanism why wound healing is 
delayed in diabetes is not fully understood. A number of mechanisms including 
changes in granulocyte function, alteration in collagen synthesis and accumulation, 
and altered re-epithelisation and blood vessel formation have been described (Mack 
& Maytin, 2010; Raja et al., 2007). Persistent inflammation is a characteristic 
feature of wounds in diabetic subjects (Wetzler et al., 2000), with increased numbers 
of neutrophils observed in humans and in rodent diabetic wound healing models 
(McLennan et al., 2008; Rayment et al., 2008; Wetzler et al., 2000). The 
inflammatory phase is a critical early component of healing and is characterised by 
an influx of inflammatory cells to the wound site. Neutrophils can be quickly and 
efficiently mobilised upon inflammation and they constitute the first line of defence 
against the pathogens. They are essential for the wound healing process; they act as 
debris scavengers and deliver chemokines to recruit other leukocytes such as 
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monocytes and lymphocytes to the wound site (Kumar & Sharma, 2010). However 
due to their toxic contents their persistence in the wound can impair progression 
from the inflammatory phase to the repair and resolution phases of healing. 
Neutrophils are also a rich source of matrix metalloproteinases (MMPs), which 
assist in the migration of monocytes and lymphocytes from the circulation to the 
wound (Alba-Loureiro et al., 2007; Houreld, 2014; Nishio et al., 2008). On 
activation the neutrophil degranulates and releases large amounts of pro and active 
MMPs including Metalloproteinase-9 (MMP-9) (Lin et al., 2005). 
 
MMP-9 is a gelatinase which degrades collagen, elastin and laminin (Chakrabarti & 
Patel, 2005). It has important roles in wound repair including modulation of growth 
factor activity, activation of other proteases and it is also implicated in the cleavage 
of the pro-inflammatory cytokines, such as pro Interleukin-β (IL-1β) to their active 
forms (Opdenakker et al., 2001). Our previous studies have shown that the wound 
fluid MMP-9 concentration at presentation can predict future healing (Liu et al., 
2009) and we and others have shown that high levels of active MMP-9 correlate 
with the severity of chronic ulcers (Rayment et al., 2008). Whilst high levels of 
MMP-9 are associated with delayed healing, MMP-9 is also essential for wound 
repair as studies in knockout models have also shown delayed healing (Kyriakides et 
al., 2009). Despite the knowledge that high MMP-9 is associated with delayed 
healing the mechanism for the increase in MMP-9 is poorly understood.  
 
The expression and activities of MMP-9 are tightly regulated at multiple levels. At 
the transcriptional level MMP-9 expression is induced by pro-inflammatory 
cytokines through binding to Activator protein 1(AP-1), Nuclear factor-kappaβ (NF-
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κβ) and specificity protein 1(Sp-1) binding sites (McLennan et al., 2007). MMP-9 is 
synthesised as an inactive pro-zymogen which is activated by other MMPs, plasmin 
or neutrophil elastase which remove the pro-peptide and cause disruption of the zinc 
binding site which is essential for its activity. At the post translational level, MMP-9 
activities are regulated by Tissue Inhibitor of Metalloproteinase-1(TIMP-1), which 
binds to the active site and inhibits its degradative activity. In most cell types TIMPs 
are secreted in 1:1 stoichiometry with the MMPs. The exception to this are 
neutrophils which produce and secrete MMP-9 in the absence of TIMPs 
(Opdenakker et al., 2001). The activities of MMP-9 can also be modulated by 
neutrophil gelatinase associated lipocalin (NGAL) or Lipocalin-2, a 25kda secreted 
protein that binds covalently with MMP-9 to form an NGAL/MMP-9 complex to 
stabilise MMP-9 by protecting it from degradation (Chakraborty et al., 2012). 
NGAL like MMP-9 is stored in the primary granules of neutrophils and is secreted 
on activation and degranulation. Neutrophils are a major source of NGAL (Bu et al., 
2006) and it is also involved in the innate immune response, where it is strongly up-
regulated in response to encountering invading bacteria (Grutzner et al., 2004). It has 
also been reported to play a role in cell homeostasis (Gwira et al., 2005). Whether 
NGAL expression is altered in wounds and its association with MMP-9 and 
neutrophils has not been systematically examined in diabetes.  
 
In normal wound healing the highest expression of MMP-9 is seen in the 
inflammatory phase in association with the influx of neutrophils and monocytes and 
its expression is decreased as the wound heals (McLennan et al., 2008). Serra et al. 
have reported increased wound and plasma levels of both NGAL and MMP-9 in 
persons with chronic ulcers including some diabetic persons (Serra et al., 2013) and 
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soluble NGAL and MMP-9 levels have been shown to correlate with the clinical 
course of venous ulcers (Serra et al., 2013). However the effect of diabetes on 
wound fluid NGAL/MMP-9 complex concentration and its association with overall 
wound NGAL and MMP-9 levels have received little attention. We hypothesised 
that the increased activities of MMP-9 in diabetic wounds maybe in part caused by 
induction of inflammatory cell NGAL and NGAL/MMP-9 concentrations.  
 
Wound tissue and cells obtained from two different wound models were studied. 
Using a simple excisional model in diabetic rats we showed decreased wound 
closure and increased expression of MMP-9 and NGAL mainly localised to 
inflammatory cells (Chapters 3 and 4). To more specifically investigate the effect of 
diabetes on inflammatory cells we used a sponge implant wound model. In this 
model PVC sponges (4x1cm
2
) were subcutaneously implanted. At sacrifice, the 
sponges were excised and the contained cells and fluids separated for measurement 
of gene and protein expression. The results of these studies showed, in the absence 
of change in expression of inflammatory markers of Toll-like receptor 4 (TLR4), 
Toll-like receptor 2 (TLR2), and Tumour Necrosis Factor alpha (TNFα), diabetes 
significantly increased NGAL and MMP-8 mRNA and wound fluid NGAL/MMP-9 
complex as well as all forms of MMP-9 (all >2 fold, P<0.05). Soluble NGAL tended 
to be lower (Chapters 3 and 4). Interestingly, in wounds in diabetic animals 
compared to control neutrophil apoptosis as measured by expression of the anti-
apoptotic marker MCL-1 is also delayed.   
 
The effects of insulin treatment (Chapter 3) to regulate blood glucose level, or 
doxycycline (Chapter 4), as a regulator of MMPs, on wound inflammatory cell and 
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circulating neutrophil NGAL and MMP-9 expression was also investigated. In the 
excisional wound model insulin treatment prevented the diabetes associated decrease 
in wound closure. Wound closure was also improved in diabetic animals by 
treatment with 20mg/kg doxycycline. Insulin treatment also normalised the diabetes 
related changes in NGAL gene expression and MMP-9 activity. Doxycycline 
treatment only partially improved NGAL gene expression and had no effect on 
MMP-9 activity.  
 
Whether diabetes altered circulating neutrophil MMP-9, MMP-8 and NGAL 
expression was also studied. In the circulation, compared to control, wounding 
increased the circulating neutrophil number and their activation in diabetic animals. 
The expression of pro-inflammatory markers of TLR4, TLR2, and TNFα was also 
increased. Insulin treatment markedly prevented these changes. The same pattern 
was observed in diabetic group treated with 20 mg/kg doxycycline. In contrast to the 
pattern seen in the circulating neutrophils obtained from unwounded animals, 
neutrophil apoptosis was increased in wounded animals. 
 
In vitro studies (Chapter 3) using isolated neutrophils showed that these changes in 
NGAL and MMP-8 and MMP-9 expression can be induced by glucose treatment 
suggesting a direct effect of glucose on regulation of MMP-9 activity via NGAL and 
also on neutrophil apoptosis.  
 
Two small pilot studies in diabetic people were also performed (Chapter 5). The first 
study showed increased neutrophil activation in those who had a long duration of 
diabetes but were complications free compared to those of similar durations but had 
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developed complications. Results from this study showed NGAL was positively 
associated with neutrophil function. In the second study we examined circulating 
neutrophil activation and MMP-9 expression in association with wound healing in 
patients attending the High Risk Foot Service of the Diabetes Centre of RPA 
Hospital. Results from analysis of samples obtained at the initial visit were 
compared with those obtained from samples obtained at the last visit. The results 
from Pilot study 2 showed that decreased MMP-9 expression was related with 
increased wound closure, indicating the important role of MMP-9 in wound healing. 
Additionally, the increased expression of NGAL was associated with increased 
wound healing rate in the first visit. The results of these two small studies suggest 
increased neutrophil activation in the circulation of diabetic patient in presence or 
absence of wound. In addition, increased plasma NGAL concentration was 
associated with increased NGAL/MMP-9 complex in diabetic patients regardless of 
their complications. 
  
These results from in vitro and in vivo studies as well as human diabetes suggest that 
neutrophil activation is altered in diabetes and interestingly is exacerbated by 
wounding. In addition, in wound tissue and wound inflammatory cells (mainly 
neutrophils) NGAL levels are increased by diabetes. This increase in NGAL is also 
associated with an increase in NGAL/MMP-9 complex formation and higher wound 
fluid MMP-9 activity. Together these observations suggest that in addition to tight 
blood glucose control from the onset of diabetes therapies targeting NGAL and 
MMP activities may have utility in diabetic wound healing.  
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 Diabetes Mellitus  1.1
Diabetes is one of the oldest known human diseases. The ancient Egyptians 
described the clinical symptoms similar to diabetes mellitus 3000 years ago (Rubin, 
2007). Diabetes mellitus is a systemic metabolic disorder characterized by elevated 
blood glucose due to an absolute or relative deficiency of insulin secretion from 
pancreatic beta cells (Leonardi et al., 2003). It is a disease which is causing serious 
problems to society health. It is a leading cause of mortality, morbidity, and early 
disability. The prevalence of diabetes is increasing and has been estimated that from 
1995 to 2025 will be increased by 42% among adults living in the developed world 
and by 170% in adults living in developing countries (Costacou & Mayer-Davis, 
2003). This will lead to an increase in the number of people with diabetes worldwide 
estimated to rise to 366 million by 2030 (Rathmann & Giani, 2004). Diabetes 
mellitus is also a growing public health concern in Australia. It has been reported 
that the number of diabetic individuals is rising and there are currently over 1.5 
million people with diabetes including those who are undiagnosed (Shaw, 2012). 
According to estimates two million Australians have pre-diabetes and are at risk of 
developing diabetes (Health Direct Australia Health Information, 2011). These 
figures mean that there are approximately eight people with diabetes for every 100 
adults. In 2008, a study of Australian children revealed that 5,700 children aged 0-14 
years have diabetes. Assuming that new cases of diabetes in 0-14 year old children 
continues to increase at the rate observed between 2000 and 2008, it is estimated 
that the prevalence rate will increase by 10% between 2008 and 2013 (Australia's 
Health 2014).  
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Diabetes mellitus can be divided into two major types. Type 1 (T1DM) or insulin 
dependent diabetes mellitus, and Type 2 (T2DM) or non- insulin dependent diabetes 
mellitus  (Mohana et al., 2012). Type 1 diabetes can be diagnosed at any age but 
frequently is diagnosed from infancy to the late 30s.  This type of diabetes is 
primarily caused by autoimmune pancreatic β cell destruction and is characterized 
by an absolute insulin deficiency.  
 
Type 2 diabetes mellitus which has been increasing alarmingly worldwide is 
characterized by reduced insulin secretion in response to glucose and insulin 
resistance which ultimately leads to the inefficient absorption of glucose into the 
cell. Insulin resistance is a risk factor for development of diabetes and heart disease. 
It is present in 90% of the people who are diagnosed with diabetes and affects 18% 
of the population above 65 years of age (Inzucchi et al., 2015; Mohana et al., 2012).  
 
 Despite all treatments for reduction of hyperglycemia such as insulin, metformin, 
glibenclamide, diabetes is associated with major complications which affect almost 
all organs including heart, kidney, eyes, liver, and vessels. Another important but 
less well-known complication of diabetes is impaired wound healing. This 
complication affects 10-15% of all people with diabetes. Non-healed ulcers often 
require hospitalisation and in some cases fail to heal and can lead to amputation. 
This failure to heal precedes 84% of all diabetes-related lower-leg amputation (Brem 
& Tomic-Canic, 2007) and those who have an amputation are more likely to die 
within the next 5 years than those with no amputation (Brod, 1998; Nabuurs-
Franssen et al., 2005). The prevalence of foot ulcer is greater for diabetic individuals 
diagnosed at age less than 30 years and it is slightly higher in men than in women. 
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The prevalence increases with age, especially in diabetic patients diagnosed at age 
less than 30 years (Palumbo & Melton, 1995; Wu et al., 2007). Despite the 
prevalence of this condition the pathophysiology of poor wound healing in diabetes 
is not well understood and an aspect of this is the focus of the research described in 
this thesis. 
 
 Diagnostic criteria of diabetes mellitus  1.1.1
Based on the reports from the World Health Organization (WHO) National diabetic 
group criteria of 2006, in a normal individual, the fasting blood glucose 
concentration in most mammals is between 4.5-5.5 mmol/l. Irrespective of the type 
of diabetes, individuals with a fasting blood glucose concentration greater than 7.0 
mmol/l (126 mg/dl) or a non-fasting blood glucose concentration of 11.0 mmol/l 
(200 mg/dl) or higher are considered as having diabetes (Olokoba et al., 2012).  
 
 Metabolic Pathways Altered by Diabetes 1.1.2
Hyperglycemia causes tissue damage through some main mechanisms including: 1) 
increased flux of glucose and other sugars through the polyol pathway 2) increased 
intracellular formation of advanced glycation end products (AGEs) and expression 
of their receptors 3) activation of protein kinase (PKC) isoforms and 4) increased 
activity of the hexosamine pathway (Giacco & Brownlee, 2010). Each of these 
mechanisms will be discussed briefly in the following sections.  
 
 Increase polyol pathway flux 1.1.2.1
The polyol pathway of glucose metabolism becomes active when intracellular 
glucose levels are elevated (Lorenzi, 2007). The activity of aldose reductase, a rate 
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limiting enzyme in the pathway, converts glucose to sorbitol using nicotinamide 
adenine dinucleotide phosphate (NADPH) as a cofactor. Sorbitol is then metabolised 
to fructose by sorbitol dehydrogenase in a process that uses nicotinamide adenine 
dinucleotide (NAD+) as a cofactor (Brownlee, 2001; Lorenzi, 2007) shown 
schematically in Figure 1-1. The polyol pathway activation results in an increase of 
intracellular sorbitol, and fructose both of which are 10 times more potent glycation 
agents than glucose. Intracellular accumulation of sorbitol can also result in osmotic 
stress which damages proteins via oxidation reactions (Forbes & Cooper, 2013). 
NADPH is required for regeneration of reduced glutathione (Brownlee, 2001). As 
glutathione functions as a direct free-radical scavenger, as well as a co-substrate for 
glutathione peroxidase activity, and a cofactor for many other enzymes (Waggiallah 
& Alzohairy, 2011) these events could induce or impair intracellular oxidative stress 
(Brownlee, 2001). This increased oxidative stress and production of free radicals 
results in activation of inflammatory pathways and is thought to be one of the major 
reasons why diabetes complications including poor wound healing develop and 
progress (Maritim et al., 2003). 
 
 
Figure ‎1-1: Hyperglycemia increases flux through the polyol pathway.  
Adapted from (Tang et al.,  2012).  
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 Increased formation advanced glycation end-products (AGEs) 1.1.2.2
The accumulating metabolites from the polyol pathway result in the formation of AGEs 
(Lorenzi, 2007). AGEs are formed continuously in the body and the rate of 
formation are markedly increased in the presence of hyperglycemia and increased 
oxidant stress (Peppa & Vlassara, 2005). AGEs are formed by the non-enzymatic 
reaction of glucose and other glycating compounds derived both from glucose and 
from increased fatty acid oxidation with proteins (Giacco & Brownlee, 2010).  
 
As shown in Figure 1-2, AGEs can modify cells and their matrix. With regard to the 
matrix, AGE precursors modify matrix to cause them to interact abnormally with 
other matrix components as well as cell membrane bound molecules such as 
integrins (Giacco & Brownlee, 2010). Modification of plasma proteins by AGE 
precursors also creates ligands that bind to AGE receptors (RAGE) and induce 
changes in gene expression (Brownlee (M, 2001). Increased amounts of AGEs are 
also found in long lived proteins such as collagens which are found in the 
extracellular matrix. This can accelerate collagen cross-linking which for example 
contributes to myocardial stiffness in people with diabetes (Candido et al., 2003). 
AGEs and their receptors negatively affect various aspects of the abnormal 
inflammatory response in the diabetic wound. AGEs induce the production of 
oxygen-reactive intermediates from inflammatory and endothelial cells via NADPH 
activation leading to increased proinflammatory cytokine expression and persistent 
inflammatory phase in a diabetic wound-healing process (Berlanga et al., 2005). 
RAGEs are multi-ligand receptors which bind not only to AGEs but bind several 
ligands to mediate their biologic effects. These ligands include high mobility group 
box 1 protein (HMGB1), the group of calcium binding cellular factors S100, 
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amyloid beta peptides and Macrophage-1 antigen (Mac-1) (Mosquera, 2010). RAGE 
is expressed on several cell types such as monocytes/macrophages (Ohashi et al., 
2010) endothelial cells (Pollreisz et al., 2010), fibroblasts (Liu et al., 2010), and 
keratinocytes (Zhu et al., 2012). Ligation of RAGE by AGEs can directly induce 
generation of reactive oxygen species (ROS) and the up-regulation of inflammatory 
pathways and activate the NF-κB, causing multiple pathological changes in gene 
expression (Giacco & Brownlee, 2010) ultimately leading to inflammation 
(Mosquera, 2010) and diabetic complications (Bierhaus et al., 2001). RAGEs are 
highly expressed in a number of diabetic tissues, including blood vessels, 
atherosclerotic lesions, infected periodontal tissue, and glomeruli (Tanji et al., 
2000). Blockade of RAGE restores physiological migration of inflammatory cells 
(Goova et al., 2001). Induction of type IV collagen by AGEs is mediated by RAGE 
can be blocked in cells by anti-RAGE ribozyme (Tsuji et al., 1998). Blockage of 
RAGE has also been shown to suppress levels of TNFα, interleukin-6, and MMPs-2, 
-3, and-9 (Goova et al., 2001). Many strategies have been tried to either impair AGE 
formation or to decrease cross-linking of longer-lived proteins. These strategies have 
not been pursued, as they have been largely ineffective. 
8 
 
 
 
Figure ‎1-2: Increased production of AGE precursors and its pathologic consequences.  
Covalent modification of intracellular proteins by dicarbonyl AGE precursors 
alters several cellular functions. Modification of extracellular matrix p roteins 
causes abnormal interactions with other matrix proteins and with integrins. 
Modification of plasma proteins by AGE precursors creates ligands that bind 
to AGE receptors, inducing changes in gene expression in endothelial cells, 
mesangial cells and macrophages. Adapted from(Brownlee, 2001) 
 
 
 Activation of protein kinase C (PKC) 1.1.2.3
PKC is a family of protein kinase enzymes which is comprised of a group of related 
serine/threonine kinases involved in controlling the function of other proteins (Koya, 
2014; Mochly-Rosen et al., 2012). PKC is a calcium and phospholipid dependent 
enzyme which is activated by a variety of signals including increases in the 
concentration of diacylglycerol (DAG) or calcium ions. Therefore; PKC enzymes 
play important roles in several signal transduction cascades. With regard to diabetic 
complications they have an important role in microvascular complications in 
particular retinopathy, nephropathy, and neuropathy (Mochly-Rosen et al., 2012). As 
shown in Figure ‎1-3 activation of PKC contributes to increased microvascular 
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matrix protein accumulation by induction of expression of Transforming Growth 
Factor beta 1(TGF-β1), fibronectin and type IV collagen (Brownlee, 2001; Koya et 
al., 1997). This activation causes a variety of pathologies involved in the 
development of diabetic complications such as cytokine activation and inhibition, 
vascular alterations, abnormal angiogenesis, increased risk of insulin resistance, and 
glucose intolerance (Mochly-Rosen et al., 2012). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure ‎1-3: Consequences of hyperglycemia-induced activation of PKC.  
Hyperglycaemia increases diacylglycerol (DAG) content, which activates PKC, 
primarily the β- and δ-isoforms. Activation of PKC has a number of pathogenic 
consequences by affecting expression of endothelial nitric oxide synthetase 
(eNOS), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), 
transforming growth factor-β (TGF-β) and plasminogen activator inhibitor -1 
(PAI-1), and by activating NF-κB and NAD(P)H oxidases. Adapted from 
(Brownlee, 2001). 
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 Increased hexosamine pathway activity 1.1.2.4
In the hyperglycemic milieu most of glucose is metabolized through the glycolysis 
pathway. As shown in Figure ‎1-4 if glucose is in excess some fructose-6-phosphate is 
diverted into a signaling pathway and converted to glucosamine-6-phosphate and 
uridine diphosphate (UDP) N-acetyl glucosamine by glutamine fructose-6 phosphate 
amidotransferase (GFAT) (Brownlee, 2001). In aortic endothelial cells hyperglycemia 
can activate the hexosamine pathway via its effect on mitochondrial superoxide (Du et 
al., 2000). In mesangial cells flux of glucose through this pathway can to increase TGF-
β and lead to increased matrix production (Kolm-Litty et al., 1998).  
 
 
Figure ‎1-4: Hyperglycemia increases flux through the hexosamine pathway. 
The glycolytic intermediate fructose-6-phosphate (Fruc-6-P) is converted to 
glucosamine-6-phosphate by the enzyme glutamine: fructose-6-phosphate 
amidotransferase (GFAT). Intracellular glycosylation by the addition of N -
acetylglucosamine (GlcNAc) to serine and threonine is catalysed by the 
enzyme O-GlcNAc transferase (OGT). Increased donation of GlcNAc moieties 
to serine and threonine residues of transcription factors such as Sp1, often at 
phosphorylation sites, increases the production of factor s as PAI-1 and TGF-
beta1. AZA, azaserine; AS-GFAT, antisense to GFAT. Adapted from Brownlee, 
2001). 
 
11 
 
 Complications Associated with Diabetes 1.1.3
With the frequency and occurrence of diabetes increasing, so are the diabetes related 
complications. Despite a variety of treatments to improve blood glucose control, 
chronic hyperglycemia is associated with impaired lipid and lipoprotein metabolism, 
increased oxidative stress, inflammation, vascular endothelial dysfunction and 
hypertension (Forbes & Cooper, 2013). As mentioned these metabolic changes can 
lead to the development of long-term pathogenic conditions such as micro vascular 
complications, involving damage to small blood vessels, and macro vascular, 
damage to the arteries (Forbes & Cooper, 2013; Mogensen, 2000). These 
pathological changes contribute to an increased risk for development of chronic 
disease such as atherosclerosis, coronary heart disease, stroke, peripheral vascular 
disease, hypertension (Selvin et al., 2006) eye disease, and kidney failure (Forbes & 
Cooper, 2013). Diabetic patients also have higher risk of poor wound healing and 
limb amputation. Neuropathy, vasculopathy and immunopathy are all implicated in 
the poor healing of diabetic foot ulcers (Hobizal & Wukich, 2012). Other risk 
factors like infection, smoking and ischemia also contribute to impaired wound 
healing ability in diabetic foot ulcers (Leung, 2007). As the focus of the work 
described in this thesis is poor wound healing, factors such as neuropathy and 
peripheral vascular disease which are associated with delayed wound healing in 
diabetes will be discussed in more detail in the following sections.  
 
 Diabetic neuropathy 1.1.3.1
Neuropathy or poor nerve function occurs in both types of diabetes and is 
characterised by changes to cellular and non-cellular components of the nervous 
system. Neuropathy affects the central and peripheral nervous system and is more 
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common with increasing age and longer duration of diabetes (Farmer et al., 2012). 
Ischemia as a result of poor blood supply has been implicated in the 
pathophysiology of diabetic neuropathies and it results in axon loss and 
demyelination of nerves in these subjects. In addition to direct effects on the nerve, 
ischemia affects the growth of blood vessels which can also impair nerve fibres 
function (Levin, 2002). Irrespective of the cause, ischemic neuropathy is dominated 
by pain or sensory loss and weakness in peripheral nerves (Armstrong et al., 1998; 
Hirsch et al., 2001).   
 
Most diabetic patients have painful neuropathic symptoms and loss of sensation. 
This loss of sensation can result in a lack of recognition of trauma. This can then 
contribute to progressive worsening of the injury and by this mechanism contribute 
to poor wound healing (Clayton & Elasy, 2009). Painful neuropathy occurs in the 
16-34% of people with diabetes and the prevalence of this type of neuropathy is 
greater in those with T2DM (Abbott et al., 2011). Several of the previously listed 
mechanisms are involved in the development of diabetic neuropathy. Including 
increased activity of the polyol pathway, formation of AGEs, activation of PKC, 
enhanced modification of proteins with N-acetylglucosamine via the hexosamine 
pathway. Other factors such as increased inflammation, and a reduction in 
neurotrophic factors are also involved (Farmer et al., 2012).  
 
Pro-inflammatory cytokines produced from lymphocytes, macrophage, neurons, and 
Schwann cells can all cause damage to peripheral nerves (Hur et al., 2011). In 
diabetic nerves an increased inflammatory response has been reported to lead to 
excessive injury to the axons and Schwann cell via activation of downstream 
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pathways such as NF-κB (Wang et al., 2006). Proteases, among them the MMPs, 
have also emerged as important modulators of non-neuronal pain pathways. 
Amongst the MMPs cellular expression of MMP-9 and MMP-2 is involved in 
generation and maintenance of neuropathic pain through degenerative and pro-
inflammatory mechanisms (Zhang et al., 2011).The MMPs stimulate the generation 
of chemokines and cytokines (Cross et al., 1999) such as IL-β and TNF-α, that in 
turn activate chemokine and cytokine receptors on microglia and astrocytes. 
Activation of these receptors stimulates MAPK and NF-κB pathways to finally up-
regulate the synthesis of IL-β, TNFα, and Interleukin-6 (IL-6) in the microglia (Ji & 
Suter, 2007). After nerve damage, the Schwann cells release MMP-9, initiating 
macrophage infiltration and degradation of myelin basic protein (Kobayashi et al., 
2008). Inhibition of MMP-9 activity has been shown to reduce neuropathic pain 
without systemic effects (Kawasaki et al., 2008).  
 
 Peripheral vascular disease  1.1.3.2
Peripheral vascular disease means blockage of the larger arteries in the thigh and leg 
causing a reduction in blood circulation and in particular limb ischemia. It can occur 
in individuals without diabetes but is more common and more severe in people with 
diabetes (Jude et al., 2010) and is increased by age, duration of diabetes, and 
presence of peripheral neuropathy. The most common symptom of peripheral 
vascular disease is cramping, or aching in the thighs, or buttocks that appears 
reproducibly with walking exercise and is relieved by rest (Sheehan, 2004).  As 
mentioned poor blood supply can exacerbate neuropathy and in addition can 
decrease flow of important cells to and from the wound site to either commence 
repair or assist with remodelling.   
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  The Normal Wound Repair Process 1.1.4
To understand the mechanisms involved in poor wound healing, it is helpful to first 
review the normal response to injury. The pathways involved in each of the three 
distinct but overlapping phases of the normal wound healing response will be 
discussed in more detail in the following section. 
 
As shown in Figure ‎1-5 wound healing is a complicated process involving 
communication and interaction between multiple cell types including fibroblasts, 
endothelial cells, keratinocytes, inflammatory cells, and the extracellular matrix 
(Whelan et al., 2005). In normal physiological conditions the wound healing process 
can be divided into 3 overlapping but distinct phases including: hemostasis and 
inflammation, proliferation/matrix deposition, and the remodelling phase. Within 
these three broad phases is a complex and coordinated series of events that includes 
chemotaxis, phagocytosis, production of new collagen and glycosaminoglycans and 
proteoglycans, proteolytic degradation of ECM as well as collagen remodelling and 
re-epithelialization (Masre et al.; Velnar et al., 2009). Disruption of the sequence of 
these interactions can impair the orderly wound healing process resulting in a delay 
in healing (Whelan et al., 2005). Many factors can interfere with this process some 
of these which are particularly relevant to those with diabetes are inflammatory 
disease, poor blood flow and age (Guo & DiPietro, 2010). 
 
Wounds, irrespective of their cause can be categorised as acute or chronic based on 
the timeliness of healing. Acute wounds include surgical incisions and traumatic 
injuries such as lacerations, abrasions, avulsions, penetrations or bites, and burn 
injuries. Acute wounds normally precede through an orderly and timely reparative 
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process which results in sustained restoration of anatomic and functional integrity 
(Nicks et al., 2010).  In contrast chronic wounds such as: diabetic foot ulcers, venous 
leg ulcers, and pressure ulcers do not heal in a predictable time frame  (Nicks et al., 
2010). The most common causes of chronic wounds are vascular insufficiency, 
diabetes mellitus, and local-pressure effects (Eming et al., 2014). Compared with 
acute wounds, chronic wounds contains higher levels of pro-inflammatory cytokines 
such as IL-1β and TNFα (Tarnuzzer & Schultz, 1996) and lower levels of growth 
factors including TGF-β, Vascular Endothelial Growth Factor (VEGF), Platelet-
Derived Growth Factor (PDGF) (Schonfelder et al., 2005). This imbalance between 
tissue deposition stimulated by growth factors, and tissue destruction mediated by 
proteases is thought to lead to impaired wound healing (Cullen et al., 2002). Another 
factor which can impair wound healing is the presence of bacteria (Guo & DiPietro, 
2010). Delay caused by bacterial presence is likely due to the release of 
lipopolysaccharides present in membranes of gram-negative bacteria. 
Lipopolysaccaharides have been shown to reduce migration of keratinocytes across 
the wound surface and thus delay wound closure (Thamm et al., 2013).  
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Figure ‎1-5: A schematic diagram of normal wound healing (Mendes et al. 2012)
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 The inflammatory phase of healing 1.1.4.1
Within minutes after the initial injury, platelets invade the wound area and form a 
clot by releasing thrombin, which cleaves fibrinogen and forms a cross linked 
network of fibrin fibres which covers the wound area and protects it from further 
external injury (Wolberg, 2007). During the beginning of the inflammatory phase 
i.e. within 24-36 hours of injury, neutrophils which mediate the first line of defence, 
enter the wound area (Eming et al., 2007). They produce a variety of growth factors 
including VEGF which can promote re-vascularisation and tissue repair (Dovi et al., 
2004). As neutrophils play a key role in inflammation and wound healing and are 
studied in detail in this work, neutrophil structure and function and their role in 
wound healing will be discussed in more detail in a later section (section ‎1.1.6). 
 
The next inflammatory cell type that enters the wound are the macrophages, which 
produce initially pro-inflammatory and after some delay anti-inflammatory 
cytokines (Rodero & Khosrotehrani, 2010). They are attracted to the site of 
inflammation by chemotactic factors such as migration inhibitory factor, 
lymphocyte-derived chemotactic factor, macrophage activating factor, and 
macrophage stimulatory protein. Once in the wound, macrophages play a role in 
host defence, the promotion and resolution of inflammation, the removal of 
apoptotic cells, and the support of cell proliferation and tissue restoration (Koh & 
DiPietro, 2011). The phagocytosis of apoptotic neutrophils or other cells induces an 
anti-inflammatory phenotype in the macrophage. At the same time the macrophages 
release TGF-β and reduce their production of pro-inflammatory mediators such as 
TNF-α (Thomson et al., 2010). As a result in healing wounds the macrophages 
present can be a mixture of M1-like macrophages which are pro-inflammatory and 
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are characterised by the production of TNF-α, Interleukin-1 (IL-1) and IL-6 or M2-
like macrophages, which secrete fewer pro-inflammatory cytokines and assist in 
tissue repair and are characterised by their expression of IL-10 (Koh & DiPietro, 
2011). After the inflammatory cells enter the wound the deposition of granulation 
tissue commences with the appearance of fibroblasts and endothelial cells and the 
formation of capillaries in the wounded area (Eming et al., 2007). 
 
 The proliferative phase of wound healing 1.1.4.2
The proliferative phase starts approximately 3 days after wounding and continues 
for about 2 weeks. In the proliferative phase, re-epithelialization which involves the 
proliferation and migration of epithelial cells across the wound surface commences 
(Gary Sibbald & Woo, 2008). This phase is also marked by the formation of 
granulation tissue which includes a variety of cell types like inflammatory cells, 
fibroblasts and endothelial cells. New blood vessel formation commences and a 
matrix of fibronectin, collagen, glycosaminoglycans, and proteoglycans is laid 
down. The fibroblasts and myofibroblasts migrate into wound site in response to 
factors such as TGF-β and PDGF secreted or released by inflammatory cells and 
platelets (Goldman, 2004).  MMPs are secreted by a number of cell types including 
inflammatory cells, endothelial cells and fibroblasts. The increase in MMPs enables 
and facilitates cell migration, proliferation and angiogenesis and they can also 
modify inflammatory reactions (Baum & Arpey, 2005).  
 
As mentioned the growth of new blood vessels occurs at this stage. This process 
results in greater blood flow to the wound and therefore, increased perfusion of 
factors necessary to heal the wound. This process is stimulated by macrophage 
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activity as well as the tissue hypoxia resulting from the disruption of blood flow at 
the time of injury (Oike et al., 2004). The increase in MMP expression is stimulated 
by inflammatory cytokines such as TNF-α and interleukins (Siasos et al., 2012). 
MMPs also induce the release of ECM bound pro-angiogenic factors, including the 
release of VEGF from endothelial cells (Mazor et al., 2013) a process which also 
stimulates capillary growth (Mazor et al., 2013; Ucuzian et al., 2010).  
 
 The remodelling and maturation phase of wound healing  1.1.4.3
Following robust proliferation and ECM synthesis, wound healing enters the final 
remodelling and maturation phase at about 21 days after injury. This phase can last 
for many months, or even years in complex wounds (Flanagan, 2000). This is the 
final phase and it occurs once the wound has closed. It is responsible for the 
development of new epithelium and final scar tissue formation (Takeo et al., 2015). 
It involves remodelling of collagen from the less highly cross linked type III 
collagen to the more highly crosslinked type I collagen (Ramasastry, 2005). 
Fibronectin gradually disappears and hyaluronic acid and glycosaminoglycans are 
replaced by proteoglycans. Cellular activity reduces and the numbers of blood 
vessels in the wounded area regress and decrease (Ramasastry, 2005). One critical 
feature of the this phase is the remodelling of the ECM to an architecture that 
approaches that of the normal tissue (Campos et al., 2008). 
 
As mentioned previously, chronic wounds are caused by multiple factors in 
particular pressure sores, diabetic ulcers, and venous ulcers which are responsible 
for 70% to 90% of all leg ulcer cases (Mustoe, 2004). The focus of the work 
described in this thesis is impaired wound healing in diabetes and for this reason 
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factors known to be involved in poor wound healing in diabetes will be discussed in 
more detail in the following section.  
 
 Diabetes and Poor Wound Healing 1.1.5
Insufficient angiogenesis (Lim et al., 2015) disturbances in collagen metabolism and 
deposition  (Lee et al., 2015)  and decreased immune function (Takeo et al., 2015) as 
well as increased bacterial load all contribute to the delay in healing in diabetes (Xu 
et al., 2007). In addition to these factors which affect cellular function, diabetes 
specific changes in nerve function, peripheral blood supply, callus formation and 
excessive pressure to the site can all exacerbate the problem (Falanga, 2005).   
 
As mentioned (Section ‎1.1.2) the diabetic milieu affects multiple cellular pathways 
with downstream effects on cellular function. Of importance to this work is the 
effect of diabetes on inflammatory cell function in particular neutrophils. Diabetes is 
known to cause defective T-cell immunity, defects in leukocyte chemotaxis, 
phagocytosis, and bactericidal capacity (Eming et al., 2014). With regard to wound 
healing, wounds in diabetic patients show decreased early inflammatory cell 
infiltration but increased numbers of neutrophils and macrophages in the later stages 
(Wetzler et al., 2000). The initial inflammatory phase is associated with immediate 
and rapid infiltration of neutrophils into the wound. Their main function at the 
wound site involves protection against micro-organisms and destruction of 
contaminating bacteria by phagocytosis (Flanagan, 2000). Clinical investigations of 
circulating neutrophil from diabetic patients and experimental studies using diabetic 
rats and mice have clearly demonstrated a deficiency in neutrophil activation and 
function including neutrophil phagocytosis (Lin et al., 2006), adhesion to the 
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endothelium and migration to the inflammatory sites (Chanchamroen et al., 2009), 
production of pro-inflammatory cytokines (Alba-Loureiro et al., 2007) and 
bactericidal activity (Kewcharoenwong et al., 2013).  
 
In addition to alterations in neutrophil function diabetes can also impair macrophage 
function. In particular, in normal wounds the M1 macrophage phase is shorter than 
the phase with M2 macrophages. This is important as the switch from the M1 to M2 
phenotype, characterised by increased delivery of TGF-β, promotes granulation 
tissue formation angiogenesis, and re-epithelialization. In diabetic wounds there is 
prolonged M1 macrophage presence, which delays influx of M2 macrophages and 
ultimately healing (Khanna et al., 2010). For example, in non-healing diabetic 
wound tissues, increased pro-inflammatory cytokines such as TNFα and Interleukin-
6 (IL-6) and decreased anti-inflammatory cytokines such as IL-10 are observed 
(Khanna et al., 2010; Wetzler et al., 2000). Whether this delay in progression of 
macrophage phenotype from a pro-inflammatory to an anti-inflammatory phenotype 
is due to altered neutrophil function in diabetic wounds is not known. 
 
The increased level of pro-inflammatory cytokines has downstream effects to further 
exacerbate the pro-inflammatory environment by phosphorylation of inhibitor ĸB to 
cause translocation of NF-ĸB to the nucleus. Intracellular NF-ĸB can then induce the 
transcription of pro-inflammatory cytokines, adhesion molecules, chemokines and 
enzymes generating ROS (Dandona et al., 2002). These changes lead to sustained 
expression of chemokines such as Chemokine Ligand 2 (CCL2) that can lead to 
prolonged infiltration of leukocytes during impaired healing in diabetes (Wetzler et 
al., 2000).  
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Increased activation of the Toll like receptor (TLR) pathway is another factor which 
can contribute to poor wound healing. Persistent activation of TLRs is associated 
with increased levels of cytokines such as IL-1, IL-8 which can contribute to the 
non-healing of venous leg ulcers (Dunne et al., 2011).TLRs are present on immune 
cells such as macrophages, neutrophils, and dendritic cells. TLRs-1–6 recognise 
bacterial and fungal components on the cell surface whereas TLR3 recognises 
intracellular viral double-stranded RNA, viral single-stranded RNA are recognised 
by TLR7 and TLR8, and microbial DNA by TLR9 (Dasu & Isseroff, 2012). 
Increased expression of TLR2 mRNA and protein and TLR4 has been described in 
diabetic wounds and are thought to contribute to the prolonged inflammation. TLR2 
absence is associated with reduced inflammation and improved wound healing 
(Dasu et al., 2010) and increased TLR4 has been shown to alter microvascular 
leakage and leukocyte adhesion (Breslin et al., 2008). 
 
 Neutrophils and Wound Healing 1.1.6
 Neutrophil structure and function 1.1.6.1
Neutrophils are short-lived leukocytes which undergo rapid programmed cell death 
both in vitro and in vivo. The number of neutrophils varies across the species and is 
affected by age. For example in humans approximately 50-70% of blood cells are 
neutrophils whereas in mice this number is 10-25% (Mestas & Hughes, 2004). In 
addition to being different in number the circulatory half-life of neutrophils also 
varies between species. It is difficult to exactly measure the half-life of neutrophils 
and as a result it is controversial with some reports suggesting 1.5 hours in mice and 
8 hours in human (Galli et al., 2011) and others 12.5 hours for mice and up to 5.4 
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days for humans (Pillay et al., 2010). Nevertheless, the half-life for mice neutrophil 
is less than that observed for human neutrophils.  
 
Neutrophils are produced within the hematopoietic cords interspersed within the 
venous sinuses of the bone marrow at a rate of roughly 1 × 10
9
 cells per kilogram 
body weight per day (Borregaard, 2010). Their proliferation is driven by multiple 
factors including Granulocyte Colony Stimulating factor (G-CSF), which is 
produced in response to Interleukin-17A synthesized by T cells (Ley et al., 2006).  
 
Shown in Figure ‎1-6 neutrophil precursors originate in the bone marrow and undergo 
differentiation in the blood. During maturation, neutrophils progress through several 
stages including; promyelocyte, neutrophilic myelocyte, neutrophilic metamyelocyte 
and finally to a segmented or polymorphonuclear neutrophil (Kolaczkowska & 
Kubes, 2013; Nathan, 2006). 
 
Figure ‎1-6: Neutrophil maturation and granule formation.  
Adapted from (Wilgus et al., 2013) 
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Neutrophils are markedly different to other inflammatory cells as they contain a 
number of granules. These granules, in addition to contributing to their distinctive 
morphologic appearance, are critical for the neutrophil’s inflammatory functions. 
The neutrophil granules can be classified on the basis of their size, morphology, 
electron density or presence of characteristic granule proteins. According to a review 
by Borregaard & Cowland, 1997 there are three types of granules and one secretory 
vesicle which are formed sequentially during the neutrophil granulocytic 
differentiation process (Kolaczkowska & Kubes, 2013). All granule subsets share 
common structural features such as a phospholipid bilayer membrane and an 
intragranular matrix which contains proteins destined for exocytosis or delivery to 
the phagosome (Faurschou & Borregaard, 2003). 
 
The peroxidase-positive or primary granules azurophilic granules are large, round, 
and electron dense. They contain toxic mediators such as Myeloperoxidase (MPO), 
elastase, lysozyme, cathepsin G and acid hydrolases. This type of granule is formed 
in the promyelocytes (Hager et al., 2010). They are a source of enzymes for 
digestive and bactericidal functions and supply MPO to the MPO-halide-hydrogen 
peroxide bactericidal system. These enzymes also regulate inflammation by 
degrading inflammatory products (Faurschou & Borregaard, 2003). 
 
Peroxidase-negative or secondary/specific granules are smaller than primary 
granules and are electron lucent. They contain collagenase, gelatinase, NGAL, 
lactoferin and lysosomes. The specific granules also appear to be necessary for 
neutrophil recruitment to sites of inflammation, for upregulation of receptors, 
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important in the control of chemotaxis and the respiratory burst, for bactericidal 
activity, and for chemoattractant generation (Falloon & Gallin, 1986). 
 
Gelatinases are also contained in gelatinase or tertiary granules that also considered 
being peroxidase-negative granules. These granules are defined by their high 
concentration of gelatinase.  
 
 Secretory vesicles constitute a reservoir of membrane-associated receptors needed 
at the earliest phases of the neutrophil-mediated inflammatory response. Their 
membranes are rich in the β2-integrin CD11b/CD18 which was discovered in a 
systematic search for organelles that could explain the extensive and rapid 
upregulation of CD11b ⁄ CD18 in response to stimulation with fMLP or other 
chemoattractants (Hager et al., 2010). Shown in Table ‎1-1 are the contents of the 
different types of neutrophil granules (Borregaard & Cowland, 1997). Of particular 
relevance to the work described in this thesis, NGAL is located in the specific 
granules, whilst MMP-9 is located in both specific and gelatinase granules. 
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Table ‎1-1: the content of the different types of neutrophil granules 
Azurophic granules Specific granules Gelatinase granules 
Secretory 
vesicles 
Membrane 
components: 
 
CD63 
CD68 
V-typeH-ATPase 
 
Matrix components: 
 
MPO 
Lysosome 
Heparin binding 
protein 
Low molecular weight 
cationic proteins 
Acid hydroease 
Neutral protease 
Elastase 
Myeloperoxidase 
Proteinase 
Membrane 
components: 
 
CD11b 
CD66 
CD67 
fMLP− R 
Fibronectin-R 
G-protein α-subunit 
 
Matrix components: 
 
Collagenase 
Gelatinase (MMP-9) 
NGAL 
Histaminase 
Heparanase 
Lysosome 
Lactoferrin 
 
Membrane 
components: 
 
CD11b 
Cytochromeb 
fMLP− R 
VAMP-2 
 
Matrix components: 
 
Gelatinase (MMP-9) 
Lysosome 
Plasminogen 
activator 
 
Membrane 
components 
 
Alkaline 
phosphatase 
CD11b 
CD14 
CD16 
fMLP-R 
CD10, CD13, 
CD45 
 
Matrix 
components: 
 
Plasma proteins 
including 
tetranectin 
Adapted from (Borregaard & Cowland, 1997)  
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As mentioned previously neutrophil apoptosis is not only important for neutrophil 
production but also increasingly recognised to play a critical role in neutrophil 
function (Scannell et al., 2007). During neutrophil apoptosis, increased expression of 
apoptosis markers such as annexin mark the cell for phagocytosis by macrophages, 
an action which prevents dispersal of their toxic contents (Li et al., 2003). 
Additionally, the apoptosis of neutrophils is essential to wound repair as it 
stimulates macrophages to become more anti-inflammatory and to secrete TGF-β1 
which is important for myofibroblast differentiation and formation of ECM (Eming 
et al., 2007). Additionally, neutrophil apoptosis can inhibit the activities of activated 
neutrophils (Koedel et al., 2009).  
 
 Neutrophils and inflammation 1.1.6.2
Neutrophils play an important role in the innate immune response and are the first 
leukocyte to arrive at the inflammatory site. They have a special role in host 
defence, immune regulation, and in the regulation of inflammation (Houreld, 2014). 
The migration of neutrophils from the circulation to the site of inflammation is 
controlled by their interactions with the vascular endothelium. During rolling under 
inflammatory conditions, neutrophils are activated by ligation of G-protein coupled 
receptors with chemokines. They also receive signals via the engagement of 
adhesion molecules including the selectins, a family of cell adhesion molecules, and 
β2 integrin (Ley, 2002). MMPs such as MMP-9 and MMP-8 are also induced in 
response to inflammation (Nissinen & Kahari, 2014).They assist neutrophil 
migration from the blood stream across basement membrane to the site of 
inflammation (Lin et al., 2008) by degradation of ECM. MMP driven proteolysis 
can also affect the biological functions of chemokines and cytokines. Shedding and 
28 
 
release of TNFα and activation of pro-IL-β are examples of how MMPs might 
influence an inflammatory reaction by modulating cytokines (Lin et al., 2008). Other 
proteases such as elastase also contribute to this process by cleaving the pro-
gelatinase to its biologically active form (Delclaux et al., 1996). 
 
As shown in Figure ‎1-7 activation of neutrophils in response to inflammation 
increases their longevity by several fold (Colotta et al., 1992; Summers et al., 2010). 
Increased levels of ROS, acute phase proteins, pro-inflammatory cytokines, and 
fatty acids can all prime neutrophils (Hatanaka et al., 2003). This priming process 
ensures the presence of neutrophils at the site of inflammation and contributes on the 
one hand to the regulation of host resistance and resolution of inflammation. On the 
other hand as discussed earlier persistence of neutrophil in the tissue may lead to cell 
injury by activation of neutrophil and increased secretion of cytokines such as 
interleukins (IL-1, IL-6, IL-8, IL-12, IL-10), TNFα and interferon gamma (IFN-γ) 
(Cowburn et al., 2005). Cytokines such as IL-1β, TNFα, IFN-γ, G-CSF, 
Granulocyte-macrophage colony-stimulating factor (GM-CSF), and bacterial 
products have been shown to prolong neutrophil survival by inhibition of apoptosis 
(Colotta et al., 1992; Kolaczkowska & Kubes, 2013).  
.  
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Figure ‎1-7: Neutrophils and inflammation 
Resting neutrophils can become primed by agents that include bacterial 
products and cytokines or chemokines, e.g. TNF-a and primed neutrophils are 
then mobilized to the site of infection or inflammation. Activated neutrophils 
produce MMP-8 and MMP-9 and consequently increase destructive functions 
of MMPs.  
 
 
Whether these processes occur in neutrophils in diabetes is not certain. Some studies 
have shown that a high glucose environment can increase neutrophil apoptosis 
(Peleg et al., 2007). Whilst other studies investigating the effect of high glucose 
concentration in combination with exposure to Lipopolysaccharide (LPS) have 
shown a reduction in the number of apoptotic neutrophils (Tennenberg et al., 1999). 
In these later studies of neutrophils obtained from diabetic patients, LPS induced the 
production of the anti-apoptotic cytokines IL-8, IL-10 (Glowacka et al., 2002). 
Another study has shown that decreased glutamine utilisation can contribute to an 
increased rate of apoptosis in neutrophils from diabetic patients (Alba-Loureiro et 
al., 2007). Interestingly, and of relevance to this work the neutrophils used in these 
studies are circulating neutrophils obtained from people with diabetes but who do 
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not have a wound. Whether wound presence affects circulating neutrophil profile 
and additionally whether neutrophils obtained from a wound environment are altered 
in diabetes has not as yet been studied. 
 
 Neutrophils and delayed wound healing in diabetes 1.1.6.3
Neutrophils are essential for the wound healing process because they act as a wound 
site scavenger but as described above excessive neutrophils or persistence of 
neutrophils can contribute to a delay in wound healing (Dovi et al., 2003; Falanga, 
2005). Neutrophil persistence has been shown to delay wound closure by inhibiting 
re-epithelialisation (Dovi et al., 2003). In that study wound closure was shown to 
progress at a significantly faster rate in neutrophil-depleted diabetic mice than 
animals that were not neutrophil depleted (Dovi et al., 2003). Persistent 
inflammatory cells particularly neutrophils is one the feature of diabetic wounds 
(Casqueiro et al., 2012; McLennan et al., 2008). The mechanism of this effect is 
uncertain but sustained expression of Macrophage Pro-Inflammatory Proten-2 (MIP-
2) and Macrophage Chemoattractant  Protein-1 (MCP-1) during the late phase of 
wound healing in the diabetes is involved in the persistence of  both neutrophils and 
macrophages (Wetzler et al., 2000). In the diabetic condition persistence of 
neutrophils may lead to increased wound pro-inflammatory cytokines, for example 
IL-8, IL-1β, and TNFα (Hatanaka et al., 2006). The excessive production of these 
cytokines leads to reduced neutrophil clearance (Hanses et al., 2011), inappropriate 
activation and consequently tissue damage (Hatanaka et al., 2006). 
 
As mentioned in section ‎1.1.6.1 neutrophil granules contain a variety of proteases. 
Neutrophil proteases are responsible for the modulatory effects of neutrophils 
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(Gresnigt et al., 2012). For instance, elastase contributes to the regulation of 
inflammation and the breakdown of ECM proteins including collagen-IV and elastin 
fibronectin, laminin, and vitronectin (Dovi et al., 2003; Weinrauch et al., 2002). 
Neutrophils also contain MPO, a peroxidase enzyme, which can oxidatively activate 
MMP-8 and MMP-9 and consequently increase the destructive function of the 
MMPs (Nizam et al., 2014; Sorsa et al., 2006). A common feature of all poorly 
healing wounds is increased MMP content. This increase can contribute to impaired 
keratinocyte migration (Dovi et al., 2003). Previous studies in my laboratory have 
shown increased initial MMPs in particular MMP-9 which can predict future poor 
healing of wounds in persons with diabetes (Liu et al., 2009). The mechanism of this 
effect is not fully understood and will be investigated in the work described in this 
thesis. 
 
 Matrix Metalloproteinases Structure and Function 1.1.7
As discussed in preceding sections the wound healing process involves high levels 
of extracellular proteolytic activity which is mediated primarily by the MMPs, serine 
proteinases and cysteine proteinases. There is considerable evidence that shows that 
increased MMP activity is associated with poor healing of chronic wounds and 
future delayed healing in people with diabetes. Additionally, the expression of the 
TIMPs is decreased in chronic wounds and as MMP activity is regulated by TIMPs 
this altered balance between MMPs and TIMPs also likely contributes to poor 
healing. In addition to regulation by TIMPs the expression and activity of MMPs 
can be regulated by other factors. Interestingly, neutrophils are different to other cell 
types and they do not express TIMPs, suggesting that MMP activities in this cell 
type are regulated in a different manner. The next section will discuss MMPs and 
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their role in wound healing including in poorly healing wounds in those with 
diabetes.  
 
The MMPs also referred to as matrixins, are a large family of at least 24 
endopeptidases whose activities depend on metal ions, such as Zn
+2
 and Ca
+2
. They 
play a key role in normal physiology including in connective tissue formation during 
development, morphogenesis and healing (Klein & Bischoff, 2011). Based on 
domain organisation and substrates the MMPs are classified into the following 
groups: collagenases (MMP-1, -8, -13, -18), gelatinases (MMP-2, -9), stromelysins 
(MMP-3, -10, -11), and a heterogeneous group containing matrilysins (MMP-7), 
metallo elastase (MMP-26) and epilysin (MMP-28). Another class of MMPs are the 
membrane-type MMPs or MT-MMPs which consist of MMPs-14, -15, -16, -17, -24, 
-25) (Marco et al., 2013; Nagase et al., 2006). As Figure ‎1-8 shows MMPs share 
specific functional and structural components. Most contain a pro-peptide domain of 
approximately 80 amino acids, a metalloproteinase domain of about 170 amino 
acids, a linker peptide of variable lengths, and a hemopexin domain of about 200 
amino acids (Nagase et al., 2006). The pro-peptide domain contains a conserved 
cysteine residue that links to the catalytic zinc site and sustains the latency of the 
MMP. The hemopexin like C-terminal domain is linked to the catalytic domain by a 
short hinge region and domain binds endogenous TIMPs (Bauvois, 2012). The 
hemopexin domain is also essential for the collagenolytic activity of collagenases. 
The catalytic domains of MMPs can hydrolyse non-collagenous proteins but they 
cannot cleave triple helical collagens without the hemopexin domain (Clark & 
Cawston, 1989). The gelatinases including MMP-2 and MMP-9 are different from 
the other MMPs. They contain three repeats of the fibronectin type II motif in the 
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metalloproteinase domain which facilitates their binding to gelatin and collagen 
(Klein & Bischoff, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1-8: Basic structure of MMPs. 
The typical structure of MMP is made of a prodomain, a furin cleavage site 
(all MT-MMPs, MMP-21, -23, and -28), a catalytic metalloproteinase domain 
with fibronectin type II repeats (MMP-2, MMP-9), a linker peptide and a 
haemopexin domain (except for MMP-7, -26, and -23), a linker peptide, a 
transmembrane domain and cytoplasmic tail (MMP-14, -15, -16, -24) or 
glycosylphosphatidylinositol (GPI) anchor (MMP-17, -25). MMP-23 bears C-
terminal cysteine-rich (Cys-rich) and Ig-like (Ig) domains and its propeptide 
lacks a cystein switch motif . Adapted from (Paulissen et al., 2009) 
 
 
Most MMPs are secreted as inactive zymogens; they need to be activated usually by 
proteolytic cleavage of their NH2-terminal pro-domains (Woessner et al., 1991). 
They are processed to their active forms via several mechanisms all of which lead to 
disruption of the cysteine switch and cleavage of the pro-peptide. They can be 
activated by tissue or plasma proteinases by proteolytic cleavage of their NH2-
terminal pro-domains. This proteolytic removal of the prodomain by other serine 
proteases such as plasmin and furin is one of the most common mechanisms of 
N-terminus C-terminus 
Catalytic domain 
Hemopexin 
domain 
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activation.  Other mechanisms of activation include activation by other MMPs 
(Klein & Bischoff, 2011). One example is the role played by MT1-MMP in 
activation of MMP-2 (Brew et al., 2000; Rundhaug, 2003). For activation of MMP-2 
by this mechanism pro-MMP-2 forms a complex with MT1-MMP and paradoxically 
TIMP-2.  
 
As mentioned the activities of MMPs are inhibited by TIMPs, which are secreted by 
most cell types except neutrophils. There are four family members: TIMP-1, TIMP-
2, TIMP-3 and TIMP-4 (Brew et al., 2000).  All TIMPs have two distinct domains, 
an N-terminal domain of about 125 amino acid residues and a C-terminal domain 
with about 65 residues; the conformation of each domain is stabilised by disulphide 
bonds. The structure of the N-terminal region is highly conserved, it binds to the 
active site of the MMPs in such a way that the conserved N-terminal Cysteine 1 of 
the TIMP lies above the catalytic Zn
2
+ of the MMPs (Murphy, 2011). The C-
terminal also make some connections with the protease, but these are not important 
contributors to complex formation (Brew & Nagase, 2010).  
 
All four TIMPs inhibit MMPs but structural studies of TIMP–MMP complexes have 
explained some differences in inhibitory properties between the different TIMPs. 
For example, TIMP-1 has inhibitory actions against most MMPs and it has a 
relatively low affinity for the MT-MMPs, MMP-14, MMP-16, MMP- 24, and 
MMP-19 (Baker et al., 2002; Brew & Nagase, 2010). Additionally, TIMP-2 and 
TIMP-3 are weaker inhibitors than TIMP-1 for MMP-3 and MMP-7. The interaction 
between TIMPs and the various pro-MMPs is relatively specific: TIMP-2, TIMP-3 
35 
 
and TIMP-4 can interact with pro-MMP-2 and TIMP-1 and TIMP-3 can interact 
with pro-MMP-9 (Brew et al., 2000; Brew & Nagase, 2010; Hamze et al., 2007).  
 
Apart from activation, MMP activities are regulated at the level of transcription. A 
number of different signalling pathways have been implicated in this process 
including activation of MAPK, NF-κB or Smad-dependent pathways by growth 
factors/cytokines, activation of Focal Adhesion Kinase (FAK) by integrin activation, 
or activation of β-catenin signalling by cadherins (type-1 transmembrane proteins) 
(Martins et al., 2013). 
 
The main physiological function of the MMPs is the modulation and regulation of 
ECM quantity (Galis & Khatri, 2002). They selectively degrade most ECM 
components including collagen, fibronectin, laminins and proteoglycans. The MMPs 
are also increasingly recognised as having roles in the release and activation of 
biologically active proteins. Some of these are growth factors such as Insulin-Like 
Growth (IGF) (Nakamura et al., 2005), VEGF (Bergers et al., 2000) and TGF-β (Yu 
& Stamenkovic, 2000). Cytokines such as IL-1β are also activated by MMPs 
(Schonbeck et al., 1998). They can also cleave cell surface proteins such as cytokine 
receptors, and cell adhesion molecules (Bauvois, 2012; Klein & Bischoff, 2011).  
 
 Matrix metalloproteinases in wound healing 1.1.7.1
The MMPs have many roles in wound repair being involved in each step of the 
process, that is inflammation, granulation tissue formation, angiogenesis, wound 
remodelling and maturation (Muller-Quernheim, 2011). Most cell types involved in 
wound repair including fibroblasts, keratinocytes, and endothelial cells express the 
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MMPs. They are also expressed by inflammatory cells such as neutrophils, 
monocytes/macrophage and lymphocytes (Martins et al., 2013). In general MMPs 
are constitutively expressed and their synthesis is up regulated by growth factors 
such as Epidermal Growth Factors (EGF), Keratinocyte Growth Factor (KGF), 
Fibroblast Growth Factor (FGF), VEGF, PDGF, Hepatocyte Growth Factor (HGF), 
and TGF-β. These growth factors have all been reported to transcriptionally activate 
MMPs (Martins et al., 2013). The pro-inflammatory cytokines TNF-α and IL-1α are 
also known to be potent inducers of both MMPs and TIMPs (McCarty & Percival, 
2013) although this effect appears to be concentration dependant. In the low 
concentration, TNF-α can increase TIMP production and regulate MMP activities 
whereas higher concentrations have been reported to stimulate the production of 
MMPs and suppress the production of TIMPs -1, -2, and -3 (Medina et al., 2005).  
 
As discussed above MMPs are activated by the removal of the pro-peptide fragment 
and this form of MMP can facilitate activation of pathways leading to the 
regeneration of injured tissues. This activation includes pathways which can increase 
migration of neutrophils to the wound area and activation of TGF-β to induce 
granulation tissue formation (McCarty & Percival, 2013). These activation pathways 
also contribute to the regulation of barrier function, inflammatory cytokines, as well 
as chemokine activity and gradients, resolution of infection, and tissue repair 
(Lagente & Boichot, 2010). Controlled expression of MMPs is important to the 
progression of the normal wound healing process (Martins et al., 2013) but elevated 
and prolonged expression of MMPs disrupts this balance. The increased MMPs can 
lead to degradation of ECM components, persistence activation of cytokines and 
degradation of growth factors. Together these factors have all been associated with 
37 
 
impaired healing (Schultz & Wysocki, 2009). Whether persistence of MMPs leads 
directly to poor wound healing or is a consequence of persistently high levels of 
wound pro-inflammatory cytokines is not clear. The high cytokines may induce 
increased expression of MMPs (Mott & Werb, 2004) and down regulate TIMP 
expression to collectively cause an environment consistent with an excess of MMPs 
activity (McCarty & Percival, 2013). This excess MMP activity can subsequently 
destroy growth factors, receptors, and matrix proteins essential for initiation of the 
wound healing process (Lobmann et al., 2006). In the diabetic environment gene 
expression and protein levels of MMP-1, MMP-2, MMP-8, and MMP-9 have all 
been shown to be increased (Lobmann et al., 2002). On the other hand the level of 
TIMP-2 is decreased (Rysz et al., 2007). Together these changes support the 
contention that impairment of wound healing in diabetic ulcers is due to prolonged 
inflammation and an increase in the proteolytic wound environment (Stechmiller et 
al., 2006; Weckroth et al., 1996). The biological activities mediated by MMPs 
during wound healing are shown in Table ‎1-2. 
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Table ‎1-2: The roles of MMPs in wound healing 
 
Adapted from (Martins et al., 2013; Nagase et al., 2006) . 
Biological effect  Responsible MMPs 
Increase cell migration, proliferation, Keratinocyte migration 
and reepithelialisation 
MMP-1 
 Mesenchymal cell differentiation with inflammatory phenotype, 
epithelial cell migration, enhanced collagen affinity, increased 
bioavailability of TGF-β 
MMP-2 
Generation of angiostatin-like fragment, enhanced collagen 
affinity, increased bioavailability of TGF-β 
MMP-3 
Require for wound closure and generation of antimicrobial 
activity, Promotes neutrophil activation 
MMP-7 
Mainly expressed by neutrophils promotes cutaneous wound 
healing  
MMP-8 
Generation of angiostatin-like fragment, enhanced collagen 
affinity, pro-inflammatory, promotes cell migration and re-
epithelialisation 
MMP-9 
Expressed by the keratinocyte at the edge of the wound MMP-10 
Macrophage specific, potential regulator of angiogenesis  MMP-12 
Promotes keratinocyte migration and invasion, regulate 
epithelial cell proliferation 
MMP-14 
Widely expressed in many organs including proliferating 
keratinocytes in healing wounds 
MMP-19 
Expressed by migrating keratinocytes during cutaneous wound 
healing 
MMP-26 
Expression is associated with cell proliferation during epithelial 
repair 
MMP-28 
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The work described in this thesis focuses on one of the MMPs, the gelatinase called 
MMP-9. This MMP is of interest as our group has previously shown that its activity 
is increased in wound fluids in diabetic wounds and that its level can provide 
information about future wound healing rate in diabetic wounds (Liu et al., 2009). 
MMP-9 has been shown to directly delay wound healing by interference with re-
epithelialisation (Reiss et al., 2010). Unlike most of the other MMPs, which are 
constitutively expressed, MMP-9 expression is induced in a variety of cell types in 
response to inflammatory stimuli (Martins et al., 2013). 
 
As previously described (Section ‎1.1.4) and shown in Figure ‎1-9 acute wound 
healing proceeds through several overlapping phases that involve an inflammatory 
response and associated cellular migration, proliferation, matrix deposition, and 
tissue remodelling (Nicks et al., 2010). Interruption or disruption of one or more of 
these phases leads to failure of the wound to heal i.e. a chronic wound. In people 
with diabetes, some wounds heal albeit at a slower rate than in those without 
diabetes. In others despite best care the wounds are trapped in a destructive and 
ongoing cycle in the inflammatory stage. This persistence of inflammation is a 
common feature of diabetic wounds and can lead to an increase in the number of 
inflammatory cells in particular neutrophils and macrophages. These inflammatory 
cells can be induced to increase MMP expression and their presence is likely 
responsible for the persistence of MMPs (Martins et al., 2013) .   
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Figure ‎1-9:  Increased level of MMPs in chronic wounds.  
The inflammatory phase of healing is exaggerated in chronic wounds leading 
to an excess of proteases and inflammatory cytokines released by neutrophil s 
and macrophages. Excess of MMPs degrade ECM components and causes 
tissue damage and poor wound healing.  
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 MMP-9 structure and activity  1.1.7.2
 Shown in Figure 1-10 at the transcriptional level, MMP-9 is positively regulated by 
multiple factors, including E-26 (Ets) transcription factors, NF-κB, Polyomavirus 
Enhancer A-binding protein-3 (PEA3), Activator Protein-1 (AP-1), specificity 
protein 1 (Sp-1), and Serum Amyloid A-activating Factor (SAF)-1 (Crawford & 
Matrisian, 1996). MMP-9 is secreted as inactive zymogen (proMMP-9) with a 
molecular weight of 92 kDa. Cleavage of the prodomain yields the biologically 
active form of MMP-9 with a molecular weight of 82 kDa (Bauvois, 2012). The pro 
form of MMP-9 can be activated by a number of proteases including plasmin, 
trypsin-2, MMP-2, MMP-13, MMP-3, serine elastase and kallikrein (Klein & 
Bischoff, 2011). Inhibition of MMP-9 is performed by TIMPs binding to the pro 
forms of the enzyme. TIMP-1 binds to pro-MMP-9, in addition to inhibiting its 
active form (Brew & H. Nagase, 2010).  
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Figure ‎1-10: MMP-9 structure and factors regulating MMP-9 transcription and 
translation.  
Ets, E-26 transcription factor; NF-κB, nuclear factor κB; PEA-3, polyomavirus 
enhancer A-binding protein-3; AP-1, activator protein 1; SAF-1, serum 
amyloid A-activating factor 1; HSP60, heat shock protein 60; TIMP, tissue 
inhibitor of metalloproteinase; uPA, urokinase plasminogen activator. Adapted 
from (Yabluchanskiy et al., 2013)  
 
 
MMP-9 is produced and secreted by a number of different cell types including 
neutrophils, macrophages, monocytes, fibroblasts, and keratinocytes (Cullen et al., 
2002). In neutrophils, MMP-9 is synthesised during the late stage maturation 
process in the bone marrow and thereafter is stored in the specific and gelatinase 
granules. MMP-9 is constitutively expressed by mononuclear cells and keratinocytes 
(Fang et al., 2010) and is an important factor in the remodelling and re-
epithelialisation of wounds (Rowe & Weiss, 2008). Increased levels of MMP-9 have 
been shown to inhibit keratinocyte migration, attachment, and re-establishment of 
the epidermis (Reiss et al., 2010). In wound fluids high levels of MMP-9 correlate 
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with the severity of the ulcer (Rayment et al., 2008) and as mentioned our group has 
shown that wound fluid MMP-9 can predict future poor wound healing of diabetic 
foot ulcers (Liu et al., 2009). The wound fluid MMP-9 is thought to come mainly 
from neutrophils or macrophages as these are the main cells present in the fluids 
(Cullen et al., 2002). 
 
One of the important heteromeric complexs of MMP-9 isolated from neutrophils is a 
complex between proMMP-9 and neutrophil gelatinase associated lipocalin-2 or 
NGAL. This composite is a 125 KDa disulphide-bonded complex between cysteine 
residue 87 (C87) of NGAL and an unidentified cysteine in residue in the 
hemopexin-like C-terminal domain of MMP-9 (Bouchet & Bauvois, 2014). This 
formation of the NGAL/proMMP-9 complex precedes the formation of a ternary 
complex with TIMP-1 which is mediated by the C-terminal of proMMP-9 and the 
non-inhibitory C-terminal of TIMP-1. When the free N-terminal of TIMP-1 in the 
NGAL/MMP-9/TIMP-1 complex is activated, a quaternary complex is generated 
which upon activation of proMMP-9 exhibits a sixfold higher proteolytic activity 
than the active ternary complex (Kolkenbrock et al., 1996). Interestingly, MMP-9 
secreted by neutrophils is different from that secreted by other cells. It is TIMP free 
and is often covalently associated with NGAL. This special feature of MMP-9 
secreted by neutrophils and the ability of the NGAL/MMP9 complex to form 
extracellulary a complex with TIMP-1 explains its high specific activity when 
compared to MMP-9 from other cell types (Hibbs et al., 1985; Kjeldsen et al., 1993). 
In addition to delivering a more highly active MMP-9 the degradation of MMP-9 is 
significantly inhibited in the presence of NGAL. Together these changes result in 
the preservation of MMP-9 enzymatic activity and suggest a potential regulatory 
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role for NGAL in the modulation of MMP-9 activity (Yan et al., 2001). The 
presence of NGAL-MMP-9 complex has been observed in a number of different 
diseases in particular cancer (Bouchet & Bauvois, 2014) and diabetic nephropathy 
(Thrailkill et al., 2010) and its detection in tissues such as plasma, urine, saliva, and 
tissue lysates has been suggested as a marker of disease (Thrailkill et al., 2010). 
Whilst these functions of NGAL in regulation of MMP-9 activity are known, little is 
known regarding its level in wound fluids and its association with poor wound 
healing. 
 
 
 
 Neutrophil Gelatinase a Member of the Lipocalin Family  1.1.8
The Lipocalin protein family is a large group of small extracellular proteins which 
fulfil a variety of different functions including roles in the regulation of the immune 
reaction and the mediation of cell homoeostasis (Flower et al., 2000). They are 
characterised by their ability to bind small mainly hydrophobic molecules such as 
retinol, their binding to specific cell-surface receptors and their formation of macro-
molecular complexes (Flower et al., 2000). One of these complexes includes the 
complex formed between NGAL and MMP-9. NGAL is encoded by the LCN2 gene 
(Chakraborty et al., 2011) and was originally isolated from the specific granules of 
human neutrophils (Kjeldsen et al., 1993).   
 
The calculated structure of Lipocalins shows NGAL to be a 178-residue protein with 
a lipocalin fold as depicted in Figure ‎1-11. The protein sequence has been shown to 
share similarity with the amino acid sequences of the rat α2-microglobulin-related 
protein and the mouse 24p3 protein (Coles et al., 1999; Kjeldsen et al., 1994) with 
highest degree of similarity 63.5 and 62% identity, respectively. Additionally it is 
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highly similar to the homologue present in chimpanzees with about a 98% identity 
(Chakraborty et al., 2011). 
 
 
Figure ‎1-11: Schematic representation of the lipocalin fold.  
The characteristic feature of lipocalins is the “lipocalin fold” which 
comprises of an N-terminal 3-10 helix. This domain which is responsible for 
binding of lipocalins to their ligands is structurally comprised of an eight 
stranded β barrel with its loops running in an antiparallel direction.  The 
eighth beta sheet is connected to an alpha helix (α1), which is in turn 
connected to a C-terminal beta sheet. The beta sheets are connected by loops 
(L1-L7). Loops L1, L3, L5 and L7 form the open end of the molecule (i.e. the 
opening to the ligand binding site of NGAL).  Adapted from (Chakraborty et 
al., 2011) 
 
 
NGAL is resistant to degradation and under non-reducing conditions exist as a 25 
kDa monomer, a 45 kDa disulphide-linked homodimer, a 75kDa trimeric NGAL 
complex, and as mentioned also covalently bound to MMP-9 as a 125 kDa 
heterodimeric form shown schemmatically in Figure 1-12. This covalent complex 
can form in vitro and studies mixing MMP-9 with NGAL have generated MMP 
activities with two different molecular sizes of 125 kDa and 115 kDa. These 
represent complexes of MMP-9 with the monomeric and the dimeric forms of 
NGAL, respectively (Yan et al., 2001). 
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Figure ‎1-12: A representative sample containing different forms of NGAL 
∼125-kDa purified human neutrophil NGAL/MMP-9 complex as well as NGAL 
in monomeric, dimeric, and trimeric forms. Adapted from (Yan et al., 2001) 
 
 
NGAL is secreted by activated neutrophils and it is also expressed albeit at very low 
levels by macrophages. Its expression can be induced in epithelial cells, and 
keratinocytes during inflammation (Borregaard et al., 2005). NGAL has been 
reported to be expressed in several tissues including the kidney, liver, lungs, trachea, 
small intestine, bone marrow, thymus, prostate, adipose tissue, hepatocytes, renal 
tubular cells (Aigner et al., 2007; Chakraborty et al., 2011), and the epidermis of the 
fetal skin (Mallbris et al., 2002). Measurement of circulating NGAL levels have also 
been discussed as possible diagnostic markers of neutrophil activity in disease such 
as chronic obstructive pulmonary disease and asthma (Keatings & Barnes, 1997) and 
in arteriosclerosis (Elneihoum et al., 1997). 
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The expression level of NGAL in the circulation may be influenced by the presence 
of renal diseases, hypertension, inflammatory conditions, hypoxia and malignant 
diseases (Chakraborty et al., 2011). NGAL is an inflammatory marker which is 
associated with obesity, insulin resistance, and hyperglycemia (Wang et al., 2007). 
NGAL is also a marker of renal structural damage and is mainly produced in renal 
tubules in response to structural kidney injury during diabetes (Bolignano et al., 
2008). Elevated NGAL expression in the kidney, as well as elevated urinary NGAL 
levels have been observed in diabetic kidney injury (Demir et al., 2012; Nielsen et 
al., 2010). Similarly, elevated NGAL levels have been observed in chronic kidney 
injuries and correlate with severity of renal impairment (Bolignano et al., 2008).  
 
An important function of NGAL is to act as a bacteriostatic agent with actions 
against gram-negative bacteria and mycobacteria (Flo et al., 2004). In this role 
NGAL binds to bacterial proteins and captures iron-laden bacterial siderophores, 
such as enterochelin and carboxymycobactins (Holmes et al., 2005). This interaction 
of an iron-siderophore complex with NGAL results in the import of iron into host 
cells and limits bacterial growth by depriving bacteria of essential nutrients. NGAL 
deficiency in genetically modified mice leads to an increased bacteremia and 
bacterial burden in the liver and spleen (Flo et al., 2004). This function is likely 
important in neutrophils, where iron is required not only during their development in 
the bone marrow but also for their bacterial activity (Walter et al., 1986). 
 
In skin keratinocytes NGAL levels are increased on wounding and its expression is 
upregulated in response to microbial stimulation and pro-inflammatory cytokines 
such as IL-1a (Bando et al., 2007). NGAL expression is also regulated by cytokines 
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including GM-CSF, IL-α, IL-β, IL-6 IL-17, IL-22 and TNFα. Its expression is also 
stimulated by growth factors including IGF-1, and EGF (Barresi et al., 2011). 
NGAL expression can be also regulated by NF-κB, a regulator of several key 
pathways (Florin et al., 2004) including by TLR ligands and TNFα 
(Kewcharoenwong et al., 2013). 
 
NGAL is rarely detectable in normal skin cells and only is restricted to the hair 
follicle compartments in normal tissue (Seo et al., 2006). There are only a few 
studies which have examined NGAL levels in chronic wounds. Wound fluid NGAL 
levels in healing wounds which correlate with wound area. In contrast, there was no 
significant change in the NGAL level in non-healing wounds (Pukstad et al., 2010). 
Additionally, increased wound and plasma levels of both NGAL and MMP-9 have 
been reported in persons with chronic ulcers (Serra et al., 2013). High levels of 
circulating soluble NGAL and MMP-9 have also been shown to correlate with the 
non-healing venous ulcers (Serra et al., 2013; Serra et al., 2013). However, the effect 
of diabetes on wound fluid NGAL/MMP-9 complex concentration and its 
association with overall wound NGAL and MMP-9 levels, has received little 
attention.  
 
Therefore, in this study the effect of diabetes on the relationship between NGAL and 
MMP-9 and NGAL/MMP-9 complex in inflammatory cells in wounds and 
peripheral blood neutrophils in two different wound-healing models was examined 
in detail. In addition the mechanism of the effect was studied in isolated neutrophils 
and pilot studies in patients were performed.  
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 Hypothesis and Aims 1.2
In this study we investigated the effect of diabetes on the relationship between 
NGAL and MMP-9 and NGAL/MMP-9 complex in inflammatory cells in wounds 
and peripheral blood neutrophils in two different wound healing models.  Our aims 
of this study were:  
 
 To examine expression of NGAL in diabetic wounds and its association with 
MMP-9  
 
 To examine the effect of interventions such as insulin treatment (to improve 
diabetic control) or Doxycycline (a regulator of MMPs) on NGAL and 
MMP-9 levels in diabetic wounds 
 
 To examine in vitro the mechanism of the effect of glucose on neutrophil 
NGAL expression 
 
 To examine the expression of NGAL and MMP-9 in circulating white blood 
cells in people with diabetes 
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 CHAPTER 2: MATERIALS 2
AND METHODS 
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 Animal Studies 2.1
The methods in this chapter describe techniques used in the animal studies and in 
vitro studies. The methodologies specific for the human study have been included in 
Chapter 5 where the human studies are presented. 
 
 Experimental Design and Induction of Diabetes 2.2
A summary of the experimental design is depicted in Figure ‎2-1. Male Sprague-
Dawley rats (200-250g) obtained from Australian Laboratory Supply (Perth, 
Australia) and aged between 5 and 6 weeks were used to investigate the effect of 
diabetes on wound healing in both an excisional wound model and a sponge implant 
model. The excisional model enabled investigation of wound closure and tissue 
morphology, whilst the sponge implant model was used for examination of 
inflammatory cells.   
 
In both studies diabetes mellitus was induced by intraperitoneal injection of 
streptozotocin (STZ; 65mg/kg in 0.1M citrate buffer, pH4.5, Sigma, S0130-USA) 
and confirmed by a tail vein blood glucose level > 11mmol/L from three days after 
injection. Diabetic animals were treated with a low dose insulin regimen (2-4IU 
insulin, twice weekly) to maintain their body weight and prevent ketoacidosis. Six 
weeks later, diabetic and control animals were anesthetised by using a combination 
of Ketamine (85mg/kg; Provet, Sydney, Australia) and Xylazine-20 (5mg/kg) prior 
to wounding or implantation of sponges as described in more detail below. 
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After induction of diabetes, in independent parallel studies, the diabetic animals 
were divided into different subgroups as shown in Table ‎2-1. 
 
All animal experiments in this study were approved by the Animal Ethics 
Committee of this institution (Protocol No: 2010-024).  
 
 
 
Table ‎2-1: Description of animal groups and treatment durations for the various studies 
Groups Abbreviation Duration of treatment 
 Control animals with no 
treatment 
CON ------ 
 Control animals treated with 
oral doxycycline (100mg/kg) by 
oral gavage  
 
CON+HDOX 6 days from time of 
wounding 
 Control animals treated    with 
doxycycline (20mg/kg) by oral 
gavage 
 
CON+LDOX 6 days from time of 
wounding 
 Diabetic animals with no 
treatment 
DM ------ 
 Diabetic animals treated with 
insulin (10 IU daily) 
 
DM+INS 6 weeks from diabetes 
induction 
 Diabetic animals treated    with 
doxycycline (100mg/kg) by oral 
gavage 
 
DM+HDOX 6 days from time of 
wounding 
 Diabetic animals treated   with 
doxycycline (20mg/kg) by oral 
gavage 
DM+LDOX 6 days from time of 
wounding 
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 Figure ‎2-1: Schematic representation of the experimental design 
Induction of diabetes (DM: 65 mg/kg STZ) 
BGL>11mmol/L 
Experimental design 
   + Insulin*                                - Insulin 
#
 
                                   
*insulin: 10 IU injection, daily for 6 weeks 
#insulin: 2-4 IU twice a week  
   + Doxycycline*                  - Doxycycline 
                                   
*100 mg/kg for 6 days post wounding 
* 20mg/kg for 6 days post wounding 
Excisional wound model 
 Four full-thickness circular wounds (8mm) 
Sponge implant model  
PVC sponge (1cm
2
) was inserted under the skin 
Samples (Skin wounds, Wound fluid, Inflammatory cells, Plasma, Circulating neutrophils) 
were harvested after surgery (wounding) 
qRT-PCR, Zymography, western blot, IHC and IF staining, Flow cytometry studies 
   
5
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 Measurements of body weight and blood glucose concentration  2.2.1
All animals were weighed at the beginning of the study and then once per week 
throughout the study. Non-fasting blood glucose concentration was measured once 
per week for the duration of the study using a Freestyle Lite glucometer (Abbott). 
To obtain the blood the tip of tail was nicked with a scalpel blade and blood glucose 
was monitored by blood glucose test strip using the blood glucose monitor. 
 
 Wound models   2.2.2
In the excisional wound healing model four full-thickness circular wounds were 
created on the dorsum of the rats using an 8mm skin biopsy punch as previously 
described (McLennan et al., 2008). The wounds were then covered with transparent 
dressing (Coloplast, Comfeel® Plus Transparent 3533) and redressed as needed. For 
the wound sponge model PVA sponges (1cm
2
; KCL) were sterilized by gamma 
irradiation (5Gy) and were inserted surgically, 4 sponges per animal via 2cm skin 
incisions (one incision per sponge) on the dorsum of the animal and the incisions 
were closed with suture. At the time of surgery each animal received a single dose of 
ampicillin (50 mg/kg) and Buprenorphine (Temgesic 0.03 mg/kg) for prevention of 
infection and pain relief. 
 
 Excisional wound model  2.2.3
 Macroscopic wound closure was determined at the time points mentioned by 
placing a transparency film on the wound surface and tracing the wound area. 
Measurements were made at day 0 (time of incision), day 3 and at termination day 6.  
The wound tracings were scanned and wound area was measured using Image J 
software (NIH Image) and then the change in wound area was calculated and the 
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results were expressed as a change in area from day 0. Wound closure rate was 
evaluated based on the following formula: 
% wound closure = 100 × (wound area at day 0 – wound area at day x) /wound area 
at day 0. 
At termination (day 6), the skin containing the wound tissue was excised and treated 
as follows. Two wounds were snap frozen in liquid N2 for later measurement of 
gene expression and protein levels. The other two wounds were divided in half, one 
half was fixed in formalin (10%) for histological and immunohistological studies 
and the other half was placed in OCT and frozen for immunofluorescence studies. 
 
 Sponge implant wound model 2.2.4
Animals were terminated at days 3, 6 and 12 after the sponge implantation. At 
termination blood was obtained by cardiac puncture and collected into heparin blood 
collection tubes for quantification of neutrophil and monocyte number, isolation of 
neutrophils and measurement of plasma MMP activity as described in following 
sections. The implanted sponges were removed and the fluids and cells removed by 
gentle squeezing. This process removed the majority of the cells. An aliquot (100 
µL) of the extract was used for determination of neutrophil and monocyte number 
by flow cytometry. The remaining fluids and cells were placed in a tube and the 
cellular component was pelleted by centrifugation at 800 ×g for 10 min using a 
swing out rotor (Eppendorf 5810R). The supernatant was collected and stored at -
80
0
C for later analysis of protein content by BioRad DC Protein assay as well as the 
measurement of NGAL protein by ELISA and MMP activity by zymography.  
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The red blood cells were removed from the pelleted cells by incubation in red blood 
cell (RBC) lysis buffer (Appendix-1) prior to centrifugation at 800 ×g for 10 min. 
The supernatant was discarded and the pellet containing the cells was divided as 
follows: re-suspended in Tri-reagent for later RNA extraction and measurement of 
gene expression or spun onto slide for histological examination. 
 
 Isolation of Rat Neutrophils 2.3
Neutrophils were isolated from rat blood using a modification of the histopaque and 
dextran segmentation methods as described by (Kumar et al., 2010). Briefly, blood 
samples were centrifuged at 800 ×g for 15 minutes and the plasma was removed. 
The pelleted cells were then re-suspended in sterile Hanks’ balanced salt solution 
(HBSS; 1:1 vol/vol, Gibco), and applied to an equal volume of Histo-Pacque 
(Sigma, Histopaque-1083) prior to centrifugation at 400 ×g for 45 min. At the end of 
centrifugation four distinct phases were observed Figure 2-2. The mononuclear cells 
were removed using sterile pipette from the upper layer.  
 
The lower layer from the Histo-Pacque gradient, containing the neutrophils was then 
pipetted onto 2 ml of Dextran (6%, Sigma) and incubated at 37
◦
C. After 20 min the 
supernatant containing the neutrophils was removed and centrifuged at 270×g for 10 
min. The neutrophil pellet was then washed using RBC lysis buffer, 5 min later an 
equal volume of HBSS was added and the solution was centrifuged at 480×g for 10 
min. The neutrophil pellet was washed with HBSS (10mL) and the neutrophils were 
again pelleted by centrifugation (480g for 10 min). The pellet was then resuspended 
in HBSS (1mL) and the isolated neutrophils were examined for purity (>90%) using 
May-Grunwald-Gimsa or DAPI stain (Figure 2-2). The neutrophils were then stored 
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as follows; i) Tri-reagent for later RNA extraction ii) RIPA buffer (Appendix-2) for 
protein analysis or ii) spun onto slides for histological examination of purity or 
protein expression by immunofluorescence. 
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                    Figure ‎2-2 : Purification of neutrophils from rat blood 
                
 
Purification of Neutrophils from Rat Blood 
Blood               
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Layer onto 6.0% dextran to separate erythrocytes 
and eosinophils from neutrophils 
  
Wash with red cell lysis buffer and re-suspend in 
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For the primary cell culture studies the isolated neutrophils were washed with RPMI 
and then plated in 6-well-plates at a density of 1×10
6
. The neutrophils were then 
cultured in RPMI medium containing either normal glucose (5mM) glucose, a high 
glucose environment (25mM), or high glucose and 10 IU/ml insulin. The plated 
neutrophils were then incubated at 37
°
C in 95% O2 and 5% CO
2
 for 1, 2, and 6 
hours. At each time point the cells were harvested and centrifuged at 1000 rpm for 5 
min. The cell pellet was then resuspended in TRI-reagent for later RNA extraction. 
In addition the media was stored at -80°C for later analysis. 
 
 Preparation and Analysis of Protein 2.4
 Measurement of protein concentration 2.4.1
The protein concentration of all samples was measured using the BioRad DC protein 
assay with BSA as a standard (0-5mg/ml). For this assay, 5µl of the diluted samples 
in PBS (1:20) were incubated in 20µl of reagent A and 200 µl of reagent B and then 
were shaken on for 15 sec with 5 sec break for a total 15 min. The resulting colour 
developed was then read using a Multiskan plate reader at 690nm filter. The protein 
concentration was calculated from the BSA standard curve. 
 
 Western blot analysis 2.4.2
Western blot analysis was used to examine the specific proteins semi quantitatively 
in plasma and wound fluid. For these measurements the total protein concentration 
was determined as described. Equal amount of proteins (50µg) from each sample 
were loaded onto 10% non-reducing SDS-PAGE gels and the gels were run at 135V 
until the dye reached the bottom of the gel. The proteins on gel were then transferred 
to a Nitrocellulose membrane (Hybond-C Extra) for 7 min using the Trans-Blot 
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Turbo Transfer System (Bio Rad). After transfer the Nitrocellulose membrane was 
incubated for 1 hour with 5% non-fat milk in Tris Buffered Saline containing Tween 
20 (TBS-T) (Appendix) at room temperature to block non-specific protein binding. 
Excess milk was removed by washing three times (5 min each) in TBS-T. Specific 
proteins were then detected by incubation in the following antibodies: anti-NGAL 
(1:500, ab63929, Abcam) or anti-MMP-9 (1:1000, ab38898, Abcam). The 
membranes were then washed with TBS-T buffer 3 times for 5 min at room 
temperature followed by incubation with horse radish peroxidase (HRP) conjugated 
anti-rabbit secondary antibody (1:10,000, SIGMA A-0545) in TBS-T buffer for 1 
hour at room temperature. Proteins were visualised using the Enhanced 
Chemiluminescence (ECL) detection kit according to the manufacturer’s 
instructions. Images were captured using the Syngene GBox-HR Gel Doc System. 
 
 ELISA to measure soluble NGAL concentration  2.4.3
The soluble form of NGAL was measured in plasma and wound fluids of 
experimental animals using an ELISA (Enzyme-linked immune-Sorbent Assay) kit 
(R&D Systems). Briefly, the primary monoclonal antibody (goat anti-rat Lipocalin-
2, 0.8μg/mL in PBS pH 7.0, 100μL) was coated onto 96 well microplates by 
overnight incubation. The excess antibody was removed by washing three times in 
400μL of washing buffer. Non-specific binding sites were blocked by incubation in 
300μL of blocking buffer (1% BSA in PBS, pH 7.2) for 1 hour. The wells were then 
washed (3 times) and 100 µl of sample (1:20) or standards diluted in reagent diluent 
was added per well in duplicate and incubated for two hours at room temperature. 
The wells were again washed and then the detection antibody (150 ng/ml) 
(biotinylated goat anti-rat Lipocalin-2) was added to each well (2 hours, room 
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temperature). Colour development was performed after addition of 100μl of HRP-
conjugated streptavidin for 20 min. Followed by removal of excess HRP-conjugated 
streptavidin and 100μL of 1:1 mixture of Colour Reagent A (H2O2) and Colour 
Reagent B (Tetramethylbenzidine) were added. The optical density of each well was 
measured using a microplate reader set to 450 nm and also 570nm for correction for 
variation in plate optical density. As shown in Figure ‎2-3 results were calculated by 
comparison with absorbance for known standards. 
  
 
Figure ‎2-3: A representative standard curve for NGAL ELISA 
 
 
 Gelatin zymography for the measurement of MMP-9 and NGAL/MMP-2.4.4
9 complex 
The pro and active forms of MMP-9 as well as the NGAL/MMP-9 complex were 
quantified in wound fluid and plasma using MDPF-labelled gelatin zymography as 
previously described (Min et al., 2006). By this technique, proteins are separated by 
size and MMP-9 activity is identified by their ability to degrade the gelatin substrate 
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contained within SDS-PAGE (Sodium Dodecyl Sulfate- Polyacrylamide Gel 
Electrophoresis) gel. For this study, the diluted samples (wound fluid: 1:10, plasma; 
1:20) were mixed with SDS loading buffer (Appendix) and then loaded into an 8% 
polyacrylamide gel (Appendix). The gel was then run at a voltage of 135V for 1.5 
hours. Gels were then incubated in a series of 3 wash buffers all at pH 7.5 with 
constant shaking at room temperature for 30 min each wash (see Appendix for 
Buffers recipes). The gels were then incubated in buffer III overnight at 37°C. A 
sample containing a known concentration of MMP-9 was included on each gel as 
control and a pre-stained molecular weight marker (BenchMark Pre-Stained Protein 
Ladder, Invitrogen) was used to confirm protein size. 
 
For quantitation, the gels were scanned using the Bio-Rad ChemiDoc MP Imaging 
system and band intensities were determined using Phoretix 1D Advanced version 
3.01 densitometric software. Bands corresponding with NGAL-MMP-9 complex 
(~125 kDa), pro MMP-9 (~92kDa) and active MMP-9 (~82 kDa) were observed and 
their identity was confirmed by western blot analysis using anti NGAL (ab63929) 
and anti MMP-9 (ab38898) antibodies respectively. 
 
 Extraction of RNA and Quantification of Gene of Interest by  2.5
RT-PCR  
 Primer design  2.5.1
All primers which are listed in Table ‎2-2 were designed using primer-blast at Blast 
(Basic Local Alignment Search Tool).NIH http://www.ncbi.nih.gov 
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Table ‎2-2: Primer sequences of the genes of interest 
Target gene (rat) Forward primer (5-3) Reverse primer (5-3) 
NGAL(Lipocalin-2) TCCATCCTCGTCAGGGGCCA AGTGTCGGCCACTTGCACATCG 
36B4 GTACCATTGAAATCCTGAGCGA GCCATTGTCAAACACCTGCT 
MMP-9 GCTTAGATCATTCTTCAGTGCC GTTTAGAGCCACGACCATACAG 
MMP-8 CAAGACTCCAAGAATTACAACCTG TCTCTGTAACCATAGTTTGGGT 
TLR4 ATTGTTCCTTTCCTGCCTGAG CTAGGTTCTTGGTTGAATAAGG 
TLR2 AGGTCTCCAGGTCAAATCTC CTTTGTCTTTGCTGTGAGTCC 
TNFα GCCTCTTCTCATTCCTGCTC AAGATGATCTGAGTGTGAGGGT 
MCL-1 TTGTAAGGACGAAGCGGGAC GCCACTTTCTTTCTGCCGTG 
 
 
 RNA extraction from cells 2.5.2
RNA was isolated from infiltrated cells obtained from the sponge implant or 
wounded skin after homogenisation using TriReagent (Sigma). Tissue samples were 
homogenized in 1ml Tri-reagent using a tissue homogeniser. The homogenised 
suspension was centrifuged for 10 min at 14000 rpm to remove cellular debris and 
large tissue fragments. A 200µl 1-Bromo-3 chloropropane was then added to the 
supernatant for each 1ml Tri-reagent and mixed well for 15 seconds. The samples 
were left at room temperature for 5 min until the two phases were separated. The 
samples were then centrifuged (14000 rpm) at 4°C for 15 min. After centrifugation 
three clear layers were observed. The top and clear layer containing RNA was 
removed and transferred into a new microcentrifuge tube containing 500µl 
isopropanol and incubated at -20°C overnight.  
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After incubation, the samples were centrifuged at 14000 rpm for 15 min to pellet the 
RNA from the isopropanol. The obtained pellet was washed twice in 70% cold 
ethanol (14000rpm, 15min, and 4°C). The pellet was then left at room temperature 
to dry and then dissolved in 20µl RNase- free water. RNA concentration and purity 
was determined using the Nanodrop (BioRad) and only those samples with 260/280 
ratio greater than 1.80 were used. Total RNA was stored at -80°C for later analysis. 
 
 Reverse transcription of RNA 2.5.3
RNA was reverse transcribed into cDNA using oligo-dT 18 and Superscript III 
Reverse Transcriptase (Invitrogen) according to the manufacturers’ instructions. The 
following RNA/Primer mixture was prepared: 10 µL RNA, 0.5μl Random Hexamer 
(RH) (20 nM), 0.5μl Oligo (dT)13-18 with the remaining volume of up to 12.5μl 
provided by addition of RNase- free water. The mixture was then incubated at 70°C 
for 10 min using a PCR machine (Bio Rad).  
 
The following reaction mixture was then prepared: 4μl 5x RT-Buffer (PCR buffer), 
2μl 0.1M DTT and 1μl dNTPs, and 0.5μl of Superscript III RT (except for the 
negative controls). For the reverse transcription reaction 7.5μl of reaction mixture 
was added to each tube, mixed gently and collected by spinning down. The mixture 
was then incubated at 25°C for 10 min. The reaction was completed by increasing 
the temperature to 50°C for 60 min, and then 70°C for 10 min followed by cooling 
to 4°C. cDNA was stored at –20°C for later quantitative gene expression. 
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 Polymerase chain reaction (PCR) 2.5.4
To confirm the PCR products of gene of interest as a single band with the correct 
size, PCR reaction was set using the following mixture: 0.5μl 100mM dNTP mix, 
0.8μl Red Taq DNA Polymerase PCR enzyme, 19.2μl RNAse free water, 1μl  
cDNA template (see‎2.5.3), 0.5μl NGAL or 36B4 Forward and  0.5μl NGAL or 36B4  
Reverse primer (20μM). The samples were run using the following PCR cycle: 
denaturing at 95°C for 3min, and amplified through 40 cycles with denaturing at 
95°C for 15sec, annealing at 58°C for 30sec, followed by extension at 72°C for 30 
sec and final elongation at 72°C for 10 min.  
 
The size of the amplicons products were examined on agarose gels as follows: the 
PCR products and 1 kb DNA ladder were run at 110V on 1.8% agarose gels using 
1x Tris-Acetate-EDTA Buffer (TAE) buffer. Gels were viewed using the Syngene 
GBox-HR Gel Doc System. As shown in the representative gel for NGAL 
amplicons (Figure 2-4) a single band at 100bp was observed for NGAL obtained 
from neutrophils and wound fluid cells, the kidney tissue was used as a positive 
control. Amplicons for other genes studied were also examined in a similar manner 
and were also shown to produce amplicons of the expected size (not shown). 
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Figure ‎2-4: The amplified NGAL qPCR product. 
NGAL qPCR product was confirmed as a single band (135 bp for NGAL in 
agarose gel (1.8%). The loading order is: (L) DNA ladder (1) no template 
control, and NGAL in (2) neutrophil (3) kidney (4) wound fluid cells. 
 
 
 Quantitative real time polymerase chain reaction 2.5.5
Quantitative RT-PCR was used to detect relative or absolute gene expression level. 
The cDNA was amplified in duplicate using a Rotor-Gene 6000 (Corbett) and 
SensiMix SYBR Hi-ROX kit (Bioline) and primers specific for MMP-8, MMP-9, 
NGAL the inflammatory markers TNFα, TLR4 and TLR2, and the anti-apoptosis 
marker MCL-1, 36B4 was used as a housekeeper (Table ‎2-2). All PCR products 
were shown to amplify in parallel with 36B4, the no template control (NTC) failed 
to amplify in the range of Ct studied. The melt curve analysis showed a unique peak 
for all primer pairs. For each gene the linear range of amplification was determined. 
Representative example for NGAL is shown in Figure 2-5.  
 
 
 L         1        2        3           4                     
100bp 
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Figure ‎2-5: A representative images for establishment of linear range of amplification of 
NGAL.  
Shown in (A) amplification plots (B) melt curve (C) and standard curve 
showing linear amplifications over ½ dilution range for NGAL and (C)1/5 
dilution for 36B4.   
 
 
 Tissue Preparation  2.6
 As mentioned skin samples containing wounds were obtained at termination and 
wounds were divided in half and snap frozen in OCT and liquid nitrogen. Other wounds 
were fixed in 10% Formalin for 24 hours at room temperature. The fixed tissues were 
then incubated in 70% ethanol at 4°C overnight and then dehydrated using a series of 
alcohols (70%, 80%, 90%, and 100%, respectively). The tissues were then cleared in 
Cycling green Melt curve 
CT = -3.347*log (conc) + 18.789 CT = -3.232*log (conc) + 19.923 
36B4 standard curve  NGAL standard curve  
(A)                                                                 (B) 
(C)                                                               (D) 
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xylene and embedded in paraffin. Each sample was embedded perpendicular to the 
surface and serial sections of 5μm thickness were cut using a microtome, placed on a 
slide, dried and stored at 4°C for latter histological and immunohistological studies. 
 
 Histological analysis 2.6.1
For morphological analysis of wound tissue, samples were stained with 
Hematoxylin (H), and counterstained with Eosin (E). To stain for collagen I and III, 
sections were stained with hematoxylin for nuclei and then in PSR (Picro-Sirius Red 
Stain) for one hour. For both types of stain the slides were washed and dehydrated 
and coverslipped. 
 
Analysis of histological staining was achieved by 2 independent observers who were 
blinded to the source of tissue. The scoring system used was based on a score of 0-3 
where 0 represented light colour intensity and 3 were intense staining. Additionally, 
as there are three distinct zones in the granulation tissue each zone (top, middle, and 
bottom) was independently scored (Figure ‎2-6). Lesions relating to histopathological 
changes were scored in the granulation tissue of stained slide shown in Table 2-3. 
For analysis the score for each zone was added and the data was analysed with a 
staining intensity cut off at > 6, by Chi squared analysis. 
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Figure ‎2-6: Three distinct zones in the granulation tissue for PSR staining 
 
 
Lesions relating to histopathological changes were scored in the granulation tissue 
of stained slide shown in Table ‎2-3. 
 
Table ‎2-3: Scoring of PSR results for collagen deposition in skin wounds. 
 
 
 
 
 Granulation tissue 
PSR Scores                      Zone ( Top         Middle            Bottom) 
0 No staining 
1 Low staining 
2 Moderate staining 
3 Intense staining 
Top 
Middle 
Bottom 
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 Immunohistochemical staining  2.6.2
All antibodies used for immunohistochemical staining were first titrated and then 
used at an appropriate concentration. Isotype controls, a control to measure the level 
of non-specific background staining were used at the same concentrations as the 
respective primary antibodies listed in the Table ‎2-4.  
 
 To determine the NGAL, and MMP-9 positive cells, immunohistochemical staining 
was performed on the skin sections of the experimental animals. The wounded skin 
tissue was prepared as previously described in section 2.6. Antigenicity was 
retrieved by boiling (20 min) in target retrieval solution (Tris EDTA, PH 9.0) in a 
microwave; the slides were cooled for 20 min and placed in TBST. The slides were 
incubated with a peroxidase block solution (3% H2O2) in TBS-T for 10 min and then 
immersed 3 times with TBST for five min each. Non-specific binding was then 
prevented by incubation of the slides in a blocking reagent (10% Normal Goat 
Serum NGS) for 10 min. The sections were then incubated with the appropriate 
primary antibody overnight at 4°C. The rest of the staining was performed at room 
temperature. The slides were washed 3 times in TBST and incubated with the 
appropriate secondary antibody (Table ‎2-4). After 40 min the slides were washed in 
TBST (3×5) and incubated with Vectastin ABC kit (Vector, PK-4000) for 60 min. 
To develop the color, the slides were incubated with 3, 3-diaminobenzidine (DAP) 
substrate for 1-2 min. The slides were then counterstained with hematoxylin to stain 
the nuclei and mounted with coverslips. All slides were examined by light 
microscopy (× 200) (Olympus AX-70 - Fluorescence). 
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Table ‎2-4: Antibodies used in the immunohistochemical study. 
Primary Ab Application Description Secondary Ab 
NGAL 1:800 ab41105, Abcam  1:200 goat anti rabbit, Vector  
MMP-9 1: 4000 ab76003, Abcam 1:200 goat anti rabbit, Vector 
 
 
All samples stained for NGAL expression were examined in the epithelial (top), 
granulation tissue (middle) and inflammatory (basal) zones. Scoring was based on a 
scale of 0-3 where 0 represented no staining above isotype control and 3 were 
intense staining (Table ‎2-5).  For MMP-9 scoring the percentage of positive stained 
cells was calculated using ImageJ software. 
 
Table ‎2-5: scoring method for NGAL expression in skin wounds. 
 
 
 Immunofluorescence staining 2.6.3
NGAL localisation and expression was studied in the wound tissue, sponge 
inflammatory cells and isolated neutrophils. The cells expressing NGAL (M145, 
Santa Cruz) were identified by co-localisation with MPO (ab45977, Abcam) for 
neutrophils and CD68 (ab31630, Abcam) for macrophages. The co-localisation of 
 Epidermis Dermis Hypodermis 
               
NGAL 
scores 
Tip Top Bottom Inflammatory 
cells 
Endothelial 
cells 
Fibroblasts inflammatory 
cells 
0 No staining 
1 Less staining 
2 Moderate staining 
3 Intense staining 
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NGAL and MMP-9 in isolated circulating neutrophils was also investigated as a 
marker of neutrophil activation.  
 
For these studies, cryo sections of wound tissue and cytospun cells were fixed with 
cold methanol for 15 min and permeabilised with 0.2% TritonX-100. After washing 
in PBST, the slides were incubated overnight in NGAL antibody (1:500) at 4°C. The 
slides were then washed (PBST) and incubated in secondary antibody (1:200, Alexa 
Fluor 488, goat anti rabbit, Invitrogen). After removal of excess antibody by 
washing in PBST, the slides were incubated with antibodies to MPO, CD68, or 
MMP-9 (at 1:1600, 1:400, 1:4000 respectively) for 1 hour at RT. After 3 washes (5 
min) the MPO, CD68 or MMP-9 were visualised by incubation with secondary 
antibody (1:200, Alexafluor 594, goat anti rabbit/or goat anti mouse Invitrogen). 
Stained cells were then mounted and the nuclei were visualised by staining with 
DAPI. Images were captured at magnification 200× using a fluorescence microscope 
and the number of positive cells per 100 cells was determined. 
 
 Flow Cytometric Studies  2.7
Flow cytometry was used for determination of the number of neutrophils and 
monocytes as well as neutrophil apoptosis in whole blood and also in the samples 
collected from the implanted sponges. For flow cytometric analysis, blood or sponge 
infiltrate (100 µL) was added to an equal volume of RBC lysis buffer. After lysis, 
the reaction was stopped by addition of PBS (900 µL) and the pellet was collected 
by centrifugation at 300g for 5 min. The pellets were washed by resuspension in 
FACS buffer (1% BSA, PBS, and 0.1% sodium azide) and re-pelleted by 
centrifugation (5min at 300g). The supernatant was then decanted and the cell pellet 
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was re-suspended in 100-µL FACS buffer for flow cytometric analysis (FACS 
Canto flow cytometer).  
 
Neutrophil and monocyte numbers were calculated based on their morphology by 
forward scatter (FSC) and side scatter (SSC). Neutrophil viability and apoptosis was 
determined after staining with PE-conjugated mouse anti-rabbit RP-1 (BD 
Biosciences) as a rat neutrophil marker and annexin V (Biolegend) and Near-IR 
Dead Cell Stain (LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit: Life Tech.) as 
live and dead cell markers respectively. For this analysis, cells were incubated with 
Annexin V and Near-IR prior to fixation with 1% paraformaldehyde for 10 min at 4ᵒ 
C. The cells were then permeabilised by incubation with saponin buffer (0.5% 
saponin, 0.5% BSA, 0.05% NaN3 in PBS) for 15 min at room temperature. After 
permeabilisation cells were spun for 5 min at 300g and the pellets were washed with 
FACS buffer and spun (300g, 5min). The cells were then stained with RP-1 (3μL). 
Cells stained with PE-conjugated mouse anti-rabbit isotype (PE Mouse IgG2a, BD 
Biosciences) were used as negative controls. Analysis of data was performed using 
Flowjo software (Treestar Flowjo V.X10). 
 
  Statistical Analysis 2.8
Datasets were tested for their conformance to normality and subjected to the analysis 
of variance. Analyses were carried out with the Statistical Package for the Social 
Science (SPSS for Windows, version 20). The effects of treatments on diabetic 
animals were then compared across normal, diabetic, and treatment groups using 
one-way ANOVA followed by Tukey's post-hoc test for multiple comparisons. 
Values are expressed as mean ± standard error (SEM) and all statistical tests are 
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conducted at 95% confidence level (P<0.05). Independent sample T-Test was used 
for statistical comparison of two groups. Chi square test was used for comparison of 
the histopathological scores.  
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 CHAPTER 3: Effect of Diabetes 3
on Wound Healing and 
Neutrophil Activity 
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 INTRODUCTION 3.1
There are several factors that influence wound healing in a diabetic patient. Some of 
these factors include hyperglycemia, macrovascular and microvascular disease, 
immune system deficiency and infection may contribute to wound infection and 
delayed wound healing in diabetic patient. In addition, leukocytes in particular 
neutrophils are not only involved in protection against invading environmental 
microorganisms but they also participate in the inflammatory stage of wound 
healing (Wilgus et al., 2013). Matrix metalloproteinase that are proteases, are stored 
in neutrophil granules in their latent form and are activated on release. Of the MMPs 
present in neutrophil granules, the functions of MMP-8 (Pirila et al., 2007), and 
MMP-9 (Liu et al., 2009) are associated with chronic wounds. NGAL which is 
secreted from activated neutrophils can bind to MMP-9 to prevent its degradation 
(Kjeldsen et al., 2000) but whether it plays a role in increased MMP activities in 
poorly healing wounds in diabetes is not known. Our previous studies have shown 
that increased level of MMP-9 can predict poor wound healing in diabetic foot 
ulcers (McLennan et al., 2008) and diabetes can affect circulating neutrophil 
function. Whether neutrophil activities increase MMP-9 activity in diabetic wounds 
is not known.  
 
Insulin plays a critical role in regulation of wound healing and impairment of insulin 
signalling has been shown to contribute to impaired wound healing. It is well 
documented that insulin signalling pathways such as  Insulin receptor substrate 1 
(IRS-1), SHC, Protein kinase B (AKT), and Extracellular Signal-Regulated Kinases 
(ERK1/2) are significantly decreased (Lima et al., 2012). Insulin treatment can 
accelerate wound healing rate and is accompanied by decreased inflammation,  
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increased collagen deposition (Madibally et al., 2003) and increased proliferation 
and migration of keratinocytes (Brem & Tomic-Canic, 2007). In terms of the effect 
of insulin on inflammatory cells, insulin treatment decreased the number of 
infiltrating neutrophils by inhibiting expression of macrophage inflammatory 
protein-2 and stimulating neutrophil function (Sunahara et al., 2012). For instance, 
insulin improves neutrophil migration, phagocytosis and ROS production in the 
diabetic environment (Alba-Loureiro et al., 2007) and prevents the increased 
neutrophil numbers in the peripheral blood (Walrand et al., 2004). Insulin has a 
potent anti-inflammatory effect by reduction of pro-inflammatory transcription 
factors, suppression of MMP concentration (P. Dandona et al., 2002) and inhibition 
of the pro-inflammatory transcription factor early growth response gene-1 
expression in mononuclear cells (Aljada et al., 2002).  
 
In this chapter to investigate the effect of diabetes on the relationship between 
MMP-9 and neutrophil activities in wound healing, two wound healing models were 
used. In addition, a small pilot study at 3 week diabetes duration time point served to 
establish the methodology for circulating neutrophil isolation. The data from this 
pilot study are included in this chapter.  
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The studies described in this chapter were designed to investigate: 
 The effect of diabetes on wound NGAL and MMP-9 levels 
 The effect of diabetes on gene expression of NGAL and MMP-9 in 
inflammatory cells in the wound and circulation 
 The association between NGAL and MMP-9 activity in wound fluid and 
plasma 
 The effect of insulin on NGAL and MMP-9 levels in inflammatory cells and 
fluids 
 
 MATERIALS AND METHODS 3.2
As previously described in Chapter 2, male Sprague-Dawley rats were used to 
investigate the effect of diabetes on wound healing in both an excisional wound and 
a wound sponge implant model. Diabetes mellitus was induced using STZ (65 
mg/kg) as described in Chapter ‎2.2. To investigate the effect of diabetes and the 
combination of diabetes and wounding on circulating inflammatory cells, a sub 
study was performed in animals with 3 weeks duration of diabetes and the results 
were compared with results obtained from a larger study in animals with 6 weeks 
duration of diabetes.  
 
For the study at 3 weeks duration of diabetes, the study animals were divided into 
control and diabetic groups as shown in Figure 3-1. 
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Figure‎3-1: Experimental design for 3 weeks duration of diabetes studies. All animals 
were terminated at Day 6 and the wound tissue and sponge implants were removed for 
analysis. 
 
 
 
 
 
 
 
 
 
Circulating neutrophils 
 
3 weeks duration of 
diabetes  
 
Wound 
 
Unwounded 
N=4-5 /group  
 
Excisional 
 Wound model 
N=5-6/group 
 
Sponge implant 
model  
N=6-7/group 
             CON                 DM    
Skin wounds, Plasma, 
Circulating neutrophils 
 
Wound fluid, Inflammatory 
cells, Plasma  
Circulating neutrophils 
 
80 
 
Shown Figure 3-2 is the study design for animals with 6 weeks duration of diabetes. 
All animals were divided into following groups. 
 
1) Control animals that did not receive any treatment (CON) 
2) Diabetic animals were treated with a low dose insulin regimen (2-4IU 
insulin, twice weekly) to maintain their body weight and prevent 
ketoacidosis (DM) 
3) Diabetic animals that were intensively treated with a dose of insulin 
(10IU/day) (DM+INS), which aimed to maintain near normal glycemia.   
Samples studied included i) wound tissue from the excisional model, ii) sponge 
inflammatory cells and wound fluid from the sponge implant model, and iii)  
circulating neutrophils which were isolated from whole blood.  
 
For these studies the wounds in the excisional wound healing model four full-
thickness circular wounds were created on the dorsal of the rats and at termination 
(day 6) the skin containing the wound tissue was excised for further experiments.  
 
For the wound sponge model sterilised PVC sponges were inserted surgically on the 
dorsum of the animals and the incisions were closed. Animals in this model were 
terminated at day 3, 6, and 12 days after sponge implantation. The implanted 
sponges were removed and inflammatory cells were removed by centrifugation from 
wound fluid. In both animal models blood was obtained by cardiac puncture and 
collected into the heparinised blood tubes for isolation of neutrophils, quantitation of 
the number of neutrophil and monocyte and detection of the plasma MMP activity 
as described in Chapter 2. 
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Neutrophil specific genes MMP-8, MMP-9, NGAL and other pro-inflammatory 
markers TNFα and TLR4 and TLR2 were measured from the sponge implant 
inflammatory cells as well as in circulating neutrophils. The NGAL/MMP-9 
complex and pro and active forms of MMP-9 in the wound fluid, and plasma were 
also quantified.  Flow cytometry was used to investigate the effect of diabetes on 
inflammatory cell numbers in blood and wound fluid. 
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   Figure ‎3-2: Experimental design for insulin treatment studies 
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 RESULTS 3.3
  Effect of 3 Weeks Duration of Diabetes on Wound Healing 3.3.1
 Blood glucose concentration in experimental animals 3.3.1.1
Body weight and blood glucose level was measured after 3 weeks diabetes. The 
body weight in diabetic animals (396.1± 8.7 g) was significantly lower than control 
(471.5 ± 7.1 g). Diabetic animals had also a significantly higher non-fasting blood 
glucose level than control non-diabetic animals (22.7 mmol/L in diabetic vs. 
5.1mmol/L in control animals; P<0.05). 
 
 Effect of diabetes on excisional wounds 3.3.1.2
In this series of studies wounds were placed dorsally after 3 weeks duration of 
diabetes. Wound healing was monitored as described (Chapter ‎2.2.3). Six days later 
the animals were terminated and the skin tissue containing the wound was excised 
and treated for MMP and NGAL measurement by RT-qPCR, zymography, IHC and 
IF as described (Chapter ‎2.6.1).  
 
3.3.1.2.1 Effect of diabetes on wound closure  
Wound area was measured at day 3 and 6 and the percentage wound closure was 
determined.  Shown in Figure ‎3-3 the wounds in diabetic animals displayed delayed 
healing in particular at day 3 when it was significantly slower than controls (11% vs 
26%, diabetic and control respectively). They also tended to be delayed at day 6 but 
the difference was not significant (49% vs 42% respectively). 
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Figure ‎3-3: Percentage wound closure in animals with 3 weeks duration of diabetes 
compared with age matched controls. 
Control (CON: n=5) and diabetic (DM: n=5) animals at 3 and 6 days after 
wounding.  
Results are expressed as Mean ± SEM.*P<0.05 compared  to control.  
 
 
 
3.3.1.2.2 Effect of diabetes on wound NGAL expression by IHC  
The expression and cellular localisation of NGAL was examined by IHC staining. 
As shown in Figure ‎3-4 even at this relatively early time point of 3 weeks, the 
expression of NGAL was increased in the diabetic animals compared with the 
controls (Figure ‎3-4-A). NGAL expression appeared to be localised to the 
inflammatory cells, and to lesser extent fibroblasts, endothelial cells and 
keratinocytes (Figure ‎3-4 B). 
 
 
 
 
 
 
 
* 
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Figure ‎3-4: Representative images of skin wounds showing NGAL expression in skin 
wounds of control and diabetic rats with 3 weeks duration of diabetes.   
(A) NGAL expression in skin wounds control  (CON) and diabetic (DM) animals  
at 3 weeks study. Expression of NGAL in the fibroblasts, endothelial, and 
keratinocyte cells in the diabetic skin wounds shown in (B). Black arrow shows 
some inflammatory cells.  Image magnification (A) ×200, (B) ×400. 
 
 
 
 
 
(A)               Isotype control                         CON                                            DM 
(B)           Fibroblasts                                   Endothelial cell                                  Keratinocytes  
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3.3.1.2.3 Effect of diabetes on wound MMP-9, NGAL and TLRs gene 
expression  
The gene expression of markers of neutrophil activity NGAL and MMP-9 as well as 
pro-inflammatory markers TLR4 and TLR2 were measured in the RNA extracted 
from skin wounds. As shown diabetes increased NGAL mRNA level (by 1.8 fold) 
and but had no effect on MMP-9 mRNA. The effect of diabetes on TLRs was also 
measured as a marker of differences in bacterial load and /or altered inflammatory 
pathways. At the mRNA level, no differences in the expression of these markers 
were observed (Figure ‎3-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-5: Gene expression of NGAL, MMP-9, TLR4 and TLR2 in the skin wounds at 3 
weeks duration of diabetes.  
Control (CON: n=5), and diabetic (DM: n=5) animals. Values are corrected 
for the expression of 36B4 as a housekeeper gene and expressed as fold change 
from control. Data are Mean ± SEM.*P <0.05 vs. control.   
 
* 
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 Effect of diabetes on the sponge implant inflammatory cells 3.3.1.3
The effect of diabetes on the sponge implant inflammatory cells was studied at two 
different durations of diabetes, i.e. 3 and 6 weeks diabetes duration. In this series of 
studies sponges were implanted sub-dermally in the flanks of animals, at defined 
time points (3, 6, and 12 days after sponge implant) the sponges containing the cells 
and fluids were removed and the cells and fluids isolated as described in 
Chapter ‎2.2.4.  
 
3.3.1.3.1 Effect of diabetes on the sponge implant inflammatory cell NGAL 
gene expression  
In the animals with 3 weeks duration of diabetes, animals were terminated at day 6 
after implantation of the sponge. The cells and fluids were removed and the cellular 
NGAL mRNA level was determined by qRT-PCR. Results in Figure ‎3-6 showed 
that the NGAL mRNA was significantly increased (4 fold) in the diabetic animals 
compared to controls. 
 
 
 
 
 
 
 
 
 
Figure ‎3-6: NGAL gene expression in the sponge implant inflammatory cells at day 6 in 
animals which had 3 weeks duration of diabetes. 
Control (CON, n=5) and DM (diabetic, n=5) animals. Values are corrected for 
the expression of 36B4 as a housekeeper gene and expressed as fold change 
from control. Data are Mean ± SEM.*P <0.05 vs. control.   
* 
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 Effect of diabetes on the circulating neutrophils 3.3.1.4
To investigate the effect of diabetes and/or wounding on circulating neutrophils, the 
neutrophils were isolated from whole blood obtained at termination from the control 
and diabetic animals in both wounding models. In a parallel experiment neutrophils 
from unwounded animals with the same duration of diabetes were also studied. The 
cellular protein concentrations of NGAL were examined by immunofluorescence 
and their gene expression of markers of activated neutrophils and inflammation by 
qRT-PCR. Plasma MMP-9 activity and NGAL/MMP-9 was also measured by 
zymography.  
 
3.3.1.4.1.1 Effect of diabetes on the circulating inflammatory cells 
The profile of expression of NGAL was examined in the circulating neutrophils and 
monocytes by IF staining. As shown in the representative photos in the Figure ‎3-7 
neutrophils were the main source of NGAL. 
 
 
 
 
 
 
 
 
Figure ‎3-7: Representative images showing NGAL expression in monocytes and 
neutrophils isolated from blood in animals which had 3 weeks duration of diabetes. Red 
colour shows the expression of NGAL in the circulating monocytes and neutrophils.  
Image magnification ×400. 
. 
 
 
Monocytes Neutrophils 
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3.3.1.4.2 Effect of diabetes on the circulating neutrophils by qRT-PCR 
In the short duration of diabetes, gene expression of markers of activated neutrophils 
NGAL, MMP-8 and MMP-9 and inflammation markers TLR2 and TLR4 and TNFα 
was measured in the circulating neutrophils by qRT-PCR. As shown in Figure ‎3-8 in 
unwounded animals diabetes tended to increase the gene expression of neutrophil 
NGAL and MMP-8, but neutrophil MMP-9 was not altered. On the other hand 
analysis of circulating neutrophils obtained from animals six days after wounding 
showed increased expression of NGAL, MMP-9, and MMP-8 mRNA in the diabetic 
animals. However no change in expression of these genes was observed in 
circulating neutrophils isolated from animals in which the sponges had been 
implanted.  
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Figure ‎3-8: NGAL, MMP-9, and MMP-8 gene expression in the circulating neutrophils 
from (A) unwounded, (B) excisional and (C) sponge implant models in animals which 
had 3 weeks duration of diabetes. 
Control (CON, n=5) and diabetic (DM, n=5) animals. Values are corrected for 
expression of 36B4 as a housekeeper gene and expressed as fold change fro m 
control. Data are Mean ± SEM.*P <0.05 vs. control.   
* 
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3.3.1.4.3 Effect of diabetes on neutrophil apoptosis by gene expression 
Neutrophil clearance is important for the resolution of inflammation and their 
apoptosis is critical for their uptake by macrophages. Whether diabetes and 
wounding can alter circulating neutrophil apoptosis is not known. In this study 
neutrophil apoptosis was examined by measurement of the anti-apoptotic marker 
MCL-1 in the neutrophils. As shown in Figure ‎3-9 diabetes alone significantly 
decreased MCL-1 gene expression by 0.5 fold compare to control. In contrast, 
diabetic animals wounded with an excisional wound, had significantly increased 
neutrophil MCL-1 gene expression (by 2.2 fold, P<0.05) compared to control. 
Consistent with a lack of change in expression of neutrophil activation markers 
neutrophil MCL-1 mRNA was not altered in the circulating neutrophils obtained 
from the sponge implant model.   
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Figure ‎3-9: MCL-1 gene expression in the circulating neutrophils from (A) Unwounded, 
(B) excisional wounds and (C) sponge implant models in animals which had 3 weeks 
duration of diabetes.  
Control (CON, n=5) and diabetic (DM, n=5) animals. Values are corrected for 
expression of 36B4 as a housekeeper gene and expressed as fold ch ange from 
control. Data are Mean ± SEM.*P <0.05 vs. control.   
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  Effect of Longer Duration of Diabetes (6 Weeks) on Wound Healing 3.3.2
 Blood glucose concentration in experimental animals 3.3.2.1
As expected the diabetic animals had a higher non-fasting blood glucose level and 
lower body weight than control animals. Insulin treatment at a dose of 10IU/ day 
partially normalised these parameters. To establish that the insulin treatment 
regimen was effective in normalisation of blood glucose levels we performed serial 
measurements of blood glucose levels and showed near normal levels 4 hours and 
12 hours post injection Table ‎3-1. 
 
Table ‎3-1: Blood glucose level and body weight in the experimental animals 
 
 
 
 
Groups 
 
Start weight 
(g) 
Week1 
   
Termination 
weight (g) 
 
 
BGL 
(mmol/L) 
4hr after 
insulin 
injection 
Week 6 
BGL 
(mmol/L) 
12 hr after 
insulin 
injection 
Week 6 
BGL 
(mmol/L) 
24hr after 
insulin 
injection 
 
 
CON 338.5±7.4 488.3±9.9 5.01±0.1 5±0.1 5.07±0.1  
DM 334.8±6.3 373.8±10.2* 19.1±0.8* 21.3±0.8* 21.2±1.4*  
DM+INS 329.1±11.2 421.7±9.6* 3.4±0.4# 9.2±1.6*# 17.12±0.6*#  
Results are expressed as Mean ± SEM, *P<0.05 different from Control (CON) 
#
P<0.05vs diabetes. n=8/group 
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 Effect of diabetes on skin wounds  3.3.2.2
Excisional wounds were created on the dorsal of rats and monitored during wound 
healing for 6 days. Six days later the animals were terminated and skin wounds were 
excised for measurement of gene and protein levels as described. 
 
3.3.2.2.1 Effect of diabetes on wound closure 
At day 6 the wounds were not fully closed in any of the groups. However the 
wounds in the control animals were significantly smaller than those in the diabetic 
group with a reduction wound area from day 0 (time of incision) of 65% ± 2% and 
50% ± 2% in control and diabetic animals respectively (P ≤ 0.05).  Intense insulin 
treatment prevented the diabetes associated decrease in wound closure such that the 
reduction in wound area was not different to control at day 6 (Figure ‎3-10).  
 
Figure ‎3-10: Percentage of wound closure in 6 weeks experimental animals after 6 weeks 
duration of diabetes.  
Wound area was measured in control (CON, n=8) and diabetic (DM, n=8) and 
insulin-treated (DM+INS, n=8) animals at 3 and 6 days post wounding. 
Results are expressed as percentage of the initial area and expressed as Mean 
± SEM.* P<0.05 vs CON.  
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3.3.2.2.2 Effect of diabetes on skin wounds (Morphology) 
The histological profile of the wounds was also studied and representative H&E 
results are shown in Figure ‎3-11. As shown, in the wound from the diabetic animal 
the extracellular matrix was less well formed, (i.e. less thickness and less intense 
staining, suggesting less matrix volume), than that seen in the wound from the 
control animal. Insulin treatment partially prevented these changes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-11: Representative images of skin wounds from excisional wounds. 
Wound morphology by H&E staining in control (CON, n=4) diabetic (DM, 
n=3) and insulin-treated (DM+INS, n=4) groups. Image magnification ×400. 
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The sections were also stained with PSR and the PSR sections were also examined 
using polarised light microscopy, to detect and analyse collagen I and III fibres. 
Using the PSR stain the collagen deposition was scored from light (0) to dark (3) in 
the dermis of skin wounds and analysed using Chi-Square Tests (Table ‎3-2). Results 
showed the mature collagen bundles in control animals are long, thick, and wavy. 
The collagen bundles were appeared thin and less formed in diabetic wounds 
(P<0.01). Insulin treatment partially improved collagen deposition (Figure 3-12-A). 
 
In the present study, picrosirius red stained tissues under polarising microscopy 
showed different colour and orientation of collagen fibres between different groups. 
Control groups showed predominantly yellow-orange birefringence combined with 
some amount of yellowish-green birefringence towards hypodermis. In contrast, in 
diabetic group the predominant birefringence was red yellowish and yellowish-green 
was less formed. Yellow-orange birefringence was observed mainly in thick fibres 
and red-yellowish was localised in thin fibres (Figure 3-12-B). 
 
Table ‎3-2: Chi-Square tests for analysis of PSR staining in the skin wounds.  
 Dermis 
Scores < 2 Scores ≥ 2 
CON 0 4 
DM 3 0 
DM+INS 3 1 
Asymp. Sig. (2-sided) 0.01* 
*P<0.05 different between groups 
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Figure ‎3-12: Representative images of skin wounds from excisional wounds.  
Showing collagen deposition by (A) PSR staining and (B) polarised light 
microscopy in control (CON, n=4) diabetic (DM, n=3) and insulin-treated 
(DM+INS, n=4) groups. Image magnification ×400. White arrow thin fibres. 
Blue arrow thick fibres.   
 
 
 
3.3.2.2.3 Effect of diabetes on wound NGAL and MMP-9 expression   
The expression and localisation of NGAL and MMP-9 in wounded skin was studied 
by IHC and in a parallel series NGAL co-localisation with MMP-9 was examined by 
IF staining. 
 
As shown in Figure ‎3-13 the representative photos NGAL staining was increased in 
the diabetic wounds tissue (Chi-Square Tests, P<0.01). Histopathology changes 
were scored from none (0) to intense brown (3) based on the isotype control as 0. 
The average of scores were then grouped into scores less than 2 and scores greater 
(A) 
 
 
(B) 
                CON                                         DM                                            DM+INS 
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than 2 for Chi-Square Tests. As shown in Table ‎3-3 significant changes were only 
observed in the dermis area, where the count number greater than 2 was higher in 
the diabetic group than the control group.  
 
Table ‎3-3: Chi-Square tests for analysis of NGAL staining in the skin wounds.  
 Epidermis Dermis Hypodermis 
Scores < 2 Scores ≥ 2 Scores < 2 Scores ≥ 2 Scores <  2 Scores ≥ 2 
CON 4 1 5 0 1 4 
DM 5 0 1 4 0 5 
DM+INS 4 0 4 0 1 3 
 Asymp. Sig. (2-sided) 
Epidermis .37 
Dermis 
.006* 
Hypodermis .5 
Overall .045* 
*P<0.05 different between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-13: IHC representative images of skin wounds for NGAL expression. 
Showing NGAL in control (CON, n=5) diabetic (DM, n=5) and insulin-treated 
(DM+INS, n=4) animals by IHC in the wound granulation tissue. Image 
magnification×400.  
  
 
 
  
                CON                                         DM                                            DM+INS 
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MMP-9 expression was also examined in the wound skins by IHC staining and 
representative images are shown in (Figure ‎3-14). The number of MMP-9 positive 
cells which were calculated using ImageJ was significantly higher in diabetic 
animals compared to control. These changes were prevented by insulin treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-14: IHC representative images and group data for MMP-9 staining in skin 
wounds. 
Representative images of skin wounds showing MMP-9 staining and the 
localisation as well as the group data in control (CON, n=5) diabetic (DM, 
n=5) and insulin-treated (DM+INS, n=4) animals. Data are Mean ± SEM. 
Image magnification ×400.*P<0.05 vs. control .  
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The results from IF staining for NGAL/MMP-9 co-localisation showed that the 
majority of NGAL positive cells were co-localised with MMP-9 in the skin wounds 
(Figure ‎3-15). 
 
 
 
 
 
 
 
Figure ‎3-15: IF representative images of skin wounds for NGAL/MMP-9 co-localisation.  
Showing IF pattern of expression of NGAL and MMP-9, and NGAL/MMP-9 co-
localisation in the wound granulation tissue in diabetic animals. Image 
magnification ×200. 
 
 
3.3.2.2.4 Effect of diabetes on skin wound gene expression 
The skin wounds were obtained at termination (day 6) and frozen at -80
º
C until use. 
The wound tissue was then homogenised in Tri Reagent and RNA was extracted as 
described in Chapter 2. As shown at the gene level diabetes increased NGAL (by 2 
fold compared to control) and this change were prevented by insulin treatment 
Figure ‎3-16. The expression of MMP-9 was not different across the groups and 
MMP-8 tended to be increased in the diabetic and insulin-treated animals but this 
failed to reach statistical significance. Pro-inflammatory mediators TLR-4 and TLR-
2 were increased in diabetic animals. Insulin treatment significantly prevented the 
increase in expression of TLR-2 in diabetic animals (P<0.05, T-test) and partially 
normalised TLR-4. 
 
   
                NGAL (Green)                          MMP-9 (Red)                      NGAL/MMP-9 (Yellow) 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-16: Gene expression of (A) NGAL, MMP-9, MMP-8, (B) TLR4 and TLR2 in the 
skin wounds. 
Control (CON, n=12), diabetic (DM, n=5) and insulin-treated (DM+INS, n=6) 
animals. Values are corrected by 36B4 as housekeeper gene and expressed as 
fold change from control.  Data are Mean ± SEM.*P<0.05 vs. control.  
┼
P<0.05 
vs. diabetic by T-test. 
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 Effect of diabetes on sponge implant wound cells  3.3.3
To determine the effect of diabetes on wound inflammatory cells a wound implant 
model was used. The cells and fluids were extracted from the implant at days 3, 6 
and 12 post implant and the expression of NGAL, MMP-9 and MMP-8 as well as 
some pro-inflammatory mediators was analysed.  
 
 Effect of diabetes on wound inflammatory cell gene expression 3.3.3.1
Shown in Figure ‎3-17 the gene expression of NGAL was significantly up regulated 
in the diabetic animals at day 6 and persisted at day 12 (each approximately 3.5 fold 
vs. control, P<0.05). MMP-8 expression was increased at day 6, but not day 3 and 
day 12. In contrast the expression of MMP-9 was not altered at any of the time 
points studied. Additionally, diabetes had no effect on the expression of TLR2, 
TLR4, and TNF (Figure 3-18). The diabetes associated increase in NGAL and 
MMP-8 gene expression was prevented by insulin treatment. Interestingly in the 
insulin-treated animals the expression of MMP-9 was significantly increased at day 
12 (P<0.05).  
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Figure ‎3-17: Gene expression of NGAL, MMP-9, and MMP-8 of sponge implant 
inflammatory cells.  
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals (A) 
3days, (B) 6 days, and (C) 12 days after wounding. Values are corrected for 
the expression of 36B4 as the housekeeper gene and expressed as fold change 
from control. Data are Mean ± SEM. *P<0.05 vs control. 
#
P<0.05 vs. diabetic.
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Figure ‎3-18: Gene expression of TLR4, TLR2, and TNFα in sponge implant 
inflammatory cells.  
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals (A) 
3days, (B) 6 days, and (C) 12 days after wounding. Values are corrected for 
expression of 36B4 as housekeeper and expressed as fold change from control.  
Data are Mean ± SEM.*P<0.05 vs. control. # P<0.05 vs. diabetic.  
# 
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 Effect of diabetes on wound inflammatory cell number 3.3.3.2
The implant inflammatory cell number and in particular the numbers of neutrophils 
and macrophages was counted at day 6 by immunofluorescence using MPO and 
CD68 (red) respectively. Shown in Figure ‎3-19-A compared with controls, in 
diabetic fluids the percentage of MPO positive cells were significantly increased (by 
2 fold). A similar trend was observed for the macrophages but this failed to reach 
significance. Insulin treatment prevented these changes. 
 
Co-localisation studies showed that whilst some macrophages stained positively for 
NGAL (yellow) it was predominantly associated with neutrophils. The percentage of 
NGAL positive cells (green) was significantly increased (P<0.05) in the diabetic 
animals and this increase was seen in both neutrophils and macrophages. The 
increase in the percentage of NGAL positive cells was not observed in the insulin- 
treated animals (Figure ‎3-19).   
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Figure ‎3-19: Representative images of sponge inflammatory cell infiltrates. 
Showing (A) NGAL (green), MPO (red), and CD68 (red) expression and 
percentage (B) NGAL/MPO (yellow) and NGAL/CD68 (yellow) co-localisation. 
Representative images from control (CON) diabetic (DM) and insulin-treated 
(DM+INS) animals by IF. Image magnification ×400. Group data is 
percentage positive cells. Data are Mean ± SEM. *P<0.05 vs control. 
#
P<0.05 
vs diabetic. 
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 Flowcytometric identification of wound fluid neutrophils 3.3.3.3
Flow cytometry was also used to examine the wound fluid for neutrophil number. In 
these studies the RP-1 antibody a specific rat neutrophil markers was used.  
 
Figure ‎3-20-A shows a representative dot plot of inflammatory cells in the rat 
wound fluid. Neutrophil population was first identified by size and granularity and 
the percentage of neutrophils calculated. Using this approach and by their staining 
with RP-1 no difference in the number of neutrophils as a percentage of the total cell 
population was observed (Figure ‎3-20-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-20:  Sponge implant inflammatory cells numbers by flow cytometry. 
Control (CON, n=6), diabetes (DM, n=6) and insulin-treated (DM+INS, n=6) 
animals 3, 6, 12 days after wounding. Data are Mean ± SEM.  
(A)                     CON                                               DM                                            DM+INS 
0
20
40
60
80
100
D3 D6 D12
N
eu
tr
o
p
h
il
 (
%
) 
CON DM DM+INS
Day  
(B)                      
108 
 
 Western blot analysis  3.3.4
To identify the NGAL/MMP-9 complex, plasma samples were first subjected to 
western blot analysis using an antibody against NGAL, as well as an anti-MMP-9 
antibody. Under non-reducing conditions a high-molecular-weight form of NGAL at 
115kDa was detected with the anti-NGAL antibody and a band at the same 
molecular weight was detected with the anti-MMP-9 antibody (Figure 3-21-A). 
These results suggested that the band at 115kDa is a complex between 
NGAL/MMP-9. A similar complex was also observed in wound fluid samples 
(Figure 3-21-B). In wound fluids there was an additional NGAL/MMP-9 complex 
that was identified by both NGAL and MMP-9 antibodies at approximately 
125kDA.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-21: Representative images showing western blot analysis of NGAL and MMP-9 
in (A) plasma and (B) wound fluid. 
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 Effect of diabetes on implant fluid MMP-9 activity and NGAL levels 3.3.5
Gelatin zymography was used as a tool to measure MMP-9 protein in its pro as well 
as biologically active forms. Bands of gelatinolytic activity at 115 and 125 kDA 
were also observed and from our western blot analysis this band corresponded with 
the NGAL/MMP-9 complex, enabling us to also examine NGAL/MMP-9 complex 
formation in these samples. Results are shown in (Figure ‎3-22).  In diabetic animals 
there was a transient increase in total MMP-9 (TMMP-9) at day 6 (P<0.001) but this 
was not apparent at day 3 and day 12. This increase in TMMP-9 was due to an 
increase in the active form of MMP-9 at day 6 and was prevented by insulin 
treatment. Dysregulation between NGAL and MMP-9 levels were observed. In 
diabetic animals increased levels of NGAL/MMP-9 complex were observed at day 6 
and unlike the levels of MMP-9, which decreased, the increase in NGAL/MMP-9 
complex persisted at day 12. Interestingly compared with both non-treated diabetic 
and control animals insulin treatment decreased total MMP-9 (both pro and active 
forms) at day 3 and increased its levels at day 12. Insulin treatment prevented the 
diabetes associated increase in NGAL/MMP-9 complex becoming significant at day 
12.   
 
By ELISA the free NGAL concentration tended to be decreased in the implant fluids 
from diabetic animals but this failed to reach significance (Figure ‎3-22-B).  
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Figure ‎3-22: The effect of diabetes on MMP-9 activity and NGAL level in wound fluid. 
A representative zymograph showing the enzymatic activity of MMP-9, (total: 
TMMP-9, pro: PMMP-9 and active: AMMP-9) as well as NGAL/MMP-9 
complex. Whole group data 3, 6, 12 days after wounding are shown 
graphically.(B) NGAL in wound fluid, measured by ELISA 6 days after 
wounding in control (CON), diabetic (DM) and insulin-treated diabetic 
(DM+INS) animals. AUC (Area Under Curve).  Data are Mean ± SEM,*P <0.05 
vs control. 
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 Effect of Diabetes on Circulating Neutrophil Gene Expression 3.3.6
 Effect of diabetes on the circulating neutrophils gene expression in 3.3.6.1
unwounded animals  
To investigate the effect of diabetes on circulating neutrophil activation, the gene 
expression of NGAL, MMP-9, MMP-8 as well as TLR4, TLR2, and TNFα was 
measured in the plasma of blood obtained at termination from unwounded normal 
and diabetic animals with 6 weeks duration of diabetes. 
 
As shown in Figure ‎3-23, in diabetic animals the gene expression of NGAL, MMP-
9, MMP-8 was increased, however this was only statistically significant for MMP-9 
(P<0.05, T-test). The gene expression of TLR4 tended to increase, and TLR2 mRNA 
was not changed across the groups. The expression of TNFα gene was significantly 
increased in the diabetic animals by 4 fold. Insulin treatment did not prevent the 
diabetes-induced changes but interestingly compared to control significantly 
increased the circulating neutrophil NGAL and TNFα gene expression by 3 and 25 
fold respectively. 
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Figure ‎3-23: Gene expression of (A) NGAL, MMP-9, MMP-8, (B)TLR4, TLR2 and (C) 
TNFα in circulating neutrophils from unwounded animals. 
Control (CON, n=5), diabetic (DM, n=4) and insulin-treated (DM+INS, n=5) 
animals. Values are corrected by 36B4 as housekeeper gene and expressed as 
fold change from control.  Data are Mean ± SEM.*P <0.05 vs. control.  
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 Effect of wounding on the circulating neutrophils gene expression in 3.3.6.2
diabetic animals 
The effect of diabetes on circulating neutrophil mRNA, the gene expression of 
NGAL, MMP-9, MMP-8 as well as TLR4, TLR2, and TNFα was first measured in 
the animals in the excisional wound models.  As shown in Figure ‎3-24, compared to 
similarly treated controls, diabetes and wounding increased the gene expression of 
the activated neutrophil markers NGAL, MMP-9, and MMP-8, as well as TLR2, and 
TNFα, but this increase was only statistically significant for TLR2. Insulin treatment 
prevented the increase in NGAL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-24: Gene expression of (A) NGAL, MMP-9, MMP-8, (B) TLR4, TLR2 and 
TNFα in circulating neutrophils from the excisional wound models.  
Control (CON, n=7), diabetic (DM, n=9) and insulin-treated (DM+INS, n=6) 
animals. Values are corrected by 36B4 as housekeeper gene and expressed as 
fold change from control. Data are Mean ± SEM.*P<0.05 vs. control.  n=4-5 
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We had previously in the pilot study in rats with 3 weeks duration of diabetes 
observed a different pattern of expression of neutrophil activation markers in the 
different wound models. Therefore, we also investigated circulating neutrophil 
activation markers in the animals that had received the sponge implant. In this group 
of animals neutrophils were isolated from blood obtained at termination i.e. 3 days, 
6 days, and 12 days after wounding.  
 
As Figure ‎3-25 shows, compared to similarly treated controls the neutrophil 
expression of MMP-9 and MMP-8 was significantly increased in diabetic animals at 
day 3 and day 6 after wounding, and similar trend was observed at day 12 but this 
failed to reach significance. The expression of NGAL, TLR4, TLR2, and TNFα 
were also increased in diabetic animals at day 6 but returned to control levels at day 
12 (Figure ‎3-26).  Insulin treatment prevented these changes. 
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Figure ‎3-25: Gene expression of NGAL, MMP-9, and MMP-8, in circulating neutrophils 
from sponge implant model (A) 3, (B) 6 , and (C) 12 days after wounding. 
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals. Values 
are corrected by 36B4 as housekeeper gene and expressed as fold change from 
control. Data are Mean ± SEM.*P<0.05 vs. control. 
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Figure ‎3-26: Gene expression of TLR4, TLR2, and TNFα, in circulating neutrophils from 
sponge implant model (A) 3, (B) 6 , and (C) 12 days after wounding. 
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals. Values 
are corrected by 36B4 as housekeeper gene and expressed as fold change from 
control. Data are Mean ± SEM. *P <0.05 vs. control. 
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 Effect of diabetes on NGAL and MMP-9 protein in circulating 3.3.6.3
neutrophils  
Representative immunofluorescence staining of circulating neutrophils obtained 
from sponge implant model at day 6 after wounding showed that approximately 20% 
of all neutrophils were NGAL positive (green) whilst 40% were MMP-9 positive 
(red). Diabetes significantly increased both the NGAL positive cells and the MMP-9 
population. Insulin treatment attenuated the increase in NGAL but had no effect on 
MMP-9. Double-immunofluorescence staining showed that NGAL was co-localised 
with MMP-9 predominantly in the peri nuclear regions of the neutrophils 
irrespective of the presence of diabetes. The diabetes associated increase in 
NGAL/MMP-9 co-localisation (yellow) was not altered by insulin treatment 
(Figure ‎3-27). 
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Figure ‎3-27: Representative images of Neutrophil NGAL (green), MMP-9 (red) 
expression and percentage and NGAL/MMP-9 (yellow) co-localisation in circulating 
neutrophils. 
Control (CON), diabetes (DM) and insulin-treated (DM+INS) animals.  Data 
are presented as Mean ± SEM. *P<0.05 vs control. 
#
P<0.05 vs diabetic.  
 
                NGAL                                                                        MMP-9 
  
 
                 NGAL/MMP-9                                                          
* 
* 
* 
# 
120 
 
 Effect of diabetes on MMP-9 activity and NGAL levels in the circulation 3.3.7
in the wounded animals 
The effect of diabetes on the circulating levels of MMP-9 showed no change at the 
plasma levels at day 6. The concentration of NGAL/MMP-9 complex in the 
circulation was also determined and it was significantly decreased in the circulation 
of diabetic animals compared to controls (2.26 ± 0.33 vs 3.76 ± 0.03, P<0.05 
respectively) (Figure ‎3-28). By ELISA the free NGAL concentration tended to be 
decreased in the diabetic animals but this failed to reach significance level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-28: The effect of diabetes on MMP-9 activity and NGAL level. 
Plasma level of AMMP-9, PMMP-9, and TMMP-9 and NGAL/MMP-9 complex 
measured by zymography and (B) soluble form of NGAL 6 days after wounding .  
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals. Data 
are Mean ± SEM. *P <0.05 vs. control.  
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 Effect of diabetes on the neutrophil apoptosis by gene expression 3.3.8
To investigate the effect of diabetes on neutrophil apoptosis MCL-1 gene expression 
was measured in the circulating neutrophils. As shown in Figure ‎3-29 in the 
unwounded group no changes were observed in the diabetic animals in compared to 
control. Insulin increased MCL-1 gene expression but it failed to reach a significant 
level. MCL-1 gene expression also did not alter in circulating neutrophils in 
excisional wound model, whereas, significantly increased levels of MCL-1 were 
observed in the circulation of diabetic animals in the sponge implant model. This 
increase was improved by insulin.  
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Figure ‎3-29: Gene Expression of MCL-1 in the circulating neutrophils from (A) 
unwounded, (B) excisional wounds, and (C) sponge implant model. 
Control (CON), diabetic (DM) and insulin-treated (DM+INS) animals.  Values 
are corrected for the expression of 36B4 as housekeeper and expressed as fold 
change from control. Data are Mean ± SEM. *P <0.05 vs. control.  
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 Effect of diabetes on the inflammatory cell number (Flow Data) 3.3.9
 In order to measure the neutrophil concentration in rat blood; a flow cytometric 
method was developed and the effect of diabetes and wounding was investigated.  
 
As shown in Figure ‎3-30 by flow cytometry, circulating neutrophil and monocyte 
numbers were not altered by diabetes. In contrast, in the sponge implant model, 
wounding significantly increased circulating neutrophil number at days 3 and 6 and 
monocyte number at day 3 and day 12.  These changes were not seen in the insulin- 
treated group Figure ‎3-31.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3-30: Analysis of circulating cell morphology and numbers by flow cytometry. 
Control (CON, n=8), diabetes (DM, n=10) and insulin-treated (DM+INS, n=8) 
animals before wounding. Data are Mean ± SEM. *P<0.05 vs. control.  
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Figure ‎3-31: Analysis of circulating cell morphology and numbers by flow cytometry 
from animals after wounding.   
Control (CON), diabetes (DM) and insulin-treated (DM+INS) animals (A) 3, 
(B) 6, and (C) 12 days after wounding. Data are Mean ± SEM. *P<0.05 vs. 
control. 
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In the circulating neutrophils from the sponge implant model we also used flow 
cytometry with a combination of AnnexinV and near IR to analyse neutrophil 
apoptosis. Rat neutrophils were identified by RP-1 which was positive in 78%, 82% 
and 77% of neutrophils from control, diabetic and insulin-treated animals 
respectively (Figure ‎3-32). Early apoptosis (AnnexinV
+
, near IR
—
) was significantly 
higher (by 9 fold) in the diabetic animals (P≤0.05) compared with control and was 
abolished by insulin treatment (Figure ‎3-33).  
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Figure ‎3-32: Analysis and percentage of circulating neutrophil positive RP-1 by flow 
cytometry.  
In control (CON), diabetes (DM) and insulin-treated (DM+INS) animals 
before wounding. No significant change across the groups. 
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Figure ‎3-33: Analysis of dead and apoptotic neutrophils before wounding. 
Control (CON, n=6), diabetes (DM, n=9) and insulin-treated (DM+INS, n=9) 
animals. Data are Mean ± SEM. *P<0.05 vs. control by ANOVA. 
┼
P<0.05 vs 
diabetic by T-test. 
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 Primary Cell Culture Studies  3.3.10
Some in vitro studies were performed to examine the direct effect of high glucose 
concentration and insulin on neutrophil activation. In this study neutrophils were 
isolated from whole blood as described in detail in Chapter 2 ‎2.3 and cultured in 
RPMI media for 1, 2, and 6 hours. The gene expression of activated neutrophil 
markers NGAL, MMP-9, and MMP-8 as well as TLR4, TLR2, and TNFα as pro-
inflammatory mediators was measured by qRT-PCR. Neutrophil apoptotic state was 
also examined by measurement of the anti-apoptotic marker MCL-1 by qRT-PCR. 
 
As shown in Figure ‎3-34, high glucose did not change NGAL, MMP-9, and MMP-8 
gene expression after 1 hour of incubation. But, these genes were significantly 
increased after 2 hours. This increase was only observed for NGAL expression after 
6 hours. Insulin partially prevented increased NGAL gene expression. High glucose 
had no effect on the expression of TLR2, TLR4, and TNFα after 1 hour incubation 
but significantly increased TNFα gene expression after2 hours of incubation. 
Interestingly, gene expression of TLR2 and TNFα tended to be decreased in high 
glucose environment (Figure ‎3-35). Neutrophil apoptosis, which was measured by 
MCL-1 gene expression, was not altered by high glucose 1 and 2 hour after 
incubation, but was significantly increased after 6 hours (0.73 fold decrease in 
MCL-1 gene expression) (Figure ‎3-36).   
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Figure ‎3-34: The effect of glucose on NGAL, MMP-9, and MMP-8 gene expression in the 
cultured neutrophils. 
Normal glucose (5mM), high glucose (25mM), and presence of insulin 
(25mM+INS) after (A) 1, (B) 2, and (C) 6 hours of incubation. Values are 
corrected for the expression of 36B4 as housekeeper and expressed as fold 
change from control. Data are Mean ± SEM.*P<0.05 vs Normal glucose.  
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Figure ‎3-35: The effect of glucose on TLR4, TLR2, and TNFα gene expression in 
cultured neutrophils. 
Normal glucose (5mM), high glucose (25mM), and presence of insulin 
(25mM+INS) after (A) 1, (B) 2, and (C) 6 hours of incubation. Values are 
corrected for the expression of 36B4 as housekeeper and expressed as fold 
change from control. Data are Mean ± SEM.*P<0.05 vs Normal glucose.  
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Figure ‎3-36: The effect of glucose on MCL-1 gene expression in cultured neutrophils.  
Normal glucose (5mM), high glucose (25mM), and presence of insulin 
(25mM+INS) after (A) 1, (B) 2, and (C) 6 hours of incubation. Values are 
corrected for the expression of 36B4 as housekeeper and expressed as fold 
change from control. Data are Mean ± SEM.*P<0.05 vs Normal glucose.  
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 DISCUSSION  3.4
Delayed wound healing represents a major health problem and is a common 
experience for persons with diabetes (Brem & Tomic-Canic, 2007). Whilst intensive 
research effort has focussed on some of the complications of diabetes, the 
pathophysiology of poor wound healing has received less attention. In chronic 
wounds including wounds in diabetes, poor healing is associated with persistent 
inflammation as shown by an increase in inflammatory cells (Raffetto, 2013). The 
increased number of inflammatory cells in the wound is important as they secrete 
cytokines, MMPs and other proteinases which can further activate MMPs and 
proinflammatory cytokines (Martins et al., 2013). Together, these changes may 
contribute to the pattern of increased MMPs, frequently observed in chronic wounds 
(Liu et al., 2009; Lobmann et al., 2006). To date most studies have measured MMP 
expression in wound tissue and fluids and apart from the persistence of 
inflammatory cells the mechanism for the increased MMP activities is poorly 
understood. We have utilized two different rodent wound models to show diabetes 
related changes in wound and peripheral blood neutrophil and monocyte number. 
The wound sponge model has the advantage that the interstitial fluid and 
inflammatory cells within the defined sponge space can be harvested for analysis. 
Additionally, it uses a relatively inert material, so the site has minimal inflammation. 
At later time points (>2 weeks) the implants can also accumulate granulation tissue 
with a gradient of less well formed tissue in the center of the sponge to the most 
mature at the periphery, but this aspect was not studied in this work. Our study has 
focused on the neutrophil, and shown that in diabetic animals circulating neutrophils 
are increased in association with an increase in neutrophil numbers in the wound. 
The expression of MMP-9 and its regulator NGAL are also affected by diabetes and 
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the pattern of expression is different in the circulation and in the wound tissue. 
Further insulin treatment from the onset of diabetes can ameliorate these changes, 
suggesting that glycaemic control is important. 
 
There is conflicting data regarding the effect of diabetes on neutrophil function and 
the effect of diabetes on wound tissue neutrophils has not been extensively studied. 
In peripheral neutrophils from rodents and humans some authors have reported 
alterations in cytokine production (Alba-Loureiro et al., 2007), respiratory burst 
(Osar et al., 2004)  and bacterial killing (Kewcharoenwong et al., 2013) but others 
have failed to detect such changes (Balasoiu et al., 1997). In this study using acute 
wound models in diabetic animals healing is delayed, and inflammatory cell 
numbers are increased. In addition to change in neutrophil number by MPO staining, 
the increased neutrophil number in the sponge implant model was supported by the 
observation of increased mRNA levels of both MMP-8 and MMP-9 by neutrophils. 
This inflammatory cell profile in the wound tissue and implant is consistent with 
other studies in excisional wounds (Casqueiro et al., 2012; McLennan et al., 2008) 
as well as studies of subcutaneous wounds and foreign body implant models, which 
have described persistence or increased neutrophil numbers (Socarras et al., 2014; 
Thomson et al., 2010). The observed change in wound neutrophil number may occur 
as a result of increased circulating numbers as reported in this study. This increased 
neutrophil number, either in the wound or in the circulation, can also occur as a 
result of alteration in function e.g. increased apoptosis or decreased clearance. Data 
presented here show effects of diabetes or high glucose on apoptosis. Additionally 
the transient nature of the change and the dysregulation of markers of activation 
suggest a diabetes related functional change. The increase in wound neutrophil 
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number was unlikely to be due to increased infection in the diabetic wound tissue as 
TLR4 and TLR2 gene expression which are activated by ligands of microbial origin 
(Kawasaki & Kawai, 2014) were not altered in the wound fluid and wounded skin of 
diabetic animals.  
 
Previous studies in chronic wounds and in poorly healing wounds from diabetic 
patients have shown high levels of MMP-9. In this study we used zymography to 
examine the various forms of MMP-9 in wound fluids and in plasma. Using this 
technique we showed a transient increase in the sponge fluid MMP-9 from diabetic 
animals at day 6. This was due largely to an increase in the biologically active 
82kDa form of MMP-9 and increased formation of NGAL/MMP-9 complex. This 
change in MMP-9 activities appears to be a dynamic process, with increased levels 
of active MMP-9 preceding the formation of the NGAL/MMP-9 complex, which 
then persists. The alteration in MMP-9 activities was not accompanied by an 
increase in MMP-9 gene expression suggesting that the observed effect of diabetes 
on MMP-9 activities is not mediated by an overall increase in inflammatory cell 
activation and occurs via posttranslational mechanisms. This concept is supported 
by our observation increased formation of the NGAL/MMP-9 complex in the 
absence of change in expression of TNFα. The increased formation of the 
NGAL/MMP-9 heterodimer can stabilise MMP-9 to prevent it from degradation as 
well as support allosteric activation (Tschesche et al., 2001; L. Yan et al., 2001)  
together these changes suggest that in diabetic wounds increased NGAL can act to 
provide a reservoir of MMP-9 which would then be available for later release. 
  
135 
 
 At the cellular level the subpopulation of peripheral neutrophils, which showed 
peri-nuclear staining for both MMP-9 and NGAL was more abundant in the diabetic 
animals. This increase has potential to deliver more MMP-9 and NGAL rich 
neutrophils to the wound and by this mechanism provide a source of MMP-9, which 
can be released on neutrophil activation and degranulation. There were other 
similarities between the circulating neutrophils cells and the inflammatory cells 
obtained from the sponge implant. At day 6, the time when the most prominent 
diabetes related changes in sponge inflammatory cell neutrophil markers (NGAL 
and MMP-8) were observed, their expression NGAL, MMP-9 and MMP-8 in 
peripheral blood neutrophils was also increased. There were also some differences, 
for example at day 6 in the peripheral cells but not the wound cells, the gene 
expression of MMP-9 as well as the inflammatory markers TNFα, TLR2 and TLR4 
was increased. Why these differences in pattern occur is uncertain. The differences 
in cellular composition i.e. neutrophils in the peripheral blood versus a mixture of 
neutrophils and monocytes in the sponge implant model is one possible explanation. 
However, it is unlikely as in the implant model neutrophils are two times more 
abundant than the macrophages. Another possibility is that at day 6 there is an up-
regulation of generalised inflammation in the diabetic animal, which leads to 
increased activation of circulating neutrophils. Evidence for this is suggested by the 
increased expression of inflammatory markers (TLR2, TLR4 and TNFα). These 
changes may cause degranulation of neutrophils in the circulation, but how this is 
translated to unaltered change in expression of MMP-9 in the wound cells is not 
clear. The hyperglycemia of diabetes is known to increase monocyte TLR 
expression (Dasu et al., 2012) but little is known regarding its effect on neutrophil 
TLRs. Further, the transient nature of the observed increase and its association with 
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increased expression of inflammatory markers such as NGAL and MMP-9 suggests 
an alteration in neutrophil phenotype in response to wounding at this time point.  
 
 Insulin is known to play a critical role in regulation of wound healing and has been 
shown to have a role in insulin deficiency as well as at the level of signalling (Lima 
et al., 2012). Insulin treatment has been shown to accelerate wound healing rate by 
increased collagen deposition (Madibally et al., 2003) and increased proliferation 
and migration of keratinocytes (Brem & Tomic-Canic, 2007). In this study we have 
shown that insulin treatment to a level which partially improved blood glucose level 
and body weight in the diabetic animals was able to improve wound closure and 
prevented diabetes associated changes in wound and circulating neutrophils. Similar 
to other reports in this study insulin treatment was able to decrease inflammatory 
cell number in the wound. This effect was likely mediated impart by prevention of 
activation of circulating inflammatory cells. Insulin has been shown to have a direct 
effect on neutrophil metabolism and function, even with no significant change in 
glycemia (Alba-Loureiro et al., 2006). It has previously been shown that insulin has 
a strong regulating effect on the functional activities of immune cells (Walrand et 
al., 2006). Altered neutrophil functions of diabetic subjects could be restored by 
controlling hyperglycemia with insulin. The mechanisms of this uncertain as 
neutrophils do not require insulin for uptake glucose. Nevertheless, glucose use and 
glycogen metabolism by neutrophils are both insulin dependent (Walrand et al., 
2006).  
 
In conclusion, the main findings of this work show diabetes related differences in 
circulating and wound tissue neutrophil profiles in particular in relation to the 
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expression and activities of MMP-9.  As neutrophils are critical for the initiation and 
progression of wound repair a better understanding of the effect of diabetes on their 
function at the various phases of wound repair is required. Additionally, these 
studies examining the relationship of MMP-9 and NGAL in diabetic wounds have 
shown for the first time the persistence of the NGAL/MMP-9 complex. Whether 
these changes are exacerbated clinically in wounds in people with diabetes where 
healing is often more prominently delayed and infection risk is high remains to be 
studied. 
 
 
We next investigated the effect of doxycycline as a known medicine for inhibition of 
MMPs on the wound closure and expression of activated neutrophil markers. Some 
studies have shown the positive effect of doxycycline on wound healing with 
improved adhesion and scar formation in treated rats (Olmarker, 2010). Doxycycline 
also significantly reduces inflammation and elevates levels of pro-inflammatory 
cytokines, which degrade the ECM, and stimulate increased numbers of 
inflammatory cytokines (Mast & Schultz, 1996). However, the effect of doxycycline 
on neutrophil activity during wound healing in not well known and will be discussed 
in more detail in following section.  
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 CHAPTER 4: Effect of 4
Doxycycline on Wound Healing 
and Neutrophil Activation in 
Diabetes 
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 INTRODUCTION  4.1
The studies described in the previous chapter showed increased active MMP-9 in 
wound tissue and wound fluids from diabetic animals. The expression of NGAL a 
protein secreted by neutrophils, known to regulate MMP-9 activity as well as 
neutrophil activation was also increased. Improved blood glucose control prevented 
these changes and also improved wound healing rate. Together these results suggest 
a role for increased MMP-9 activity and altered neutrophil activation in poor wound 
healing in diabetes. In the studies described in this chapter the effect of doxycycline 
a semisynthetic, chemically modified tetracycline compound with known ability to 
inhibit MMP expression and activities was examined. Whether doxycycline could 
improve wound healing via effects on NGAL and neutrophil activation was also 
investigated.  
 
Doxycycline is widely used to treat infections caused by both gram-negative and 
gram-positive microorganisms (Wilcox et al., 2012). It has also been shown to 
inhibit the activity of MMPs by a number of mechanisms including by inhibition of 
activated MMPs, inhibition of pro-MMP-9 activation and inhibition of MMP 
expression (Gerald et al., 2001). In several animal studies, oral treatment with 
doxycycline or analogs of tetracycline have improved wound healing rate but 
mechanism of this effect in particular its effect on wound inflammatory cell MMP 
production is not known. Therefore, in this study we investigated the mechanism of 
the effect of doxycycline on MMP-9 expression and activity in inflammatory cells in 
two different diabetic wound models of wounds.  
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 MATERIALS AND METHODS  4.2
The models used for these studies were described in detail previously 
(Chapter ‎2.2.2). As described diabetes was induced by STZ (65mg/kg) in the 
Sprague Dawley rats and confirmed by tail vein blood glucose level > 11mmol/L, 
three days after injection. The experiments were commenced six weeks later using 
the experimental design shown in Figure ‎4-1. At the time of surgery control and 
diabetic animals were divided as follows:- 
 
1) Control (CON) animals that did not receive any treatment. 
2) Control animals treated with 100 mg/kg of doxycycline (CON+HDOX).  
3) Control animals treated with 20 mg/kg of doxycycline (CON+LDOX). 
4) Diabetic (DM) animals that did not receive any treatment.  
5) Diabetic animals treated with 100 mg/kg of doxycycline (DM+HDOX).  
6) Diabetic animals treated with 20 mg/kg of doxycycline (DM+LDOX). 
 
Doxycycline was administrated orally by gavage daily from the time of wounding or 
sponge implant and animals were terminated 6 days later. In the excisional model 
wound closure was measured and calculated as described previously (Chapter 2-2-
3). Skin wounds and sponge implants were removed and inflammatory cells were 
separated from the sponges as previously described (Chapter ‎2.2.4). Blood was also 
collected and the neutrophils were isolated as described (Chapter ‎2.3). Neutrophil 
specific genes NGAL, MMP-8, MMP-9 and other pro-inflammatory markers TNFα 
and TLR4 and TLR2 were measured in the sponge implant inflammatory cell 
population as well as the circulating neutrophils. The NGAL/MMP-9 complex and 
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pro- and active forms of MMP-9 in the wound fluid, and plasma were quantified by 
zymography as described in detail in Chapter ‎2.4.4.  
 
Due to the loss of the excisional skin wound samples (freezer break down), we were 
unable to undertake the analysis of skin wounds by gene expression and immuno 
fluorescence for the animals treated with 20mg/kg of doxycycline (LDOX). 
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Figure ‎4-1: Experimental design for doxycycline treatment studies  
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 RESULTS  4.3
 Animals characteristics  4.3.1
Body weight and non-fasting blood glucose levels were measured weekly from the 
induction of diabetes in all experimental animals.  
 
 As expected the diabetic rats had a significantly higher blood glucose level and 
decreased body weight when compared to the control and control treated animals 
(P<0.05). The oral administration of doxycycline (HDOX: 100mg/kg) to the diabetic 
animals had no effect on blood glucose level or body weight (Table ‎4-1). 
 
 
Table ‎4-1: Blood glucose level and body weight in the high doxycycline (HDOX) 
experimental groups. 
 
Groups 
Start weight (g) 
Week1 
Termination weight (g) 
Week 6 
Non fasting BGL (mmol/L) 
Week 6 
CON 338.5±7.5 488.3± 10 5.0±0.1 
DM 334.8±6.5 373.8±10.3* 21.2±1.4* 
CON+HDOX 339.0±11.2 516.7±0.9 4.1±0.1 
DM+HDOX 346.9±10.3 335.1±10.1* 23.4± 1.3* 
Results are expressed as Mean ± SEM,*P<0.05 different from Control (CON) .  
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The data for blood glucose level and body weight for all animals treated with 
20mg/kg doxycycline (LDOX) are shown in Table ‎4-2. Similar to the HDOX study 
the diabetic animals had higher blood glucose levels (non-fasting) and considerably 
lower body weight than control animals.  
  
Table ‎4-2: Body weight and blood glucose level in the low doxycycline (LDOX) 
experimental group. 
 
Groups 
Start weight (g) Termination weight (g) Blood glucose 
(mmol/L) 
CON 296.5 ± 5.6 428.4 ± 14.8 4.2 ± 0.3 
DM 294.5 ± 7.0 356.4 ± 37.4* 17.7 ± 3.2* 
CON+LDOX 302.1 ± 20.1 429.2 ± 36.5 4.6 ± 0.3 
DM+LDOX 303.7 ± 14.8 383.2 ± 44.4* 17.1 + 2.9* 
Results are expressed as Mean ± SEM,*P<0.05 different from Control .  
 
 
 
 Effect of doxycycline treatment on wound closure  4.3.2
Wound area was measured in all skin wounds and the percentage wound closure was 
calculated 3 and 6 days after wound creation as described in Chapter ‎2.2.3.  
 
Shown in the Figure ‎4-2-A at day 6 the wounds in control animals were significantly 
smaller than those in the diabetic group (P<0.05). As shown in Figure ‎4-2-B 
doxycycline at 100 mg/kg had no effect on wound closure in diabetic animals and it 
was significantly slower at day 3 and 6 compared to control (Figure ‎4-2-C) and 
control doxycycline -treated animals (Figure ‎4-2-D).  
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Figure ‎4-2: Effect of oral treatment with doxycycline (100mg/kg) on wound closure. 
Wound area was measured at day 3 and day 6 and the results were expressed 
as percentage of the intial wound area i.e. precentage wound closure. Control 
(CON), diabetic (DM), control doxycycline-treated (CON+HDOX) and diabetic 
doxycycline-treated (DM+HDOX) animals.Data are Mean ± SEM.*P<0.05 vs 
control. #P<0.05 vs (CON+DOX) 
 
 
 
In a parallel study the effect of a lower dose of doxycycline on wound healing in 
diabetes was examined. Similar to the previous studies diabetes significantly 
delayed wound closure (Figure ‎4-3). In contrast to the effect of high dose 
doxycycline low dose of doxycycline (20mg/kg) partially ameliorated the delay 
(Figure ‎4-3-B), such that there was no difference in percentage wound closure when 
the LDOX treated diabetic animals were compared to control (Figure ‎4-3-C) and 
control LDOX treated (Figure ‎4-3-D) animals. 
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Figure ‎4-3: Effect of oral doxycycline (20mg/kg) on wound closure. 
Wound area was measured at day 3 and day 6 and the results were expressed 
as percentage of the intial wound area i.e. precentage wound closure. Control 
(CON), diabetic (DM), control doxycycline-treated (CON+LDOX) and diabetic 
doxycycline-treated (DM+LDOX) animals. Data are Mean ± SEM. *P<0.05 vs 
Control. 
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 Effect of diabetes on skin wounds 4.3.3
Skin wound morphology was only examined in tissue from animals treated with 
HDOX (100 mg/kg Doxycycline). As previously described, the granulation tissue 
was examined by H&E and PSR staining. Representative photos of the H&E stains 
(Figure ‎4-4) show diabetic wounds contained more inflammatory cells and the 
extracellular matrix was less well formed with more gaps than seen in control 
animals. Interestingly, by H&E the wound tissue from the doxycycline-treated 
diabetic animals also showed a less dense extracellular matrix, less vessel formation 
and less fibroblasts compared to non-diabetic control animals.  
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Figure ‎4-4: Representative Hematoxylin and Eosin images showing the effect of 
treatment with doxycycline (100mg/kg) on skin wound morphology.  
H&E stain of control (CON), diabetic (DM), control doxycycline-treated 
(CON+HDOX) and diabetic doxycycline-treated (DM+HDOX) wounds at 6 
days post wounding. Black arrows show vessels and blue arrows shows 
fibroblasts. Image magnification ×400. 
 
 
 
 
 
 
 
 
                                             CON                                                                       DM                                             
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Shown in Figure ‎4-5 are representative images of the wounds after PSR staining. 
The intensity of the staining was assessed by two independent persons blinded to the 
source of the tissue. The wound scores were then analysed using a Chi-Square Test. 
The wound collagen deposition was scored based on the staining isotype control 
from light (0) to intense (3) staining. As shown in the Table ‎4-3 the staining was 
more intense in wounds from control and control animals treated with HDOX than 
the untreated and HDOX treated diabetic animals. In addition there was a distinctly 
different pattern of collagen in the granulation tissue with fewer bundles of collagen 
in wound tissue from diabetic and HDOX treated diabetic animals.  
 
Table ‎4-3: Chi-Square tests for analysis of PSR staining in the skin wounds. 
 
Groups  
Dermis 
Scores < 2 Scores > 2 
CON (n=4) 1 3 
DM (n=3) 3 0 
CON+HDOX (n=3) 1 2 
DM+HDOX (n=3) 2 1 
Asymp. Sig. (2-sided) 0.2 
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Figure ‎4-5: Representative images showing the effect of treatment with doxycycline 
(100mg/kg) on skin wound morphology after staining with PSR. 
PSR stain of Control (CON), diabetic (DM), control doxycycline-treated 
(CON+HDOX) and diabetic doxycycline-treated (DM+HDOX) wounds at day 6 
post wounding. Arrow shows collagen bundles in the skin wound. Image 
magnification×400. 
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 Effect of doxycycline (HDOX) treatment on wound tissue NGAL and 4.3.4
MMP-9 expression  
NGAL in the skin wounds was studied by IHC and representative images are shown 
in Figure ‎4-6. As previously described, the NGAL expression was examined in the 
epidermis, dermis, and hypodermis. The intensity of the stain was scored from none 
(0) to intense (3) based on the isotype control as 0. The average scores from each 
area were calculated and categorised into scores less and greater than 2 for Chi-
Square analysis. The most intense staining was observed in the dermis where the 
number of animals with a score greater than 2 was higher in the diabetic animals 
compared to control (Table ‎4-4). These changes were partially improved by 
doxycycline treatment. 
 
 
Table ‎4-4: Chi-Square tests for analysis of NGAL staining in the skin wounds. 
 
Groups 
 
Epidermis Dermis Hypodermis 
Scores< 2 Scores ≥ 2 Scores < 2 Scores ≥ 2 Scores<  2 Scores ≥ 2 
CON 4 1 5 0 1 4 
DM 5 0 1 4 0 5 
CON+HDOX 3 0 2 1 0 3 
DM+HDOX 3 0 1 2 0 3 
 Asymp. Sig. (2-sided) 
  
Epidermis .50 
 Dermis .06 
Hypodermis .50 
Overall .218 
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Figure ‎4-6: Representative images showing the effect of treatment with doxycycline 
(100mg/kg) on skin wound NGAL expression.  
Control (CON), diabetic (DM), control doxycycline-treated (CON+HDOX) and 
diabetic doxycycline-treated (DM+HDOX) wounds at day 6 post wounding. 
Image magnification×400. 
 
 
 
MMP-9 expression was also examined by IHC and representative images are shown 
in Figure 4-7-A. The MMP-9 positive cells were calculated using Image J and the 
results were analysed using ANOVA. Compared to controls, diabetes tended to 
increase skin wound MMP-9 (by 1.7 fold). Doxycycline treatment of diabetic 
animals at 100mg/kg appeared to be without effect and surprisingly in control 
doxycycline-treated animals increased compared to untreated controls (Figure 4-7-
B). 
                                CON                                                           DM                                             
 
 
 
 
                         CON+HDOX                                              DM+HDOX                                            
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Figure ‎4-7: Representative images and quantitative data of skin wounds showing MMP-9 
positive cells.  
Showing (A) MMP-9 stained cells by IHC staining and (B) percentage of MMP -
9 positive cells in wounds from control (CON, n=4), diabetic (DM, n=4), 
control doxycycline-treated (CON+HDOX n=3,) and diabetic doxycycline- 
treated (DM+HDOX, n=3) animals at day 6 post wounding. Image 
magnification×400. Results are Mean ± SEM *P<0.05 vs. control.  
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 Effect of doxycycline treatment on wound inflammatory markers 4.3.4.1
The gene expression of neutrophil markers as well as TLR4 and TLR2 in the skin 
wounds was measured in extracted RNA from homogenised skin wounds from the 
100 mg/kg doxycycline treatment study as described (Chapter 2.5). As shown in  
Figure ‎4-8 the expression of NGAL, MMP-9, and MMP-8 tended to be increased in 
the diabetic animals but this failed to reach significance. Oral doxycycline 
(100mg/kg) significantly increased MMP-8 but had no effect on NGAL and MMP-9 
mRNA. With regard to TLR2 and TLR4 in both groups, doxycycline treatment 
tended to increase their expression and this increase reached significance for the 
diabetic animals.  
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Figure ‎4-8: Effect of oral doxycycline (100mg/kg) on gene expression of (A) NGAL, 
MMP-9, and MMP-8 and (B) TLR4 and TLR2 in skin wounds.  
Wounds tissue from control (CON, n=5), diabetic (DM n=5,), control 
doxycycline-treated (CON+HDOX, n=6) and diabetic doxycycline-treated 
(DM+HDOX, n=4) animals at 6 days post wounding. Values are corrected for 
expression of 36B4 as a housekeeper and expressed as fold change from 
control. Group data are Mean ± SEM. *P<0.05 vs. control. 
#
P<0.05 vs. 
diabetic. 
≠
P<0.05 vs. CON+HDOX. 
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 Effect of Doxycycline Treatment on Sponge Implant Inflammatory Cells  4.3.5
To determine the effect of diabetes on wound inflammatory cell MMP-9 and NGAL 
expression and neutrophil activity, the cells and fluids were extracted from the 
sponge implant at day 6 post wounding. As described previously, the cellular 
fraction was analysed by qRT-PCR. As before the pro-inflammatory mediators 
TLR4, TLR2, and TNFα were also measured. 
 
 Effect of doxycycline treatment on sponge implant MMP-9, neutrophil 4.3.5.1
activation and expression of inflammatory markers  
As shown in Figure 4-9 compared to controls, the gene expression of NGAL and 
MMP-8 were significantly up-regulated in the cell infiltrates from sponges 
implanted in the diabetic animals (P< 0.05).  The diabetes associated increase in 
NGAL was improved by doxycycline treatment (100mg/kg) but the gene expression 
of MMP-9 was unaffected and MMP-8 expression up-regulated by doxycycline. The 
expression of TLR4 and TLR2 was not altered by diabetes or doxycycline. 
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Figure ‎4-9: Effect of oral doxycycline (100mg/kg) on gene expression of (A) NGAL, 
MMP-9, MMP-8, (B) TLR4, and TLR2 in the sponge implant inflammatory cells. 
Control (CON), diabetic (DM), control doxycycline-treated (CON+HDOX) and 
diabetic doxycycline-treated (DM+HDOX) inflammatory cells from animals 6 
days after wounding. Values are corrected for expression of 36B4 as a 
housekeeper and expressed as fold change from control. Data are Mean ± 
SEM. *P<0.05 vs. control. 
#
P<0.05 vs. diabetic.  
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In the sponge inflammatory cells and similar to the pattern seen with the high dose 
of doxycycline a lower dosage of doxycycline (Figure ‎4-10), up-regulated the 
expression of NGAL and MMP-8 in diabetic animals compared to control (P≤ 0.05). 
The increased expression of NGAL was partially prevented by doxycycline 
treatment and different to the high dose doxycycline, the lower dose of doxycycline 
(20mg/kg) partially prevented the increase in MMP-8 gene expression in the 
diabetic animals. The low dose of doxycycline had no effect on the gene expression 
of MMP-9, or the TLRs and TNFα. 
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Figure ‎4-10: Effect of oral doxycycline (20mg/kg) on gene expression of (A) NGAL, 
MMP-9, MMP-8, (B) TLR4, TLR2 and TNFα in the sponge implant inflammatory cells. 
Control (CON), diabetic (DM), control doxycycline-treated (CON+LDOX) and 
diabetic doxycycline-treated (DM+LDOX) inflammatory cells at 6 days post 
implant. Values are corrected for expression of 36B4 as house keeper and 
expressed as fold change from control. Data are Mean ± SEM. *P<0.05 vs. 
CON. 
≠
P <0.05 vs. CON+LDOX. 
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 Cell expression of apoptosis markers in the implant inflammatory cells  4.3.5.2
The effect of doxycycline on the expression of Bcl-2 an anti-apoptotic protein was 
then measured in implant inflammatory cells by qRT-PCR. As shown in Figure ‎4-11 
diabetes or doxycycline treatment had no effect on inflammatory cell Bcl-2 gene 
expression.  
 
 
 
Figure ‎4-11: Gene expression of Bcl-2 in the sponge implant inflammatory cells. 
Control (CON), diabetic (DM), control doxycycline-treated (CON+LDOX) and 
diabetic doxycycline-treated (DM+LDOX) inflammatory cells 6 days post 
implant. Values are corrected for expression of 36B4 as housekeep er and 
expressed as fold change from control. Data are Mean ± SEM. 
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 Effect of doxycycline treatment on wound fluid MMP-9 and NGAL  4.3.5.3
To examine whether doxycycline treatment could alter wound fluid MMP-9 activity 
as well as its ability to form a complex with NGAL, the various forms of MMP-9 
and its complex with NGAL was measured by zymography. At day 6 AMMP-9, 
TMMP-9, and the NGAL/MMP-9 complex were all significantly increased in the 
diabetic animals compared to control animals (P<0.05). Similar to the pattern seen in 
Chapter 3 the increase in TMMP-9 level was mainly due to the increase in AMMP-9 
(Figure ‎4-12). In diabetic animals doxycycline treatment (100mg/kg) partially 
prevented the increased AMMP-9 and had no effect on the NGAL/MMP-9 complex.  
 
The concentration of soluble NGAL in the wound fluid samples was not altered by 
diabetes or doxycycline treatment (Figure ‎4-12-B). 
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Figure ‎4-12: The effect of diabetes on MMP-9 activity and NGAL level in wound fluid of 
high-dose doxycycline groups. 
Enzymatic activity of MMP-9 in pro and active forms as well as activity level 
of NGAL/MMP-9 complex in control (CON, n=19), diabetic (DM, n=22) 
control doxycycline-treated (CON+HDOX, n=12) and diabetic doxycycline- 
treated (DM+HDOX, n=18) sponge inflammatory cells at 6 days post 
wounding in wound fluid by (A)zymography. (B)ELISA for soluble NGAL. Data 
are Mean ± SEM.*P <0.05 vs. control. #P<0.05 vs. diabetic.  
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As shown in (Figure ‎4-13) and seen previously in the studies described in Chapter 3, 
diabetes was associated with significantly increased wound fluid AMMP-9, TMMP-
9, and NGAL/MMP-9 levels but PMMP-9 was unaltered. Different to the effect of 
the higher dose doxycycline, the lower dose of doxycycline increased AMMP-9 and 
TMMP-9 in both control and diabetic rats compared to untreated control animals 
reaching significance for the diabetic rats (P<0.05). However, doxycycline treatment 
partially prevented the diabetes related increase in formation of NGAL/MMP-9 
complex.  
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Figure ‎4-13: The effect of diabetes on MMP-9 activity and NGAL level in wound fluid of 
low-dose doxycycline groups. 
Wound fluid enzymatic activity of MMP-9 in pro and active forms as well as 
the level of NGAL/MMP-9 complex in wound fluids obtained 6 days post 
wounding from control (CON, n=14), diabetic (DM, n=22), control 
doxycycline treated (CON+LDOX, n=10) and diabetic doxycycline-treated 
(DM+LDOX, n=10) animals. Data are Mean ± SEM.*P<0.05 vs. control. 
#
P<0.05 vs. diabetic. 
≠
P<0.05 vs. CON+LDOX.  
 
 
 
 
 
 
 
 
 
*# 
* 
* * 
* 
*≠ 
*#≠ 
* 
* 
* 
≠P=0.09 
P=0.06* 
*#≠ 
P
M
M
P
-9
 (
A
U
C
) 
A
M
M
P
-9
 (
A
U
C
) 
T
M
M
P
-9
 (
A
U
C
) 
N
G
A
L
/M
M
P
-9
 (
A
U
C
) 
165 
 
 Effect of doxycycline treatment on wound neutrophil number 4.3.5.4
The effect of doxycycline treatment on sponge implant neutrophil activity was then 
examined at 6 days after implant. Only cells from the animals treated with 20mg/kg 
doxycycline were examined and results were compared with untreated control and 
diabetic animals.  
 
Shown in Figure 4-14-A and similar to the previous study (Chapter 3) diabetes 
increased the percentage of NGAL and MPO positive cells as well as NGAL/MPO 
co-localisation reaching significance for the MPO positive and NGAL/MPO co-
localised cells. Doxycycline treatment prevented these changes. 
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Figure ‎4-14: Representative images and quantitative group data from (A) NGAL (green), 
MPO (red) staining and (B) NGAL/MPO co-localisation (yellow) in sponge implant 
inflammatory cells by immunofluorescence.  
Control (CON), diabetic (DM), control doxycycline-treated (CON+LDOX) and 
diabetic doxycycline-treated (DM+LDOX) animals. Data are Mean ± SEM. *P 
<0.05 vs. control. 
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 Effect of Diabetes and Doxycycline Treatment on Circulating 4.3.6
Neutrophils  
Results presented in Chapter 3 suggested that the circulating neutrophil number was 
increased in wounded diabetic animals compared to similarly treated controls. The 
effect of wounding on circulating neutrophil numbers as well as the expression of 
neutrophil activation markers, TLRs 2 and -4 and TNFα were quantified in animals 
treated with 100 mg/kg doxycycline. The effect of 20mg/kg doxycycline on 
circulating neutrophils was examined only in the sponge implant model.  
 
 Effect of diabetes and doxycycline on circulating neutrophil markers in 4.3.6.1
unwounded animals 
 Shown in Figure ‎4-15, in unwounded animals diabetes increased circulating 
neutrophil expression of NGAL, MMP-9 and MMP-8, but this only reached 
significance for MMP-9. Doxycycline treatment at 100mg/kg further increased 
NGAL gene expression in the diabetic and MMP-9 in both diabetic and control 
animals. In diabetic animals expression of TLR4 tended to increase but TLR2 was 
unaltered. The tendency toward increased TNFα gene expression in diabetic animals 
was further amplified by doxycycline treatment. These effects of doxycycline on 
MMP-9 and TNFα were also seen in the doxycycline-treated control animals. 
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Figure ‎4-15: Effect of diabetes and doxycycline treatment (100 mg/kg) on circulating 
neutrophil gene expression (unwounded animals). 
Shown are results for A) NGAL, MMP-9, MMP-8, B) TLR4, and TLR2 and C) 
TNFa gene expression in neutrophils isolated from control (CON, n=6), 
diabetic (DM, n=6), control doxycycline-treated (CON+HDOX, n=6) and 
diabetic doxycycline-treated (DM+HDOX, n=4) animals. Values are corrected 
from expression of 36B4 as housekeeper and expressed as fold change from 
control. Data are Mean ± SEM.*P<0.05 vs. control. 
#
P<0.05 vs. diabetic. 
≠
P<0.05 vs. CON+HDOX.  
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 Effect of diabetes and wounding on circulating neutrophils in the 4.3.6.2
excisional wound model 
The next series of experiments examined expression of neutrophil markers in 
circulating neutrophils obtained from animals that received the excisional wounds. 
Results in Figure ‎4-16 showed the gene expression of NGAL, MMP-9, and MMP-8 
was increased in wounded diabetic animals but did not reach to a significant level. 
Doxycycline treatment had no effect on TLR4 and attenuated the increase in TLR2. 
The expression of TNFα was increased by doxycycline. This increase in TNFα was 
similar to the effect observed in similarly treatment-unwounded animals. 
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Figure ‎4-16: Effect of diabetes and doxycycline treatment (100 mg/kg) on circulating 
neutrophil gene expression (excisional wound model). 
Shown are results for A) NGAL, MMP-9, MMP-8, B) TLR4, and TLR2 and 
TNFa gene expression in neutrophils isolated from  control (CON, n=7), 
diabetic (DM, n=9), control doxycycline-treated (CON+HDOX, n=6) and 
diabetic doxycycline-treated (DM+HDOX, n=5) animals. Values are corrected 
for expression of 36B4 as house keeper and expressed as fold change from 
control. Data are Mean ± SEM. *P<0.05 vs. control. 
#
P<0.05 vs. diabetic. 
┼
P<0.05 vs diabetic by T-test. 
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 Effect of diabetes and doxycycline on circulating neutrophils in the 4.3.6.3
sponge implant inflammatory model 
Gene expression of activated neutrophil markers and pro-inflammatory markers 
were also measured in circulating neutrophils from animals which received the 
sponge implants. Shown in Figure ‎4-17 at 6 days after implant of sponges the 
circulating neutrophil expression of NGAL, MMP-9 and MMP-8 as well as TLRs 2 
and 4 and TNFα were all significantly increased in diabetic animals compared with 
controls. Doxycycline (100mg/kg) attenuated the changed NGAL, TLR2 and TNFα 
but had no effect on MMP9, MMP-8 and TLR4. As before doxycycline treatment of 
control animals tended to increase MMP-9, MMP-8 and TLR4 expression.  
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Figure ‎4-17: Effect of diabetes and doxycycline treatment (100 mg/kg) on circulating 
neutrophil gene expression (Sponge implant wound model). 
Shown are results for A) NGAL, MMP-9, MMP-8, B) TLR4, and TLR2 and 
TNFa gene expression in neutrophils isolated from  control (CON, n=9), 
diabetic (DM, n=10), control doxycycline-treated (CON+HDOX, n=6) and 
diabetic doxycycline-treated (DM+HDOX, n=3) animals. Values are corrected 
for 36B4 expression as housekeeper and expressed  as fold change from 
control. Group data are Mean ± SEM. *P<0.05 vs. control. 
#
P<0.05 vs. 
diabetic. 
┼
P<0.05 vs diabetic by T-test 
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The effect of 20 mg/kg doxycycline on circulating neutrophils was also studied in 
animals wounded by implantation of the sponge. Figure ‎4-18 shows, as before 
diabetes significantly increased circulating neutrophil expression of NGAL and 
MMP-9, MMP-8 gene expression tended to increase but it was not significantly 
different from control. The expression of TLR4, TLR2, and TNFα also tended to be 
increased but this was only significant for TNFα. In contrast to the effect of the 
higher dose of doxycycline in this study the lower dose of doxycycline (20mg/kg) 
prevented the diabetes related changes and had no effect on the control neutrophils.  
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Figure ‎4-18: Effect of diabetes and doxycycline treatment (20 mg/kg) on circulating 
neutrophil gene expression (Sponge implant wound model). 
Shown are results for A) NGAL, MMP-9, MMP-8, B) TLR4, and TLR2 and 
TNFa gene expression in neutrophils isolated from control (CON, n=5), 
diabetic (DM, n=7), control doxycycline-treated (CON+LDOX, n=6) and 
diabetic doxycycline-treated (DM+LDOX, n=6) animals. Values are corrected 
for expression of 36B4 as housekeeper and expressed as fold change from 
control. Group data are Mean ± SEM. *P<0.05 vs. control. 
#
P<0.05 vs. 
diabetic. P<0.05 vs diabetic by T-test. 
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 Effect of diabetes and doxycycline treatment on protein expression in 4.3.6.4
the circulating neutrophils by immunofluorescence  
Immunofluorescence was then used to semiquantitatively examine NGAL and 
MMP-9 protein level and co-localisation in neutrophils. As shown (Figure 4-19-A & 
B & C) a significantly higher percentage of neutrophils from diabetic animals 
expressed either NGAL or MMP-9 than controls (29% vs 10 % for NGAL and 47% 
vs 26% for MMP-9). Doxycycline partially prevented the increase in NGAL 
expression and significantly increased MMP-9 expression in both control and 
diabetic animals. 
 
The percentage of neutrophils which expressed MMP-9 was higher than those 
expressing NGAL (26% vs 10% respectively for controls and 47% vs 29% 
respectively for diabetic animals) and was significantly higher in the diabetic 
animals compared to control animals. This effect was partially prevented by 
doxycycline treatment. Consistent with our previous staining results when NGAL 
was co-localised with MMP-9 the co-localisation occurred in the peri nuclear region 
and this was not altered by diabetes (Figure ‎4-19). 
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Figure ‎4-19: Effect of doxycycline (100mg/kg) treatment on neutrophil NGAL and MMP-
9.  
Representative images and quantitative data of (A) NGAL (green), MMP -9 
(red) and (B) co-localisation of NGAL and MMP-9 (yellow) in circulating 
neutrophils.Control (CON), diabetic (DM), control doxycycline-treated 
(CON+HDOX) and diabetic doxycycline-treated (DM+HDOX) animals. Group 
data are Mean ± SEM.*P<0.05 vs. control.  
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 Effect of diabetes and doxycycline treatment on neutrophil apoptosis  4.3.6.5
We have shown (Chapter 3) that circulating neutrophil apoptosis is delayed in the 
sponge implanted diabetic animals, whether doxycycline could prevent this change 
was investigated in this study. In diabetic animals which were either unwounded or 
wounded with an excisional wound no change in neutrophil MCL-1 gene expression 
was observed. As before MCL-1 gene expression was significantly increased in 
circulating neutrophils from diabetic animals in the sponge implant group; this 
increase was prevented by treatment with doxycycline (Figure ‎4-20). 
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Figure ‎4-20: MCL-1 gene expression in the circulating neutrophils from doxycycline 
treated animals (100 mg/kg) which were either (A) unwounded, or wounded with (B) an 
excisional wound or (C) by sponge implant.  
In control (CON, n=5), diabetic (DM, n=5), control doxycycline-treated 
(CON+HDOX, n=5), and diabetic doxycycline-treated (DM+HDOX, n=5) 
animals. Values are corrected for expression of 34B4 as housekeeper an d 
presented as fold change from control. Data are Mean ± SEM. *P<0.05 vs. 
control. 
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 Effect of diabetes and doxycycline on plasma MMP-9 activity and 4.3.6.6
NGAL concentration 
The activity of MMP-9 was measured by zymography in plasma from rats treated 
with high dose doxycycline. As shown in Figure ‎4-21-A at day 6 post wounding 
diabetes had no effect on the plasma MMP-9 levels including the PMMP-9 and 
AMMP-9 forms. In non-diabetic rats and similar to the effect of doxycycline on 
neutrophil activities in the wound and in the circulation, high dose doxycycline 
significantly increased plasma PMMP-9 and TMMP-9 and NGAL/MMP-9 complex 
(Figure ‎4-21-A). By ELISA the soluble form of NGAL was not affected by diabetes 
or doxycycline treatment (Figure ‎4-21-B). 
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Figure ‎4-21: The effect of diabetes and high dose doxycycline (100 mg/kg) on plasma 
MMP-9 and NGAL. 
Plasma enzymatic activity of (A) MMP-9 in pro (PMMP-9), and active (AMMP-
9) forms and total MMP-9 (TMMP-9) as well the NGAL/MMP-9 complex 6 
days after wounding and (B) soluble form of NGAL measured by ELISA in 
control (CON, n=15), diabetic (DM, n=16), control doxycycline-treated 
control (CON+HDOX, n=16) and doxycycline-treated diabetic (DM+HDOX, 
n=16) animals. Group data are Mean ± SEM. *P <0.05 vs. control.  
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A similar series of studies was performed on plasma samples of animals in the low 
doxycycline treatment study. As shown in Figure ‎4-22 and similar to the high dose 
doxycycline (100mg/kg) study diabetes had no effect on MMP-9 activity in any 
form. Interestingly, in this study low dose doxycycline (20mg/kg) treatment of 
control animals had no effect on PMMP-9 or TMMP-9 but the slight increase in the 
AMMP-9 and PMMP-9 in the doxycycline-treated diabetic animals resulted in a 
significant increase in TMMP-9 in this group. There was no significant difference in 
the concentration of NGAL/MMP-9 complex in control and diabetic animals. 
However, the low dose doxycycline decreased NGAL/MMP-9 complex formation in 
the both control and diabetic animals. 
 
 
Figure ‎4-22: The effect of diabetes on MMP-9 activity and NGAL level in plasma.  
Plasma enzymatic activity of MMP-9 in pro and active forms as well as 
activity level of NGAL/MMP-9 complex in plasma in control (CON, n=6), 
diabetic (DM, n=5), control doxycycline-treated (CON+LDOX, n=7) and 
diabetic doxycycline-treated (DM+LDOX, n=6) animals. Data are Mean ± 
SEM. *P<0.05 vs. control. 
≠
P<0.05 vs. CON+LDOX.   
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 DISCUSSION  4.4
The MMPs are key regulators of wound healing and inhibition of their activity may 
improve wound healing. Doxycycline a known weak antibiotic can inhibit MMP-9 
activity through the chelation of calcium and zinc ions. In some studies treatment 
with doxycycline has been shown to improve wound closure (Wilcox et al., 2012). 
In this study we used treatment with doxycycline to attempt to regulate MMP-9 
activity to examine the importance of MMP-9 in wound healing in our diabetic 
rodent wound models. Further, whether doxycycline treatment could regulate 
neutrophil activity and NGAL was also examined.  
 
In these studies two different dosages of doxycycline were used. We used 100 
mg/kg as high dose of doxycycline and 20 mg/kg as a low dose. Administration of a 
20 mg/kg dose of doxycycline daily is the only drug therapy approved by the United 
States Food and Drug Administration (FDA) for adult periodontitis as a collagenase 
inhibitor (Lee et al., 2004).  However, the 100 mg/kg/day dose has been shown to be 
effective for reduction of MMP-9 expression in the mice brain tissue (Lee et al., 
2006). Additionally, Chin and colleagues (2003) found that doxycycline at 50, 500, 
and 5,000 mM significantly reduced protease activity by 44%, 75%, and 89% 
respectively, in diabetic foot ulcers (Chin et al., 2003). 
  
In this work we have shown that doxycycline at a dosage of 100 mg/kg was not able 
to improve the wound closure and did not substantially alter wound MMP-9 activity. 
In addition, in both control and diabetic animals this dose of doxycycline negatively 
impacted on neutrophil function as evidenced by increased neutrophil number and 
activation in this group. These results were supported by increased gene expression 
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of NGAL, MMP-9 and MMP-8 in skin wounds as well as MMP-8 gene expression 
in the sponge inflammatory cells. On the other hand, we showed that low dose (20 
mg/kg) doxycycline improved wound closure in diabetic animals. The results from 
these studies also showed the number of neutrophils as well as gene expression of 
NGAL and MMP-8 was decreased in the sponge implant inflammatory cells in 
doxycycline-treated diabetic animals. This dose of doxycycline had no effect on 
increased MMP-9 level in the wound fluid of diabetic treated animals. Together 
these studies suggest that oral doxycycline treatment at a low dose may be able to 
prevent increased neutrophil activity and may have some utility in improvement of 
wound healing in diabetes. 
 
In this work we further investigated the effect of wounding on circulating neutrophil 
activation and apoptosis. In diabetes, wounding increased the circulating neutrophil 
expression of NGAL, MMP-9 and MMP-8 as well as TLRs -4 and -2 and TNFα. 
Moreover, the level of increase with the invasiveness of the surgery with the greatest 
increases occurring in the sponge implant model. Like the effect of the different 
doses of doxycycline on wound healing rate the dose of doxycycline also had 
substantially different effects on neutrophil activation markers. For example, 
treatment with doxycycline (100 mg/kg) attenuated the increased expression of 
NGAL in both models but had no effect on MMP-8 and MMP-9 gene expression. In 
contrast doxycycline at 20mg/kg significantly prevented the diabetes associated 
increase in expression markers of neutrophil activity NGAL, MMP-8, and MMP-9. 
The expression of pro-inflammatory markers TLR4, TLR2, and TNFα were also 
partially improved by low dose of doxycycline. Several studies in animals have 
reported that treatment with doxycycline or other tetracycline analogues improved 
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healing parameters. For example, systemic treatment of rats with doxycycline 
increased tensile strength of rat intestinal anastomoses 3 days after surgery 
(Pasternak et al., 2008). Topically applied chemically modified tetracycline 
enhances wound healing in streptozotocin diabetic rat skin (Ramamurthy et al., 
1998).  
 
The mechanism of this effect of doxycycline on neutrophil activation is not clear. 
Other workers have also shown that some members of the doxycycline family can 
decrease NGAL and MMP-9 (Serra, Buffone, et al., 2013) and TNFα (Cazalis et al., 
2009) by suppressing superoxide generation, degranulation and migration of 
neutrophils. We have shown that doxycycline can prevent the increase in TNFα. 
TNFα is an important inflammatory mediator that regulates neutrophil activity 
(Cazalis et al., 2008). TNFα is also a potent inducer of MMP-9 expression and 
activity. It is possible that the prevention of increased TNFα by doxycycline 
treatment can improve neutrophil activity and decrease their expression of MMP-9.  
 
A novel new finding of this study was the observation that diabetes and wounding 
can increase neutrophil longevity. The expression of markers of activated neutrophil 
was also increased as was MMP-9. Others have also shown that activation of 
neutrophils in response to inflammation increases their longevity (Hanses et al., 
2011; Kolaczkowska & Kubes, 2013).  Further, the presence of primed neutrophils 
at the site of inflammation can also contribute to cell injury by activation of 
neutrophil gene expression and function (Kolaczkowska & Kubes, 2013). This 
prolonged activation can produce cytokines such as interleukins and TNFα 
(Cowburn et al., 2005; Schultz et al., 2005) and in normal wounds has been shown 
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to inhibit re-epithelialisation (Dovi et al., 2004). We have shown that diabetes can 
further increase this process. These results suggest in diabetes neutrophil activation 
is prolonged as is their longevity. Together these changes can contribute to the 
increased inflammation in diabetes.  
 
In conclusion, treatment of diabetic animals with oral low dose doxycycline 
improved wound healing. The apparent beneficial effect of low dose of doxycycline 
treatment on the wound healing of our diabetic animal models was probably not due 
to the antibiotic action of doxycycline, since the expression of TLR4, and TLR2 as 
markers for bacterial infection did not alter in the wound infiltrated cells. The results 
obtained from the circulating cells suggest that low dose doxycycline treatment can 
also prevent the diabetes and wounding associated increase in neutrophil activation 
and longevity as well as a reduction in MMP-9 activities.  
 
Thus far, the results obtained from rodent studies suggest diabetes and wounding 
related increase in neutrophil activity. Whether these changes also occur in people 
with diabetes and whether neutrophil activities and apoptosis are altered in 
association with wound healing is not known. For this reason the effect of diabetes 
on inflammatory cells and expression of activated neutrophil markers NGAL, MMP-
8 as well as MMP-9 was investigated in the white blood cells of diabetic patients. 
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 CHAPTER 5: Effect of Diabetes 5
on Circulating Neutrophil 
Markers in Human 
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 INTRODUCTION 5.1
Many studies have described the association in diabetic patients between increased 
severity of infection and neutrophil function (Alba-Loureiro et al., 2007). 
Neutrophils can recognise and kill invading microorganism and to stimulate other 
immune cells to effectively eliminate threats of infection (Kumar & Sharma, 2010). 
NGAL is produced from neutrophils to participate in the antibacterial iron depletion 
strategy of the innate immune system (Goetz et al., 2002). There has been a report of 
persistent NGAL protein levels in the wound fluid (Pukstad et al., 2010) and plasma 
(Serra et al., 2013) from persons with non-healing chronic venous leg ulcers. In 
addition, recent studies have focused on NGAL as a marker of early renal tubular 
damage and its association with renal pathophysiology. For example, elevated 
NGAL expression in the kidney, as well as elevated urinary NGAL levels have been 
observed in acute kidney injury (Mishra et al., 2003) 
 
 The results from previous chapters of this thesis have shown that in rodents, 
diabetes impairs neutrophil function and activation in wound fluids with increased 
wound inflammatory cell expression of NGAL and MMP-8 and activity of MMP-9 
being observed. Whether these changes are also observed in people with diabetes is 
not as yet clear. Therefore, pilot studies were performed on two independent cohorts 
of diabetic patients and the expression of NGAL, MMP-8, as specific markers of 
activated neutrophils, and MMP-9 was also measured in the blood white cells.  
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 STUDY PROCEDURES  5.1
As mentioned, pilot studies were performed investigating circulating levels of 
NGAL, MMP-8, and MMP-9 in two different cohorts of diabetic patients. In the first 
study whether the expression of these markers was altered in association with the 
presence or absence of diabetic complications was examined.  In the second study, 
the expression of NGAL, MMP-8, and MMP-9 was measured at various time points 
in association with wound healing in patients attending the Foot Clinic of the 
Diabetes Centre of RPA Hospital. All patients regardless of the study group attended 
the Diabetes Centre of RPA Hospital. Controls were members of the Diabetes 
Centre or Laboratory staff. The ethics for the studies were approved by the Ethics 
Review Committee of the RPAH hospital and were carried out in accordance with 
the principles of the Declaration of Helsinki as revised in 2000.  
 
The details of each of the studies are as follows:- 
 
 Study 1: Seventy three individuals including control (n=22), and diabetic (n=51) 
persons participated in this study. All people with diabetes had duration of the 
disease for greater than 10 years. Based on the absence or presence of complications 
(micro or macro vascular), patients were divided into two groups: diabetic patients 
with no complications (DM+NC) and diabetic patients with complications (DM+C). 
Diabetes complications included neuropathy, retinopathy and nephropathy. 
 
In all patients the presence or absence of retinopathy was confirmed by fundal 
examination and/or photography. The presence or absence of diabetic nephropathy 
was confirmed by normal serum creatinine and urinary albumin/creatinine ratio (U 
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Alb/Cr) <2.5 mg/mmol for males and <3.5 mg/mmol for females. The characteristics 
of subjects in this group are shown in Table 5.1. 
 
 
 
Table ‎5-1: Clinical parameters of control and diabetic subjects with or without 
complications. 
 Control 
n=22 
Diabetic 
n=51 
Diabetic 
Clinical Parameters 
DM +NC 
n=24 
DM+C 
n=27 
     
Age (yrs) 47.4±2.8 62.7±1.6* 64.1±1.7* 61.6±2.6* 
Duration (yrs) NA 19.5±7.5 17.8±6.7 21.8±8.1 
Weight (kg) 75.7±4.1 80.7±2.0 80.6±2.9 80.7±2.9 
BMI (kg/m
2
) 28.5±7.8 28.7±4.9 29.1±5.1 28.2±4.7 
HbA
1c
 (%) NA 7.7±1.1 7.7±0.6 8.2±1.2
#
 
Serum Creatinine 
(µmol/L) 
69.5±3.1 83.7±3.1* 75.9±3.6 91.2±4.5*# 
U Alb/Cr Ratio 
(mg/mmol)
 
 
0.8±0.1 2.03±2.02* 1.1±0.2* 3.2±0.7*# 
eGFR (ml/min) 91.4±4 81.8±3.5* 87.3±4.9 75.8 ±4.8 
HDL cholesterol 
(mmol/L) 
0.8±0.1 1.3±0.1* 1.3±0.1* 1.2±0.1* 
LDL cholesterol 
(mmol/L) 
2.9±0.2 2.1±0.1 2.2±0.2 2.1±0.2 
 
Data are expressed as Mean ± SD, *P<0.05 different from control (CON). 
#
P<0.05 different from diabetic without complications (DM+NC).  
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Blood was obtained from all patients and the plasma and white blood cells were 
isolated (as described below). The gene expression of NGAL, MMP-9, and MMP-8 
was measured in white blood cells and NGAL, MMP-9, NGAL/MMP-9 complex 
and TNFα were measured in the plasma by ELISA and zymography.  
 
Study 2: The characteristics of the participants in the second study are shown in 
Table ‎5-2 . In this study all patients were diabetic and had a foot ulcer and were 
attending the Foot Clinic of the Diabetes Centre of RPA Hospital.  After consent 
blood samples were obtained at the initial (Visit 1) and the last visit (Visit 2: week 8 
or week 12) and wound area was also measured at each visit. All participants had 
type 2 diabetes and the duration of diabetes ranged between 3 to 24 years. 
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Table ‎5-2: Clinical parameters of diabetic subjects with foot ulcers investigated in this 
study 
 Data are mean ± SEM 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetic patient’s characteristics 
Age (yrs) 60.4 ±6.6 
Sex (male) 9:0 
Diabetes duration (yrs) 3-24 
DM (T1:T2) 0:9 
HbA1c  (%) at entry 8.1± 1.3 
HbA1c (%) at healing 7.3± 1.0 
Triglycerides (mmol/L) 1.2±0.5 
HDL cholesterol (mmol/L) 1.3±0.3 
LDL cholesterol (mmol/L) 2.6±0.9 
Ischemia present (yes: no) 2:7 
Infection present at entry (yes: no) 4:5 
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The wound severity was classified based on Texas stage as follows:  I: grade 0; pre 
or post ulcerative lesion completely epithelised II: grade 1; superficial wound, not 
involving tendon, capsule or bone, III: grade 3; wound penetrating to bone or joint. 
All wounds were either grade 1or 2 at entry and grade 0 or 1 at the last visit.  Of the 
9 patients enrolled, 5 had wounds with no evidence of clinically significant bacterial 
infection and 4 wounds were infected with the bacteria identified as Staphylococcus 
Aureus and Enterococcus Faecalis. 
 
 Isolation of White Cells and Plasma from Whole Blood 5.1.1
For the both studies white cells were isolated from heparinised blood samples as 
follows; samples were centrifuged at 2000 rpm for 15 minutes. The plasma was 
removed aliquoted and stored for later measurement of proteins of interest. To 
separate the white cells from the buffy coat, the buffy coat layer was resuspended in 
red blood cell lysis buffer and the mixture was centrifuged at 2000 rpm for 10 min. 
The pellet was resuspended in PBS (1ml) and then divided and stored in i) Tri-
reagent for later RNA extraction ii) OCT for IHC studies and iii) RIPA buffer for 
protein analysis.  
 
 Measurement of Soluble NGAL and NGAL/MMP-9 Complex by ELISA 5.1.2
The NGAL concentration was determined in the plasma samples using an ELISA kit 
which detected only Lipocalin-2/NGAL (R&D Systems). Another ELISA was used 
to measure plasma NGAL/MMP-9 complex (R&D ELISA kit, DM9L20). Each 
assay was performed according to the manufacturers’ instructions and all samples 
were assayed in duplicate. The optical density of each well was determined within 
30 min of colour development, using a microplate reader set to 450 nm. The optical 
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density of 570 nm was used for correction for plate optical densities. The 
concentrations of NGAL or NGAL/MMP-9 complex were then quantified by 
reading from a calibration curve, which used either recombinant, human Lipocalin-2 
or an NGAL/MMP-9 complex as the respective standard. A representative standard 
curve for Lipocalin-2 is shown in Figure ‎5-1. 
 
 
Figure ‎5-1: A representative standard curve for NGAL ELISA 
 
 
 Extraction of RNA and Quantification of Gene of Interest by qRT-PCR  5.1.3
 Primer design  5.1.3.1
All primers for the human study (Table ‎5-3) were designed using primer-blast at 
Blast (Basic Local Alignment Search Tool).NIH http://www.ncbi.nih.gov. For each 
product there was a single peak of the melt curve at the expected temperature. Serial 
dilutions were performed to ensure amplification at an RNA concentration in the 
linear range and for all primers the no template control failed to amplify amplicons. 
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Table ‎5-3: Primer sequence of gene of interest 
Target gene (human) Forward primer (5-3) Reverse primer (5-3) 
NGAL GGACGGAGGTGACATTGTAGCT GGCAGGGAATGCAATTCTCA 
MMP-9 CTGCCCCAGCGAGAGACTCTAC GCTGTCAAAGTTCGAGGTGGTA 
MMP-8 GACCAACACCTCCGCAAATTACA GGGTCACAGGGTTTGGGTGTGC 
 
 RNA extraction, production of cDNA and amplification from cells  5.1.3.2
RNA was extracted from isolated cells and reverse transcribed to cDNA as 
previously described in Chapter ‎2.5.3 using oligo dt primers and Superscript III 
Reverse Transcriptase (Invitrogen) according to the manufacturers’ instructions. 
Quantitative PCR was performed using a Rotor-Gene 6000 and SensiMix SYBR Hi-
ROX kit and primers specific for NGAL, MMP-8, and MMP-9 as described 
previously (Table ‎5-3). B2M was used as a housekeeper and all PCR amplicons 
were shown to amplify in parallel with B2M. 
 
 RESULTS STUDY 1 5.2
 Clinical characteristics  5.2.1
As shown the control subjects were younger than the diabetic group (average 47.5 vs 
62.5 respectively). The diabetic patients had a long duration of diabetes with an 
average of 19.5±7.5 years. As expected the HbA1c level was higher than non-
diabetic controls in those with diabetes. In the group with complications the HbA1c 
was significantly higher in those without complications compared to those without 
(P<0.05). Compared with non-diabetic controls the serum creatinine and urinary 
albumin /creatinine ratio were significantly increased by diabetes and both were 
significantly higher in the diabetic group with complications compared to those 
without complications (P<0.05). Shown in Figure 5-2 the estimated glomerular 
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filtration rate (eGFR) was also significantly decreased in the diabetic group 
compared with controls and in the diabetic group had a negative but not significant 
correlation with age. Additionally, as expected eGFR negatively correlated with 
serum creatinine (P < 0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-2: Linear correlations between (A) age and estimated glomerular filtration rate 
(eGFR) and (B) eGFR with serum creatinine in diabetic patients P<0.0001. n=50. 
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 Effect of diabetes on gene expression of NGAL, MMP-8, and MMP-9 in 5.2.2
circulating inflammatory cells  
 
The gene expression of markers of activated neutrophils was measured in the white 
blood cells of normal (n=8-12) and diabetic subjects (n=38). As shown (Figure ‎5-3) 
compared to controls the gene expression of NGAL, MMP-9 and MMP-8, were 
significantly increased in those with diabetes (all P <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-3: Effect of diabetes on NGAL, MMP-9, and MMP-8 gene expression in 
circulating inflammatory cells. 
Control (CON, n=9), diabetes (DM, n=37). Values are corrected for 
expression of B2M as a housekeeper and expressed as fold change from 
control. Group data are Mean ± SEM. *P<0.05 vs. control by Students T-test  
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The pattern of increased expression of NGAL, MMP-9 and MMP-8 in diabetes was 
apparent irrespective of the presence or absence of complications (Figure ‎5-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-4: Effect of diabetic complications presence on NGAL, MMP-9, and MMP-8 
gene expression in circulating inflammatory cells 
Control (CON, n=9), diabetic without complications (DM+NC, n=22) and 
diabetic with complications (DM+C, n=15). Values are corrected for 
expression of B2M as a housekeeper and expressed as fold change from 
control. Data are Mean ± SEM. *P<0.05 vs. control. 
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 Effect of diabetes on MMP-9 activity and NGAL levels in plasma 5.2.3
The plasma activity of MMP-9 and NGAL/MMP-9 complex was examined by 
zymography. The pro but not active forms of MMP-9 were detected. The 
NGAL/MMP-9 complex was detected in most samples but a few samples from each 
group did not have this complex. As shown in Figure ‎5-5-A the level of PMMP-9 
was significantly increased in the diabetic patients compared to non-diabetic 
controls. The level of NGAL/MMP-9 complex did not alter across the groups 
(Figure ‎5-5-B). In the diabetic group the circulating level of MMP-9 and 
NGAL/MMP-9 complex were not affected by the presence or absence of 
complications Figure ‎5-6. 
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Figure ‎5-5: Effect of diabetes on MMP-9 and NGAL/MMP-9 complex by zymography in 
human plasma.  
Plasma level of (A) PMMP-9, and (B) NGAL/MMP-9 complex measured by 
zymography. Control (CON, n=19), diabetic (DM. n=38) patients. Data are 
Mean ± SEM. *P<0.05 compared to control by Student Ttest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-6: Effect of present or absence of diabetic complications on MMP-9 and 
NGAL/MMP-9 complex by zymography in human plasma.  
Plasma level of (A) PMMP-9, and (B) NGAL/MMP-9 complex measured by 
zymography. Control (CON, n=19), diabetic without complications (DM+NC, 
n=21) and diabetic with complication (DM+C, n=17) patients. Data are Mean 
± SEM. *P<0.05 compared to control by Students T-test. 
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 Effect of diabetes on NGAL, NGAL/MMP-9, MMP-9 and TNFα levels in 5.2.4
plasma 
The plasma levels of NGAL and NGAL/MMP-9 complex were measured using an 
ELISA. Plasma NGAL was increased in diabetic patients compared with non-
diabetic controls and similar to the zymography results plasma NGAL/MMP-9 
complex was not different to control (Figure 5-7-A and B respectively).  
 
The plasma level of total MMP-9 (PMMP-9, AMMP-9), and TNFα were also 
measured and found by ELISA to be not different to control (Figure 5-7-C and D 
respectively). 
  
As shown in (Figure ‎5-8-A) when the diabetic group was divided into those with and 
without complications the increase in NGAL concentration was due to an increase in 
its level in the group with complications. Interestingly, in those with complications 
TNFα was significantly decreased compared to those without complications 
(Figure ‎5-8-D). The level of MMP-9 and the NGAL/MMP-9 complex were 
unaffected. 
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Figure ‎5-7: Effect of diabetes on (A) NGAL, (B) NGAL/MMP-9 complex, (C) MMP-9, 
and (D) TNFα concentration in plasma.  
Measured by ELISA in control (CON), diabetic (DM). Data are Mean ± SEM. 
*P<0.05 compared to control by Students T-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
(A)                                                             (B)
(C)                                                             (D)
202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-8: Relationship between presence or absence of diabetic complications on (A) 
NGAL, (B) NGAL/MMP-9 complex, (C) MMP-9, and (D) TNFα concentration in plasma.  
Plasma concentration of soluble form of NGAL, NGAL/MMP-9 complex, MMP-
9, and TNFα measured by ELISA in control (CON), diabetic without  
complications (DM+NC) and diabetic with complication (DM+C) patients. 
Data are Mean ± SEM. *P<0.05 compared to control and 
#
P<0.05 compared to 
diabetic by Students T-test. 
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 Associations between NGAL and MMP-8  5.2.5
To investigate the relationship between neutrophil markers and neutrophil activation 
the correlation between NGAL and MMP-8 mRNA levels in the diabetic white 
blood cells was calculated. As shown in Figure ‎5-9 there was significant positive 
correlation between NGAL and MMP-8 gene expression. No correlation between 
these markers and expression of TNFα were observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-9: Linear correlation between NGAL and MMP-8 gene expression in diabetic 
patients: P < 0.02. 
 
 
 
 
 
 
 
 
 
 
R
2
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 Correlations between markers of neutrophil activation and clinical 5.2.6
variables  
To determine whether there was any association between plasma NGAL and clinical 
variables, the correlation between plasma NGAL, eGFR and serum creatinine and 
diabetes duration was examined. As shown no significant correlation was found 
between NGAL and HbA1c and only weak associations were observed for NGAL 
and duration of diabetes (Figure ‎5-10-A and B respectively). There was a significant 
negative correlation between the level of NGAL and eGFR and positive correlation 
between NGAL and serum creatinine in the diabetic patients (Figure ‎5-10-C and D 
respectively).  No association between MMP-8 and clinical variables were observed.  
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Figure ‎5-10: Linear correlations between plasma NGAL and (A) HbA1c, (B) duration of 
diabetes (C) eGFR (P<0.05) and (D) serum creatinine (P<0.05) levels in diabetic patients 
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 Correlation between PMMP-9 and NGAL/MMP-9 complex  5.2.7
As described the level of pro-MMP-9 and NGAL/MMP-9 complex was measured 
by zymography. As shown in Figure ‎5-11 there was a significant positive correlation 
(R
2
 = 0.124, P < 0.05) between plasma NGAL and NGAL/MMP-9 complex in 
diabetic subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-11: Linear correlation between plasma NGAL/MMP-9 complex levels and 
PMMP-9 measured by zymography in diabetic patients: P < 0.05. 
 
 
No associations between MMP-9 or NGAL/MMP-9 complex and HbA1c, eGFR and 
serum creatinine were observed. However, the NGAL/MMP-9 complex formation 
correlated weakly with diabetes duration (data not shown). 
 
 
 
 
 
 
 
R2=0.124 
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 RESULTS STUDY 2 5.3
In the second study, we examined circulating markers of neutrophil activation in 
patients with foot ulcers attending the High Risk Foot Clinic of the Diabetes Centre 
of RPA Hospital. As for study 1 the expression of NGAL, MMP-8 and MMP-9 in 
circulating white cells were measured and their associations with wound healing rate 
were examined. 
 
 Wound area and its correlation with wound grade 5.3.1
Wound area was measured at the first visit (visit 1) and each visit until the wound 
healed. The mean wound area at visit 1 (1.8 ± 0.5 cm
2
) and
   
the area at the last visit 
in this study called (visit 2) was used for calculation of wound healing rate and 
wound closure. The wound-healing rate for the whole group was 0.02 ± 0.009 cm 
per day. However, there was variability across the group of the nine patients studied 
sequentially; only two wounds healed completely, and in two patients there was no 
change in wound area. The data for the whole group is shown in Figure ‎5-12-A and 
individually in Figure ‎5-12-B. 
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Figure ‎5-12: Wound area in diabetic patients with foot ulcer. 
Wound area measured in the entry time visit 1 and in the visit 2 (A) whole 
group (B) individual patients. Data are Mean ± SEM.*P<0.05 compared to 
visit 1 at entry to the study. 
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Wound severity was graded using the Texas scale of 0, 1, 2, or 3 as described in 
Section ‎5.1.  At the entry visit two wounds penetrated to tendon or capsule and were 
graded as Texas grade 2 and the remainders were superficial wounds, which did not 
involve tendon, capsule or bone (i.e. Texas grade 1). Some wounds at entry had 
Staphylococcus Aureus and Enterococcus faecalis infections but the wounds, which 
were healed at end of study, did not have bacterial infection. At the final visit, 2/7 
stage 1 wounds had healed completely and the remaining 7/9 wounds were level 1. 
There was no trend for wound grade and wound area. However, as shown in 
Figure ‎5-13 at Visit 2 those with a higher wound area had a greater wound severity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-13: Correlation between wound grade and wound area in visit 2 in diabetic foot 
ulcers. 
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 Change in expression of neutrophil markers and MMP-9 with healing   5.3.2
 The gene expression of NGAL and MMP-8 as specific markers of activated 
neutrophils as well as MMP-9 was measured in the inflammatory cells isolated from 
blood at visit 1 and visit 2. A sample of normal patients (WBC cDNA) was included 
for use as the internal control. As shown in the group data the overall expression of 
these markers did not change between the visits (Figure 5-14). Our data showed that 
at each visit NGAL expression was considerably higher than MMP-9 expression 
(7.5 fold and 9.5 fold, visit 1 and visit 2 respectively).  Likewise, MMP-8 expression 
at visit 1 was 4 fold and at visit 2 was 8 fold higher than MMP-9.  
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-14: Effect of diabetes on NGAL, MMP-8, and MMP-9 gene expression in 
circulating inflammatory cells.  
Diabetic foot ulcer patients in visit 1 and visit 2. Group data for NGAL, MMP-
9, and MMP-8. The data was corrected for expression of B2M as the 
housekeeper and are expressed as fold change from internal control. Data are 
Mean ± SEM. 
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The data for the individual patients also showed that the NGAL changes were 
variable whilst MMP-8 expression increased in most of the patients between the first 
and final visits (7/9 patients). Interestingly, the gene expression of MMP-9 was 
decreased and this reduction was associated with increased wound closure (8/9 
patients) (Figure 5-15-A-C). These changes were apparent regardless of the presence 
or absence of infection.  
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Figure ‎5-15: Effect of diabetes on NGAL, MMP-8, and MMP-9 gene expression in 
circulating inflammatory cells.  
Diabetic foot ulcer patients in visit 1 and visit 2. Individual patient data for 
(A) NGAL, (B) MMP-9, and (C) MMP-8. The data was corrected for expression 
of B2M as the housekeeper and are expressed as fold change from internal 
control. Data are Mean ± SEM. 
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 Wound healing rate and its correlation with gene expression 5.3.3
To examine whether baseline gene expression of NGAL or MMP-8 as specific 
markers of activated neutrophils and MMP-9 are associated with future wound 
healing rate, the baseline gene expression of each of these markers was correlated 
with the wound healing rate calculated from visit 1 to visit 2. Although the numbers 
are small the initial visit white cell NGAL and MMP-8 mRNA correlated positively 
with wound healing rate. The strongest correlation was observed for NGAL 
(P<0.02) with a lesser correlation for MMP-8. White cell MMP-9 did not correlate 
with wound healing rate (Figure ‎5-16).  
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Figure ‎5-16: Correlation between wound healing rate and circulating inflammatory cells 
gene expression of (A) NGAL, (B) MMP-8, and (C) MMP-9 at entry time (visit 1) in 
diabetic foot ulcers.  
Significant correlation between NGAL gene expression and wound healing 
rate, P<0.02. 
(A) 
 
 
 
 
 
 
(B) 
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 DISCUSSION  5.4
In the presented pilot studies the white cell mRNA levels of markers of neutrophil 
activation NGAL and MMP-8 as well as MMP-9 were studied in two different 
diabetic populations. The first study those with long-term diabetes and the second 
study a group of diabetic patients with foot ulcers. These studies were performed to 
provide information regarding the effect of diabetes alone and diabetes and wound 
healing on neutrophil activation.  
 
The results of study 1, the long-term diabetes study, albeit in a small population 
showed a significant increase in gene expression of NGAL and MMP-8 as specific 
markers of activated neutrophils in diabetic patients. Increased expression of NGAL 
was positively associated with increased MMP-8 gene expression suggesting that 
increased activation of circulating neutrophils in diabetes. Moreover, the correlation 
analysis highlighted the relationship between NGAL and some clinical parameters. 
We have also shown that the circulating NGAL concentration is increased in 
diabetes and is not affected by complications status. Other studies have also shown 
that plasma NGAL concentration correlates with parameters of kidney disease. For 
example, increased NGAL is associated with GFR in children with chronic kidney 
disease (Mitsnefes et al., 2007) and in patients with polycystic kidney disease 
(Bolignano et al., 2007; Bolignano et al., 2009). In this study NGAL was negatively 
correlated with eGFR and positively correlated with serum creatinine confirming the 
results of other work which have shown an association between plasma NGAL and 
decline in renal function (Bolignano et al., 2009).  
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Many studies suggest that inflammatory processes and immune cells are involved in 
the development and progression of diabetic nephropathy (Chow et al., 2004). In 
particular neutrophils have been shown to play a role in the development and 
progression of diabetic nephropathy (Galkina & Ley, 2006). In persons with diabetic 
nephropathy neutrophil dysfunction has been described; they have for example been 
shown to have rapid exocytosis of neutrophil primary granules as well as to 
contribute to increased vascular damage in these patients (Fardon et al., 2002). We 
found some changes in circulating factors in diabetes, but whether these changes are 
due to neutrophil dysfunction is not possible to ascertain. We have also shown in 
diabetes an increase in circulating pro-MMP-9 activity that was positively related to 
NGAL/MMP-9 complex. NGAL by formation of a complex with MMP-9 can 
prevent MMP-9 degradation. In addition, it can activate the MMP-9 precursor 
directly, and counteract the inhibiting effect of TIMP-1 (Coles et al., 1999). 
Therefore, it is likely that both increased plasma NGAL and the increase in MMP-
9/NGAL complex can preserve the enzymatic activity of MMP-9.  
 
In study 2 we performed a pilot study in a small group of diabetic subjects attending 
the Diabetes Center of RPA Hospital for treatment of a foot ulcer. It is well known 
that diabetic patients are at high risk of infection, and the infection if it occurs is 
often more serious and more prolonged than a similar infection in non-diabetic 
persons.  It has been suggested that the impaired function of neutrophils accounts for 
the increased susceptibility to infection observed in diabetic patients (Alba-Loureiro 
et al., 2007). 
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In this pilot study we focused on the expression of circulating NGAL, MMP-8 as 
specific markers of activated neutrophils and MMP-9 as one of the key regulators of 
wound healing. The white cell expression of NGAL at the first visit was not 
different to the level in white blood cell mRNA at visit 2. The white cell mRNA 
NGAL level at the first visit correlated positively with wound healing rate. The same 
pattern was observed for MMP-8 expression. Together, these data suggest that 
neutrophil activation is measureable in circulating neutrophils and increased 
activation is associated with wound healing rate. Studies by others have reported 
that innate immune responses contribute to chronic inflammation in non-healing 
venous ulcers and wound fluid NGAL is increased as a reflection of this 
contribution (Pukstad et al., 2010).  
 
 
Together, these two small pilot studies showed increased circulating neutrophil 
activity which was confirmed with high expression of specific activated neutrophil 
markers in the circulation. Additionally, in study 2 the relationship between NGAL 
and wound closure indicate an association between decreased NGAL expression and 
increased wound healing regardless of the treatment. Overall and despite the small 
sample size in each of these pilot studies in diabetic patients the data were found to 
be consistent with our rodent studies.  
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 CHAPTER 6: GENERAL 6
DISCUSSION AND 
CONCLUSION 
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Multiple physiological factors contribute to wound healing deficiencies in diabetes. 
These include decreased and impaired cytokine production and activation, altered 
growth factor production and degradation (Galkowska et al., 2006), delayed and 
impaired neovascularisation (Galiano et al., 2004), impaired keratinocyte and 
fibroblast migration and proliferation (Lerman et al., 2003) , insufficient function of 
epidermal nerves (Gibran et al., 2002), as well as macrophage (Khanna et al., 2010) 
and neutrophil dysfunction (Dovi et al., 2003). Disruption of any of these factors 
ultimately leads to delayed healing which in some patients can result in amputation 
(Reiber et al., 1999). Despite current treatments and excellent care, patients with 
diabetes are at increased risk for developing foot ulcerations. The reason why this 
occurs is uncertain but the consequences of persistent and poorly controlled 
hyperglycemia contribute  to neuropathic and vascular abnormalities that can cause 
foot deformities and ulceration (Singh et al., 2005) and result in significant 
morbidity and mortality (Wu et al., 2007). The pathogenesis of foot ulceration in 
diabetes is complex and poorly understood. As discussed in Chapter 1 there are 
several factors which are known to contribute including peripheral neuropathy, 
including ischemia, accidental trauma, limited joint mobility, and consequences of 
cardiovascular and cerebrovascular disease (Jeffcoate & Harding, 2003).  
 
The molecular environment of chronic wounds including some diabetic foot ulcers 
contains abnormally high levels of pro-inflammatory cytokines such as TNFα, 
interleukins and MMPs (Grellner et al., 2000). As discussed in detail in the Chapter 
2, the MMPs are a family of zinc-dependent enzymes with the ability to degrade all 
components of the extracellular matrix. They are produced by most cells involved in 
wound healing including keratinocytes, endothelial cells, fibroblasts, and 
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inflammatory cells such as neutrophils, macrophages, mast cells, and eosinophils 
(Nagase et al., 2006). The MMPs are essential for normal wound healing but in a 
chronic wound, abnormally high levels of MMPs contribute to the persistence of 
inflammation and maybe associated with the increase in cytokines and reactive 
oxygen species (Martins et al., 2013). Although it is well known that inflammation 
is increased in a non-healing wound, few studies have focused on the mechanism of 
the increased MMP-9. In particular the association between MMP-9 and altered 
inflammatory cell function. More specifically neutrophil activity and wound healing 
in diabetes has not been studied. Diabetes is known to impair neutrophil phagocytic 
function but whether neutrophil activation in response to wounding in diabetes is 
altered is not known.  In this study we examined the effect of diabetes and wounding 
on the expression of NGAL, and MMP-8 as specific markers of activated 
neutrophils in two different wound models (an excisional model and a sponge 
implant model). The effect of diabetes and wounding on the expression and 
activities of MMP-9 and its complex with NGAL was also examined. The results 
were compared with those obtained in unwounded animals and in non-diabetic 
animals as control. Using the sponge implant model we were able to examine the 
activity of neutrophils in the circulation and in response to a stimuli in the same 
animals. The effect of interventions such as insulin treatment to improve diabetic 
control or doxycycline a regulator of MMPs, on NGAL and MMP-9 levels in 
diabetic wounds was also examined. In vitro studies examined the effect of high 
glucose concentration on neutrophil activity in neutrophils isolated from rat blood. 
Whether the changes seen in circulating markers in wounded rats are also observed 
in diabetic patients and alter with wound healing was also examined in pilot studies. 
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The new findings of these studies are summarised below and discussed in more 
detail in the following sections (Table 6-1).  
 
Table ‎6-1: New findings of this research 
Finding Evidence 
In the wound inflammatory cells diabetes 
increased neutrophil number, and activity 
Increased neutrophil number by morphology 
and MPO staining 
 Increased NGAL and MMP8 as specific 
markers of activated neutrophils 
In unwounded animals, diabetes had no 
effect on circulating neutrophil number or 
activation 
 
 
In contrast, diabetes and wounding 
significantly increased circulating neutrophil 
number and activity 
No change in circulating neutrophil number 
which was measured by flow cytometry 
No significant change in NGAL, or MMP-8 
expression 
 
Increased circulating neutrophil number 
which was measured by flow cytometry 
Increased NGAL, MMP-8, and MMP-9 
expression 
Diabetes significantly increased MMP-9 
activity 
Increased expression of MMP-9 in 
circulating neutrophils in unwounded and 
wounded animals as well as increased 
MMP-9 activity in wound fluids  
Circulating neutrophil apoptosis was 
increased by diabetes  
 
Diabetes and wounding increased circulating 
neutrophil longevity 
Increased expression of AnnexinV as a 
marker of apoptosis 
 
Increased expression of MCl-1as a marker of 
anti-apoptosis 
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We have shown in our previous study (McLennan et al., 2008) and again in this 
work that diabetic rats have slower wound healing rate than control animals. We 
have also shown that neutrophil number is increased and this increase persists and is 
associated with increased neutrophil activity. This pattern of increased neutrophil 
numbers observed in the this study is consistent with our previous study (McLennan 
et al., 2008). Further detailed investigations in this study have shown an increase in 
activation of neutrophils by increased expression of NGAL and MMP-8, in skin 
excisional wounds as well as the infiltrated cells in the implant model. 
Immunohistochemical examination showed that diabetes increased staining for 
NGAL and MMP-9 in the inflammatory cells in skin excisional wounds. In the 
circulation, this increase in the staining was observed in diabetic neutrophils. In the 
implant model, an increased in NGAL expression was observed in neutrophils and 
macrophages with predominantly located to neutrophils. These results also indicate 
role of these markers in diabetic poor wound healing.  
 
In the results described in Chapter 3, pro and active forms of MMP-9 in wound 
fluids and in plasma were measured by zymography. There was a transient increase 
in the sponge wound fluid MMP-9 from diabetic animals which was due to 
increased formation of the biologically active form of MMP-9  (82 kDa) as well as 
increased formation of the NGAL/MMP-9 complex. This increase was not 
associated with an increase in MMP-9 gene expression and suggests that the 
observed effect on MMP-9 activity occurs via post-translational mechanisms. MMP-
9 activity can be regulated at multiple sides; for example pro-inflammatory 
cytokines can induce MMP-9 mRNA but this is unlikely as we showed no change in 
TNFα and no change in MMP-9 gene expression. MMP-9 activity can also be 
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regulated by TIMPs or by formation of a complex with NGAL. Others have 
described decreased TIMPs in diabetic wounds and in unpublished work we also 
show decreased TIMP expression suggesting that this may also play a role. In this 
work we focussed on NGAL and showed increased NGAL/MMP-9 complex 
formation. The increased formation of the NGAL/MMP-9 heterodimer can stabilise 
MMP-9 to prevent it from degradation (Tschesche et al., 2001; L. Yan et al., 2001), 
and may act as a mechanism to preserve higher gelatinolytic MMP-9 activity in 
diabetic wounds.  
 
Our results show that neutrophils are the main source of NGAL in the circulating 
inflammatory cells and we have shown that NGAL and MMP-9 are localised in 
these cells. In rodents, presence of diabetes appears to have no effect on circulating 
neutrophil number, or activation. In contrast diabetes significantly increased 
circulating neutrophil apoptosis which was confirmed by high expression of 
Annexin-V. In diabetic animals wounding altered circulating neutrophil activation 
but in this case circulating neutrophil apoptosis was delayed. Compared to controls 
in wounded diabetic animals circulating neutrophil expression of MMP-9 and MMP-
8 was transiently increased returning toward control at day 12. The expression of 
other markers of neutrophil activation (NGAL), and function i.e TLR4, TLR2, and 
TNFα were also increased at day 6 but had returned to normal at day 12. This 
abnormal response would increase in circulating cells in inflammation at the wound 
site. We have also measured expression of the anti-apoptotic marker MCL-1 and 
shown that this response appears to increase neutrophil life span, an effect which can 
and may contribute to the high pro-inflammatory environment. More specifically at 
day 6 post wounding, increased neutrophil number and decreased neutrophil 
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apoptosis in circulating neutrophil suggesting increased neutrophil longevity in 
diabetic compared to control rats. These findings are consistent with other studies 
which have shown neutrophil apoptosis was reduced in response to infection and 
inflammation was prolonged (Hanses et al., 2011). Whilst not specifically studied in 
this work it is likely that prolongation of neutrophil apoptosis leads to necrotic death 
and the release of granule proteins and pro-inflammatory cytokines to result in tissue 
damage.  
 
A summary of effect of diabetes on gene expression of NGAL, MMP-8, and MMP-9 
in three different tissues, i.e skin wounds, sponge implant inflammatory cells, and 
circulating neutrophils is shown in table below (Table 6-2).  
 
Table ‎6-2: Effect of diabetes on specific markers of neutrophils NGAL, MMP-8, as well 
as MMP-9 
 
 
Activated neutrophil 
markers  
Skin wounds Implant inflammatory 
cell 
Circulating neutrophils 
D6 D3 D6 D12 D3 D6 D12 
NGAL        
MMP-8        
MMP-9        
Black arrow significant increase, red arrow tendency toward an increase but 
not significant, blue arrow no significant change  at day 3, 6, and 12. All data 
was compared to control.  
 
 
We and others have shown that drugs or other treatments such as Propolis 
(McLennan et al., 2008)  growth factors (Wang et al., 2008) or bioengineered skin–
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tissue substitutes (Pham et al., 2007) can improve wound healing rate. As shown in 
chapter 3 controlling blood glucose with insulin treatment was able to improve 
wound healing and prevent the changes caused by diabetes. Better blood glucose 
control also effectively reduced the expression of NGAL, MMP-8 as well as MMP-9 
in the circulating neutrophils of wounded animals. The increased activity of MMP-9 
which was observed in the wound fluid of diabetic animals was also significantly 
prevented by insulin. That insulin treatment from onset of diabetes can prevent these 
changes, suggests that good lifetime glycemic control is likely an important 
protective factor. Additionally, this data also supports the concept that the effect of 
diabetes on neutrophil function plays a role in the delay in healing. Zagon et al. 
(2006) presented that intensive insulin therapy has been shown to prevent delayed 
wound healing on the ocular surface by maintaining blood glucose levels at near 
normal levels in diabetic rats (Zagon et al., 2006). A study by Guo et al. (2013) 
showed that insulin can decrease MMP-2 and -9 activities after arterial injury with 
no change in expression of their tissue inhibitors (Guo et al., 2013). In this study we 
have shown that insulin therapy can prevent the change in neutrophil function which 
is induced by wounding in diabetic animals. Further, whether this treatment is acting 
directly on the neutrophil in the tissue or effects on neutrophil developing in the 
bone marrow or activation in the circulation was not examined in this study. In this 
study the intense insulin treatment was commenced from the onset of diabetes, 
whether improved diabetic control from the onset of wounding also has the same 
effect is not known.  
 
Beside insulin therapy, whether a strategy to reduce the negative effects of enhanced 
MMP activity in impaired healing could improve healing was also investigated. For 
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this reason chemical inhibitors or regulators of MMPs are an attractive approach and 
may prove to be effective in initiating the progression of wound healing. 
Doxycycline, which belongs to tetracycline antibiotic class is a nonspecific inhibitor 
of MMPs (Wilcox et al., 2012). In this study we investigated the effect of two doses 
of doxycycline a low (20mg/kg) and a high (100mg/kg) dose on MMP-9 expression 
and activity in inflammatory cells in two different models of diabetic wounded 
animals. Whether this treatment also affected neutrophil activity was investigated. 
 
Our results, explained in detail in Chapter 4 showed that the low dose of 
doxycycline is more effective than the high dose with improved MMP-9 and 
neutrophil activity. Low dose of doxycycline also improved wound closure in 
diabetic animals and decreased the gene expression of NGAL and MMP-8 in the 
sponge implant inflammatory cells. It significantly decreased expression of 
neutrophil activity markers NGAL, MMP-8, and MMP-9 in the circulating 
neutrophils.  In contrast, the high dose of doxycycline did not improve the wound 
closure and increased neutrophil activity and numbers in the diabetic treated group. 
Similar treatment of control animals also had the same effect as evidenced by 
increased gene expression of NGAL, MMP-9 and MMP-8 in skin excisional wounds 
as well as MMP-8 gene expression in the sponge inflammatory cells. MMP-9 
activity as well as NGAL/MMP-9 complex formation was partially improved by 
high dose of doxycycline.  
 
In the circulating neutrophils the high dose of doxycycline also negatively impacted 
on neutrophil function as evidenced by increased neutrophil expression of NGAL, 
MMP-9, and MMP-8 in unwounded animals. The results suggest the high dose of 
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doxycycline used maybe exceed the standard inhibitory concentration required for 
its anti-inflammatory effect since daily administration of a 20 mg/kg dose of 
doxycycline, is the only drug therapy approved by the FDA as an MMP inhibitor in 
chronic periodontitis patients (Lee et al., 2004).  
 
Doxycycline has been shown to inhibit the activity of MMPs by a number of 
mechanisms including by inhibition of activated MMPs, inhibition of pro-MMP-9 
activation and decrease of MMP expression (Gerald et al., 2001). Inhibition of MMP 
activity by doxycycline and other chemically modified tetracycline occurs through 
the chelation of calcium and zinc ions. The chelation of calcium and zinc ions enable 
inhibition of already active MMPs, the inhibition of pro-MMP activation, or /and the 
down regulation of MMP expression (Griffin et al., 2010).  
 
In this study we have also shown that low but not high dose of doxycycline can alter 
neutrophil activity, suggesting that pathologically elevated activities of neutrophils 
can be inhibited by low dosage of doxycycline. Other workers have shown that some 
members of the doxycycline family beside of their ability to decrease the level of 
NGAL, MMP-9 (Serra, Buffone, et al., 2013) and TNFα (Cazalis et al., 2008) can 
supress neutrophil function by suppressing superoxide generation, degranulation and 
migration of neutrophils. Doxycycline treatment has a profound but selective effect 
on vascular inflammation and reduces aortic wall neutrophil (Abdul-Hussien et al., 
2009). TNFα is an important inflammatory mediator that regulates the activity of 
neutrophil therefore doxycycline by preventing expression of TNFα improves 
neutrophil activity and decrease expression of MMP-9 by neutrophils. Several 
animal studies reported that treatment with doxycycline or other tetracycline 
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analogues improved healing parameters. For example, systemic treatment of rats 
with doxycycline increased tensile strength of rat intestinal anastomoses 3 days after 
surgery (Pasternak et al., 2008). Chemically modified tetracyclines beside of their 
regulation activities of release of inflammatory cytokines (Cazalis et al., 2009), 
inhibit neutrophil elastase and MMPs, namely gelatinases (Tilakaratne & Soory, 
2014). 
 
The results of both intervention studies showed prevention of increase in circulating 
neutrophil activation by either insulin treatment or low dose doxycycline in 
association with improved wound closure. Whether it is necessary to prevent the 
increase in circulating neutrophil activation to improve healing was not specifically 
studied. However, studies using topical insulin treatment (Lima et al., 2012) and 
topical doxycycline (Chin et al., 2003) also showed improved healing. Whether the 
mechanism of this effect is via improvement of neutrophil function is not known and 
could be studied in future work.  
 
Using an in vitro cell culture system we have also shown that neutrophil activity is 
increased by high glucose concentration. This was confirmed by significantly 
increased expression of NGAL, MMP-8, and MMP-9 after 2 hours incubation in 
high glucose concentration. The increased neutrophil activity in high glucose 
concentration was also associated with increased neutrophil apoptosis after 6 hours 
incubation. These findings are in line with the results from unwounded animals that 
showed diabetes increased neutrophil apoptosis. As neutrophil apoptosis leads to 
cell death future cell culture studies examining in detail the contribution of 
neutrophil apoptosis to cytokines expression would be valuable. Comparisons of the 
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effect of diabetes and the interventions would also enable their role to be better 
understood. Further culture of neutrophils from control and diabetic wounds in the 
presence or absence and activation of stimulators such as LPS or fMLP would 
determine whether neutrophil viability in diabetes is altered. The effect of these 
stimulators on MMP-9 activity, the expression of MMP-9 and its complex with 
NGAL can also be measured in the culture media. Specific therapies targeted at 
blocking NGAL may reduce the activity of MMP-9 and provide a novel treatment to 
improve healing of wounds.  
 
Another aspect of this work which requires further investigation is the role of 
prolonged neutrophil life span. We have shown that wounding increased circulating 
neutrophil life span by delaying apoptosis. Whilst we were unable to specially 
examine this in neutrophils in the wound implant model, we showed that circulating 
neutrophil pro apoptotic marker MCL-1 was increased. Whether, these changes in 
circulating neutrophils reflect a similar pattern in wounds is not clear. Bcl-2 an 
apoptotic marker was not altered in diabetic wounds but other pathway members 
were not studied because we were unable to isolate enough neutrophils for 
examination. Further studies by immunohistochemistry may assist in answering this 
question. Manipulating of neutrophil apoptosis ex-vivo is difficult as their life span 
is short. Treatment with flavones has been shown to induce neutrophil apoptosis in 
vitro and in vivo in a zebrafish model (Lucas et al., 2013). We have previously used 
Propolis, a high flavone containing compound, to improve wound healing 
(McLennan et al., 2008). Whether it exerts some of its effects by increasing 
neutrophil apoptosis is interesting and requires investigation.   
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In these series of cell culture studies treatment of cultured neutrophils with insulin 
did not prevent increased expression of NGAL, MMP-8, or MMP-9. How the 
addition of insulin can cause this change is not known. Topical insulin has shown to 
be beneficial in stimulating re-epithelialisation, angiogenesis and in the recovery of 
both acute and chronic wounds in vitro and in vivo (Liu et al., 2009). Other studies 
have demonstrated that topical insulin can reducing wound healing times, and 
increase both protein and DNA synthesis by wound tissue (Zhang et al., 2011). The 
application of topical insulin has also been reported to increase wound closure in full 
thickness wounds via suppression of neutrophil infiltration and decreased level of 
macrophage inflammatory protein-2 expression in mice (Chen et al., 2012). 
 
As described in Chapter 3 and 4 diabetes impaired neutrophil function and activation 
in the rodents and in particular in response to wounding. Whether these changes are 
also observed in people with diabetes is not known. To attempt to address this we 
examined neutrophil activity in diabetic subjects with long duration of diabetes and 
in a second group in association with wound healing. The data were found to be 
consistent with our rodent studies and showed high gene expression of NGAL and 
MMP-8 in the both groups suggesting increased circulating neutrophil activity. In 
the diabetic subjects with long duration of diabetes expression of NGAL had 
positive relation with increased MMP-8 gene expression. Additionally, in this study 
plasma soluble NGAL was significantly increased in diabetic patients and showed a 
relationship with other indexes. In particular plasma NGAL concentration was 
negatively correlated with eGFR and positively correlated with serum creatinine 
suggests an association between plasma NGAL and decline in renal function. These 
observations are in accordance with those of a previous study that suggested 
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association of plasma NGAL concentration with kidney injury (Bolignano et al., 
2008; Mitsnefes et al., 2007).  
 
In the second study we examined the association between neutrophil activities and 
wound healing. In this study, albeit in small numbers of patients a high level of 
NGAL was positively associated with increased wound area. A similar pattern of 
increase was observed for MMP-8 expression. Together, these results suggest 
maintenance of neutrophil activation as the wound heals. Whether neutrophil 
activation alters with healing is as yet not clear and requires further study in larger 
numbers of patients.  
 
The studies described in this thesis investigated the effect of diabetes on neutrophil 
activity and the expression and activities of MMP-9 and its regulator, NGAL. In 
these studies we showed that the increased activities of MMP-9 in diabetic wounds 
are associated with induction of inflammatory cell NGAL and NGAL/MMP-9 
concentrations. However, whether these changes are markers or mediators of 
impaired healing are not yet clear. To understand the activation mechanism 
completely more research is required. Increased NGAL has been demonstrated to 
form a complex with MMP-9 and may play a role in the maintenance of MMP-9 
activity. To show this conclusively studies in models where NGAL is decreased 
such as in knocking down of NGAL knock-out mice or by topical application of an 
NGAL antibody are required. In addition, we have shown regulation of NGAL and 
MMP-9 by insulin and doxycycline. Therefore, studies using combinations of with 
good diabetic control with topical agents that reduce inflammation and protease 
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activities such as doxycycline might also be an effective adjunctive therapy for 
wound healing.  
 
In conclusion, in these uninfected wound models, we propose as shown 
schematically in Figure 6-1 that increased wound MMP-9 activities in diabetic 
animals is associated with increased circulating and wound neutrophil activity, as 
well as increased neutrophil NGAL expression and the formation and persistence of 
NGAL/MMP-9 complex. These changes may be due to the presence in the 
circulation of higher numbers of neutrophils with increased expression of NGAL 
and MMP-9. Therefore, therapies targeting NGAL and MMP-9 may have utility in 
diabetic wound healing.  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure ‎6-1: schematic diagram showing the effect of diabetes on neutrophils in the 
circulation and the implication for these changes in increased MMP-9 and poor wound 
healing. 
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APPENDIX 
 
                           Buffers 
 
 RIPA buffer 
 
Tris ; 65mM 
NaCl; 150mM; (Add dH20 make up to ~195mL, stir until clear 
and adjust to pH 7.4 with 10M HCl);  
EDTA; 5mM 
1% NP-40 = 2.5mL of 100% stock (same as Triton X-100);  
0.5% Sodium deoxycholate = 12.5mL of a 10% stock;  
0.1% SDS ( 2.5mLs of a 10% stock)  
10% glycerol = 25mLs of 100% stock 
 
 Lysis buffer NH4Cl; 155 mM, KHCO3; 10 mM, EDTA; 100 µM 
 
 TBS-T Tris; (100mM),  NaCl; (150mM), Tween 20; (1ml)  
2 L water; pH to 7.5  
 
 ×5 SDS-PAGE 
sample buffer 
Tris; (0.25M), SDS;10%, Glycerol; (50%v/v), H2O; (5 ml) 
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Zymography gels and  buffers 
 
 8%Polyacrylamide gel 
(ml) 
 
Acrylamide/Bis1M; 40%, Tris ;pH 8.8, MDPF-gelatine; 
10mg/ml 
APS; 10%, SDS; 10% , H2O;  TEMED 
 
 3% stacking gel (ml): Acrylamide/Bis1M, 40%, Tris pH 6.8; MDPF-gelatine; 
10mg/ml 
APS; 10%, SDS; 10%, H2O; TEMED 
 
 Buffer I  (2.5% Triton X-100, 50 mM Tris-HCl, 1 µM ZnCl2, 
 0.02% NaN3)  
 
 Buffer II  
 
(2.5%Triton X-100, 50 mM Tris-HCl, 1 µM ZnCl2,  
0.02% NaN3, and 10mMCaCl2)   
 
 Buffer III  (50 mM Tris-HCl, 1 µM ZnCl2, 0.02% NaN3, 
10mMCaCl2) 
 
 
 
 
 
 
 
 
 
